Ident. | Authors (with country if any) | Title |
---|
000095 |
Angelo Antonini [Italie] ; Pablo Martinez-Martin [Espagne] ; Ray K. Chaudhuri [Royaume-Uni] ; Marcelo Merello [Argentine] ; Robert Hauser [États-Unis] ; Regina Katzenschlager [Autriche] ; Per Odin [Allemagne] ; Mark Stacy [États-Unis] ; Fabrizio Stocchi [Italie] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Anette Schrag [Royaume-Uni] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] | Wearing‐off scales in Parkinson's disease: Critique and recommendations |
000096 |
Neil K. Archibald [Royaume-Uni] ; Mike P. Clarke [Royaume-Uni] ; Urs P. Mosimann [Royaume-Uni, Suisse] ; David J. Burn [Royaume-Uni] | Visual symptoms in Parkinson's disease and Parkinson's disease dementia |
000097 |
James M. Shine [Australie] ; Glenda M. Halliday [Australie] ; Sharon L. Naismith [Australie] ; Simon J. G. Lewis [Australie] | Visual misperceptions and hallucinations in Parkinson's disease: Dysfunction of attentional control networks? |
000098 |
Carmine Vitale [Italie] ; Vincenzo Marcelli [Italie] ; Teresa Furia [Italie] ; Gabriella Santangelo [Italie] ; Autilia Cozzolino [Italie] ; Katia Longo [Italie] ; Roberto Allocca [Italie] ; Marianna Amboni [Italie] ; Elio Marciano [Italie] ; Paolo Barone [Italie] | Vestibular impairment and adaptive postural imbalance in parkinsonian patients with lateral trunk flexion |
000099 |
Turi O. Dalaker [Norvège, États-Unis] ; Robert Zivadinov [États-Unis] ; Deepa Preeti Ramasamy [États-Unis] ; Mona K. Beyer [Norvège] ; Guido Alves [Norvège] ; Kolbjorn S. Bronnick [Norvège] ; Ole-Bjorn Tysnes [Norvège] ; Dag Aarsland [Norvège] ; Jan P. Larsen [Norvège] | Ventricular enlargement and mild cognitive impairment in early Parkinson's disease |
000100 |
Richard Camicioli [Canada] ; Jennifer Sabino [Canada] ; Myrlene Gee [Canada] ; Thomas Bouchard [Canada] ; Nancy Fisher [Canada] ; Chris Hanstock [Canada] ; Derek Emery [Canada] ; W. R. Wayne Martin [Canada] | Ventricular dilatation and brain atrophy in patients with Parkinson's disease with incipient dementia |
000101 |
Sun Ju Chung [États-Unis, Corée du Sud] ; Sebastian M. Armasu [États-Unis] ; Joanna M. Biernacka [États-Unis] ; Timothy G. Lesnick [États-Unis] ; David N. Rider [États-Unis] ; Julie M. Cunningham [États-Unis] ; Demetrius M. Maraganore [États-Unis] | Variants in estrogen‐related genes and risk of Parkinson's disease |
000102 |
Samantha A. Hollingworth [Australie] ; Amanda Rush [Australie] ; Wayne D. Hall [Australie] ; Mervyn J. Eadie [Australie] | Utilization of anti‐Parkinson drugs in Australia: 1995–2009 |
000105 |
S. Orimo [Japon] ; T. Uchihara [Japon] ; T. Kanazawa [Japon] ; Y. Itoh [Japon] ; K. Wakabayashi ; A. Kakita [Japon] ; H. Takahashi [Japon] | Unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve in Parkinson's disease |
000107 |
Karl Kieburtz [États-Unis] | Twice‐daily, low‐dose pramipexole in early Parkinson's disease: A randomized, placebo‐controlled trial |
000109 |
Elina Tripoliti [Royaume-Uni] ; Laura Strong [Royaume-Uni] ; Freya Hickey [Royaume-Uni] ; Tom Foltynie [Royaume-Uni] ; Ludvic Zrinzo [Royaume-Uni] ; Joseph Candelario [Royaume-Uni] ; Marwan Hariz [Royaume-Uni] ; Patricia Limousin [Royaume-Uni] | Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease |
000110 |
P. Barone [Italie] | Treatment of depressive symptoms in Parkinson’s disease |
000112 |
Gabriella Constantinescu [Australie] ; Deborah Theodoros [Australie] ; Trevor Russell [Australie] ; Elizabeth Ward [Australie] ; Stephen Wilson [Australie] ; Richard Wootton [Royaume-Uni] | Treating disordered speech and voice in Parkinson's disease online: a randomized controlled non‐inferiority trial |
000115 |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease |
000116 |
Hana Srovnalova [République tchèque] ; Radek Marecek [République tchèque] ; Irena Rektorova [République tchèque] | The role of the inferior frontal gyri in cognitive processing of patients with Parkinson's disease: A pilot rTMS study |
000119 |
Magdalena Eriksson Domellöf [Suède] ; Eva Elgh [Suède] ; Lars Forsgren [Suède] | The relation between cognition and motor dysfunction in drug‐naive newly diagnosed patients with Parkinson's disease |
000120 |
Ashley H. Spencer [Royaume-Uni] ; Hugh Rickards [Royaume-Uni] ; Alfonso Fasano [Italie] ; Andrea E. Cavanna [Royaume-Uni] | The prevalence and clinical characteristics of punding in Parkinson's disease |
000121 |
Sook K. Song [Corée du Sud] ; Ji E. Lee [Corée du Sud] ; Hae-Jeong Park [Corée du Sud] ; Young H. Sohn [Corée du Sud] ; Jong Doo Lee [Corée du Sud] ; Phil Hyu Lee [Corée du Sud] | The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status |
000123 |
Francisco A. Ponce [États-Unis] ; Andres M. Lozano [Canada] | The most cited works in Parkinson's disease |
000125 |
Alison Yarnall [Royaume-Uni] ; Lynn Rochester [Royaume-Uni] ; David J. Burn [Royaume-Uni] | The interplay of cholinergic function, attention, and falls in Parkinson's disease |
000126 |
Pablo Martinez-Martin [Espagne] ; Carmen Rodriguez-Blazquez [Espagne] ; Monica M. Kurtis [Espagne] ; K. Ray Chaudhuri [Royaume-Uni] | The impact of non‐motor symptoms on health‐related quality of life of patients with Parkinson's disease |
000127 |
Hasmet A. Hanagasi [Turquie] ; Hakan Gurvit [Turquie] ; P Nar Unsalan [Turquie] ; Hilal Horozoglu [Turquie] ; Nese Tuncer [Turquie] ; Aynur Feyzioglu [Turquie] ; Dilek Ince Gunal [Turquie] ; Gorsev G. Yener [Turquie] ; Raif Cakmur [Turquie] ; Huseyin A. Sahin [Turquie] ; Murat Emre [Turquie] | The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study |
000129 |
Corinna Vossius [Norvège] ; Jan P. Larsen [Norvège] ; Carmen Janvin [Norvège] ; Dag Aarsland [Norvège] | The economic impact of cognitive impairment in Parkinson's disease |
000131 |
Christine Klein [Canada, Allemagne] ; Rosalind Chuang [Canada] ; Connie Marras [Canada] ; Anthony E. Lang [Canada] | The curious case of phenocopies in families with genetic Parkinson's disease |
000135 |
Anne Pavy-Le Traon [France] ; Gerard Amarenco [France] ; Susanne Duerr [Autriche] ; Horacio Kaufmann [États-Unis] ; Heinz Lahrmann [Autriche] ; Stephanie R. Shaftman [États-Unis] ; François Tison [France] ; Gregor K. Wenning [Autriche] ; Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Anette Schrag [Royaume-Uni] ; Glenn T. Stebbins [États-Unis] ; Olivier Rascol [France] | The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension |
000136 |
Klaus Seppi [Autriche, Portugal] ; Daniel Weintraub [États-Unis] ; Miguel Coelho [Portugal] ; Santiago Perez-Lloret [France] ; Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Eva-Maria Hametner [Autriche] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease |
000137 |
Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease |
000140 |
Christopher G. Goetz [États-Unis] ; Glenn T. Stebbins [États-Unis] ; Ad Theeuwes [Pays-Bas] ; Fabrizio Stocchi [Italie] ; Joaquim J. Ferreira [Portugal] ; Serge Van De Witte [Pays-Bas] ; Juliana Bronzova [Pays-Bas] | Temporal stability of the Unified Dyskinesia Rating Scale |
000141 |
Lynn Rochester [Royaume-Uni] ; Katherine Baker [Royaume-Uni] ; Alice Nieuwboer [Belgique] ; David Burn [Royaume-Uni] | Targeting dopa‐sensitive and dopa‐resistant gait dysfunction in Parkinson's disease: Selective responses to internal and external cues |
000144 |
Nick Miller [Royaume-Uni] ; Emma Noble [Royaume-Uni] ; Diana Jones [Royaume-Uni] ; Katherine H. O. Deane [Royaume-Uni] ; Catherine Gibb [Royaume-Uni] | Survey of speech and language therapy provision for people with Parkinson's disease in the United Kingdom: patients' and carers' perspectives |
000145 |
Ludy C. Shih ; Daniel Tarsy [États-Unis] | Survey of U.S. Neurologists' Attitudes Towards Deep Brain Stimulation for Parkinson's Disease |
000146 |
Hélène Mollion [France] ; Peter Ford Dominey [France] ; Emmanuel Broussolle [France] ; Jocelyne Ventre-Dominey [France] | Subthalamic nucleus stimulation selectively improves motor and visual memory performance in Parkinson's disease |
000147 |
Michael S. Remple [États-Unis] ; Courtney H. Bradenham [États-Unis] ; C. Chris Kao [États-Unis] ; P. David Charles [États-Unis] ; Joseph S. Neimat [États-Unis] ; Peter E. Konrad [États-Unis] | Subthalamic nucleus neuronal firing rate increases with Parkinson's disease progression |
000148 |
Namiko Nishida [Japon] ; Tokiko Murakami [Japon] ; Kunihiro Kadoh [Japon] ; Rie Tohge [Japon] ; Miki Yamanegi [Japon] ; Hidemoto Saiki [Japon] ; Keita Ueda [Japon] ; Sadayuki Matsumoto [Japon] ; Masatsune Ishikawa [Japon] ; Jun A. Takahashi [Japon] ; Hiroki Toda [Japon] | Subthalamic nucleus deep brain stimulation restores normal rapid eye movement sleep in Parkinson's disease |
000153 |
Hideyuki Matsumoto [Japon] ; Yasuo Terao [Japon] ; Toshiaki Furubayashi [Japon] ; Akihiro Yugeta [Japon] ; Hideki Fukuda [Japon] ; Masaki Emoto [Japon] ; Ritsuko Hanajima [Japon] ; Yoshikazu Ugawa [Japon] | Small saccades restrict visual scanning area in Parkinson's disease |
000154 |
Bernardo Rodrigues [Brésil] ; Ana Caline N Brega [Brésil] ; Marília Sampaio [Brésil] ; Natalie Argolo [Brésil] ; Ailton Melo [Brésil] | Silent saliva aspiration in Parkinson's disease |
000155 |
Carl E. Clarke [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Caroline Rick [Royaume-Uni] ; Keith Wheatley [Royaume-Uni] ; Richard Gray [Royaume-Uni] | Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops? |
000156 |
Michael A. Schwarzschild [États-Unis] ; Kenneth Marek [États-Unis] ; Shirley Eberly [États-Unis] ; David Oakes [États-Unis] ; Ira Shoulson [États-Unis] ; Danna Jennings [États-Unis] ; John Seibyl [États-Unis] ; Alberto Ascherio [États-Unis] | Serum urate and probability of dopaminergic deficit in early “Parkinson's disease” |
000157 |
Carla Manuela Crispim Nascimento [Brésil] ; Florindo Stella [Brésil] ; Célia Regina Garlipp ; Ruth Ferreira Santos [Brésil] ; Sebastião Gobbi [Brésil] ; Lilian Teresa Bucken Gobbi | Serum homocysteine and physical exercise in patients with Parkinson's disease |
000165 |
Jonathan Kimmelman [Canada] ; Katherine Duckworth [Canada] ; Tim Ramsay [Canada] ; Tiffini Voss [États-Unis] ; Bernard Ravina [États-Unis] ; Marina Elena Emborg [États-Unis] | Risk of surgical delivery to deep nuclei: A meta‐analysis |
000168 |
R. Fekete [États-Unis] ; Joseph Jankovic [États-Unis] | Revisiting the relationship between essential tremor and Parkinson's disease |
000169 |
Alessandra Nicoletti [Italie] ; Giuseppe Nicoletti [Italie] ; Gennarina Arabia [Italie] ; Grazia Annesi [Italie] ; Michele De Mari [Italie] ; Paolo Lamberti [Italie] ; Lucia Grasso [Italie] ; Roberto Marconi [Italie] ; Antonio Epifanio [Italie] ; Letterio Morgante [Italie] ; Autilia Cozzolino [Italie] ; Paolo Barone [Italie] ; Aldo Quattrone [Italie] ; Mario Zappia [Italie] | Reproductive factors and Parkinson's disease: A multicenter case–control study |
000170 |
Ignacio F. Mata [États-Unis] ; Dora Yearout [États-Unis] ; Victoria Alvarez [Espagne] ; Eliecer Coto [Espagne] ; Lorena De Mena [Espagne] ; Renee Ribacoba [Espagne] ; Oswaldo Lorenzo-Betancor [Espagne] ; Lluis Samaranch [Espagne] ; Pau Pastor [Espagne] ; Sebastian Cervantes [Espagne] ; Jon Infante [Espagne] ; Ines Garcia-Gorostiaga [Espagne] ; Maria Sierra [Espagne] ; Onofre Combarros [Espagne] ; Katherine W. Snapinn [États-Unis] ; Karen L. Edwards [États-Unis] ; Cyrus P. Zabetian [États-Unis] | Replication of MAPT and SNCA, but not PARK16‐18, as susceptibility genes for Parkinson's disease |
000172 |
Anne Marthe Meppelink [Pays-Bas] ; Bauke M. De Jong [Pays-Bas] ; Laura K. Teune [Pays-Bas] ; Teus Van Laar [Pays-Bas] | Regional cortical grey matter loss in Parkinson's disease without dementia is independent from visual hallucinations |
000173 |
Nicolas Sauvageot [Luxembourg (pays)] ; Michel Vaillant [Luxembourg (pays)] ; Nico J. Diederich [Luxembourg (pays)] | Reduced sympathetically driven heart rate variability during sleep in Parkinson's disease: A case‐control polysomnography‐based study |
000175 |
Catherine L. Gallagher [États-Unis] ; Terrence R. Oakes [États-Unis] ; Sterling C. Johnson [États-Unis] ; Moo K. Chung [États-Unis] ; James E. Holden [États-Unis] ; Barbara B. Bendlin [États-Unis] ; Donald G. Mclaren [États-Unis] ; Guofan Xu [États-Unis] ; Robert J. Nickles [États-Unis] ; Robert Pyzalski [États-Unis] ; Onofre Dejesus [États-Unis] ; W. Douglas Brown [États-Unis] | Rate of 6‐[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease |
000176 |
Se-Hong Oh [Corée du Sud] ; Hye-Jin Jeong [Corée du Sud] ; Jong-Min Kim [Corée du Sud] ; Dae-Hyuk Kwon [Corée du Sud] ; Sung-Yeon Park [Corée du Sud] ; Joshua H. Park [Corée du Sud] ; Young-Bo Kim [Corée du Sud] ; Je-Geun Chi [Corée du Sud] ; Chan-Woong Park [Corée du Sud] ; Beom S. Jeon [Corée du Sud] ; Zang-Hee Cho [Corée du Sud] | Quantitative analysis of the SN in Parkinson's disease implementing 3D modeling at 7.0‐T MRI |
000177 |
M. Duleeka W. Knipe [Royaume-Uni] ; Mirdhu M. Wickremaratchi [Royaume-Uni] ; Emma Wyatt-Haines [Royaume-Uni] ; Huw R. Morris [Royaume-Uni] ; Yoav Ben-Shlomo [Royaume-Uni] | Quality of life in young‐ compared with late‐onset Parkinson's disease |
000178 |
Samay Jain [États-Unis] ; Greg J. Siegle [États-Unis] ; Chen Gu [États-Unis] ; Charity G. Moore [États-Unis] ; Larry S. Ivanco [États-Unis] ; Stephanie Studenski [États-Unis] ; J. Timothy Greenamyre [États-Unis] ; Stuart R. Steinhauer [États-Unis] | Pupillary unrest correlates with arousal symptoms and motor signs in Parkinson disease |
000181 |
Bart Post [Pays-Bas] ; Dino Muslimovic [Pays-Bas] ; Nan Van Geloven [Pays-Bas] ; Johannes D. Speelman [Pays-Bas] ; Ben Schmand [Pays-Bas] ; Rob J. De Haan [Pays-Bas] | Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease |
000182 |
Natalie R. S. Goldberg [États-Unis] ; Tom Hampton [États-Unis] ; Scott Mccue [États-Unis] ; Ajit Kale [États-Unis] ; Charles K. Meshul [États-Unis] | Profiling changes in gait dynamics resulting from progressive 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced nigrostriatal lesioning |
000185 |
Jamie M. Sheard ; Susan Ash [Australie] ; Peter A. Silburn [Australie] ; Graham K. Kerr [Australie] | Prevalence of malnutrition in Parkinson's disease: a systematic review |
000186 |
Connie Marras [Canada] ; Michael P. Mcdermott [États-Unis] ; Ken Marek [États-Unis] ; Paula Rochon [Canada] ; Gary Naglie [Canada] ; Caroline M. Tanner [États-Unis] ; Alice Rudolph [États-Unis] ; Ira Shoulson [États-Unis] ; Anthony E. Lang [Canada] | Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts |
000188 |
Georg Ebersbach [Allemagne] ; Maren Gunkel [Allemagne] | Posturography reflects clinical imbalance in Parkinson's disease |
000194 |
Marcus M. Unger [Allemagne] ; Jens C. Möller [Allemagne] ; Katharina Mankel [Allemagne] ; Katrin Schmittinger [Allemagne] ; Karla M. Eggert [Allemagne] ; Maria Stamelou [Allemagne] ; Karin Stiasny-Kolster [Allemagne] ; Katharina Bohne [Allemagne] ; Maren Bodden [Allemagne] ; Geert Mayer [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Johannes J. Tebbe [Allemagne] | Patients with idiopathic rapid‐eye‐movement sleep behavior disorder show normal gastric motility assessed by the 13C‐octanoate breath test |
000195 |
Johanna G. Kalf [Pays-Bas] ; Marten Munneke [Pays-Bas] ; Lenie Van Den Engel-Hoek [Pays-Bas] ; Bert J. De Swart [Pays-Bas] ; George F. Borm [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] ; Machiel J. Zwarts [Pays-Bas] | Pathophysiology of diurnal drooling in Parkinson's disease |
000196 |
Roberto Cilia [Canada, Italie] ; Sang Soo Cho [Canada] ; Thilo Van Eimeren [Canada] ; Giorgio Marotta [Italie] ; Chiara Siri [Italie] ; Ji Hyun Ko [Canada] ; Giovanna Pellecchia [Canada] ; Gianni Pezzoli [Italie] ; Angelo Antonini [Italie] ; Antonio P. Strafella [Canada] | Pathological gambling in patients with Parkinson's disease is associated with fronto‐striatal disconnection: A path modeling analysis |
000197 |
Atbin Djamshidian [Royaume-Uni] ; Francisco Cardoso [Brésil] ; Donald Grosset [Royaume-Uni] ; Henrietta Bowden-Jones [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Pathological gambling in Parkinson's disease—a review of the literature |
000204 |
John N. Caviness [États-Unis] ; Lih-Fen Lue [États-Unis] ; Thomas G. Beach [États-Unis] ; Joseph G. Hentz [États-Unis] ; Charles H. Adler [États-Unis] ; Lucia Sue [États-Unis] ; Ramin Sadeghi [États-Unis] ; Erika Driver-Dunckley [États-Unis] ; Virgilio G. Evidente [États-Unis] ; Marwan N. Sabbagh [États-Unis] ; Holly A. Shill [États-Unis] ; Douglas G. Walker [États-Unis] | Parkinson's disease, cortical dysfunction, and alpha‐synuclein |
000208 |
Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; And Ad Theeuwes [Pays-Bas] | Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials |
000210 |
Veit Mylius [Allemagne, France] ; Juliane Brebbermann [Allemagne] ; Helena Dohmann [Allemagne] ; Isabel Engau [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Jens C. Möller [Allemagne, Suisse, France] | Pain sensitivity and clinical progression in Parkinson's disease |
000212 |
Farzaneh Ghazavi [Iran] ; Zeinab Fazlali [Iran] ; Setareh Sadat Banihosseini [Iran] ; Sayed-Rzgar Hosseini [Iran] ; Mohammad Hossein Kazemi [Iran] ; Seyedmehdi Shojaee [Iran] ; Khosro Parsa [Iran] ; Homa Sadeghi [Iran] ; Farzad Sina [Iran] ; Mohammad Rohani [Iran] ; Gholam-Ali Shahidi [Iran] ; Nasser Ghaemi [Iran] ; Mostafa Ronaghi [États-Unis] ; Elahe Elahi [Iran] | PRKN, DJ‐1, and PINK1 screening identifies novel splice site mutation in PRKN and two novel DJ‐1 mutations |
000213 |
Fabrizio Stocchi [Italie] ; Luigi Giorgi [Royaume-Uni] ; Brian Hunter [Royaume-Uni] ; Anthony Hv Schapira [Royaume-Uni] | PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease |
000217 |
Avigayil Ribner [Israël] ; Gheona Altarescu [Israël] ; Ari Zimran [Israël] ; Deborah Elstein [Israël] | Osteopontin polymorphic susceptibility factor for Parkinson's disease among patients with Gaucher disease |
000219 |
James F. Morley [États-Unis] ; Daniel Weintraub [États-Unis] ; Eugenia Mamikonyan [États-Unis] ; Paul J. Moberg [États-Unis] ; Andrew D. Siderowf [États-Unis] ; John E. Duda [États-Unis] | Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease |
000220 |
Javier Ruiz-Martínez [Espagne] ; Ana Gorostidi [Espagne] ; Estibaliz Goyenechea [Espagne] ; Ainhoa Alzualde [Espagne] ; Juan José Poza [Espagne] ; Francisco Rodríguez [Espagne] ; Alberto Bergareche [Espagne] ; Fermín Moreno [Espagne] ; Adolfo L Pez De Munain [Espagne] ; José F. Martí Mass [Espagne] | Olfactory deficits and cardiac 123I‐MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations |
000223 |
Malene Flensborg Damholdt [Danemark] ; Per Borghammer [Danemark] ; Lars Larsen [Danemark] ; Karen Stergaard [Danemark] | Odor identification deficits identify Parkinson's disease patients with poor cognitive performance |
000224 |
Natalia Palacios [États-Unis] ; Xiang Gao [États-Unis] ; Marjorie L. Mccullough [États-Unis] ; Eric J. Jacobs [États-Unis] ; Alpa V. Patel [États-Unis] ; Tinisha Mayo [États-Unis] ; Michael A. Schwarzschild [États-Unis] ; Alberto Ascherio [États-Unis] | Obesity, diabetes, and risk of Parkinson's disease |
000226 |
Benjamin Dehay [France] ; Erwan Bezard [France] | New animal models of Parkinson's disease |
000227 |
Sharon L. Naismith [Australie] ; Zoë Terpening [Australie] ; James M. Shine [Australie] ; Simon J. G. Lewis [Australie] | Neuropsychological functioning in Parkinson's disease: Differential relationships with self‐reported sleep‐wake disturbances |
000232 |
Nick Miller [Royaume-Uni] ; Katherine H. O. Deane [Royaume-Uni] ; Diana Jones [Royaume-Uni] ; Emma Noble [Royaume-Uni] ; Catherine Gibb [Royaume-Uni] | National survey of speech and language therapy provision for people with Parkinson's disease in the United Kingdom: therapists’ practices |
000238 |
Ignacio J. Posada [Espagne] ; Julián Benito-Le N [Espagne] ; Elan D. Louis [États-Unis] ; Rocío Trincado [Espagne] ; Alberto Villarejo [Espagne] ; María José Medrano [Espagne] ; Félix Bermejo-Pareja [Espagne] | Mortality from Parkinson's disease: A population‐based prospective study (NEDICES) |
000239 |
Davide Chiasserini [Italie] ; Alessandro Tozzi [Italie] ; Antonio De Iure [Italie] ; Michela Tantucci [Italie] ; Federica Susta [Italie] ; Pier Luigi Orvietani [Italie] ; Keizo Koya [États-Unis] ; Luciano Binaglia [Italie] ; Paolo Calabresi [Italie] | Mortalin inhibition in experimental Parkinson's disease |
000240 |
Vicki Shanker [États-Unis] ; Mark Groves [États-Unis] ; Gary Heiman [États-Unis] ; Christina Palmese [États-Unis] ; Rachel Saunders-Pullman [États-Unis] ; Laurie Ozelius [États-Unis] ; Deborah Raymond [États-Unis] ; Susan Bressman [États-Unis] | Mood and cognition in leucine‐rich repeat kinase 2 G2019S Parkinson's disease |
000242 |
Julius Huebl [Allemagne] ; Thomas Schoenecker [Allemagne] ; Sandy Siegert [Allemagne] ; Christof Brücke [Allemagne] ; Gerd-Helge Schneider [Allemagne] ; Andreas Kupsch [Allemagne] ; Kielan Yarrow [Royaume-Uni] ; Andrea A. Kühn [Allemagne] | Modulation of subthalamic alpha activity to emotional stimuli correlates with depressive symptoms in Parkinson's disease |
000243 |
Alfonso Fasano [Allemagne, Italie] ; Jan Herzog [Allemagne] ; Elena Seifert [Allemagne] ; Henning Stolze [Allemagne] ; Daniela Falk [Allemagne] ; René Reese [Allemagne] ; Jens Volkmann [Allemagne] ; Günther Deuschl [Allemagne] | Modulation of gait coordination by subthalamic stimulation improves freezing of gait |
000244 |
Tito Calì [Italie] ; Denis Ottolini [Italie] ; Marisa Brini [Italie] | Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease |
000251 |
Mark Hallett [États-Unis, Royaume-Uni] ; John Rothwell [Royaume-Uni] | Milestones in clinical neurophysiology |
000254 |
Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche] | Milestones in Parkinson's disease therapeutics |
000255 |
Thomas Gasser [Allemagne] ; John Hardy [Royaume-Uni] ; Yoshikuni Mizuno [Japon] | Milestones in PD genetics |
000260 |
Rebecca Stowe [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Kelly Handley [Royaume-Uni] ; Alexandra Furmston [Royaume-Uni] ; Katherine Deane [Royaume-Uni] ; J. J. Van Hilten [Pays-Bas] ; Keith Wheatley [Royaume-Uni] ; Richard Gray [Royaume-Uni] | Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease |
000261 |
Alisha E. King [États-Unis] ; Jim Mintz [États-Unis] ; Donald R. Royall [États-Unis] | Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders |
000262 |
Giulia Longoni [Italie] ; Federica Agosta [Italie] ; Vladimir S. Kosti [Serbie] ; Tanja Stojkovi [Serbie] ; Elisabetta Pagani [Italie] ; Tatjana Stoši Pin Al [Serbie] ; Massimo Filippi [Italie] | MRI measurements of brainstem structures in patients with Richardson's syndrome, progressive supranuclear palsy‐parkinsonism, and Parkinson's disease |
000263 |
Irene Litvan [États-Unis] ; Dag Aarsland [Norvège] ; Charles H. Adler [États-Unis] ; Jennifer G. Goldman [États-Unis] ; Jaime Kulisevsky [Espagne] ; Brit Mollenhauer [Allemagne] ; Maria C. Rodriguez-Oroz [Espagne] ; Alexander I. Tröster [États-Unis] ; Daniel Weintraub [États-Unis] | MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI |
000264 |
Tamar Shachar [Israël] ; Christophe Lo Bianco [Suisse] ; Alessandra Recchia [Suisse] ; Christoph Wiessner [Suisse] ; Annick Raas-Rothschild [Israël] ; Anthony H. Futerman [Israël] | Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond |
000268 |
Elisa Garbayo [Espagne] ; Eduardo Ansorena [Espagne] ; Jose Luis Lanciego [Espagne] ; María Jose Blanco-Prieto [Espagne] ; María S. Aymerich [Espagne] | Long‐term neuroprotection and neurorestoration by glial cell‐derived neurotrophic factor microspheres for the treatment of Parkinson's disease |
000272 |
P. Stathis [Grèce] ; S. Konitsiotis [Grèce] ; G. Tagaris [Grèce] ; D. Peterson [Finlande] | Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson's disease |
000274 |
S. Sharma [Royaume-Uni] ; R. Bandopadhyay ; T. Lashley ; A. E. M. Renton [Royaume-Uni] ; A. E. Kingsbury ; R. Kumaran ; C. Kallis ; C. Vilari O-Güell ; S. S. O'Sullivan ; Andrew Lees (neurologue) [Royaume-Uni] ; T. Revesz ; N. W. Wood ; J. L. Holton | LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study |
000276 |
Lazlo Horvath [Suède] ; Ingrid Van Marion [Suède] ; Khalid Taï [Suède] ; Troels Tolstrup Nielsen [Danemark] ; Cecilia Lundberg [Suède] | Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease |
000277 |
Christine Daniels [Allemagne] ; Paul Krack [Allemagne] ; Jens Volkmann [Allemagne] ; Jan Raethjen [Allemagne] ; Markus O. Pinsker [Allemagne] ; Manja Kloss [Allemagne] ; Volker Tronnier [Allemagne] ; Alfons Schnitzler [Allemagne] ; Lars Wojtecki [Allemagne] ; Kai Bötzel [Allemagne] ; Adrian Danek [Allemagne] ; Rüdiger Hilker [Allemagne] ; Volker Sturm [Allemagne] ; Andreas Kupsch [Allemagne] ; Elfriede Karner [Autriche] ; Günther Deuschl [Allemagne] ; Karsten Witt [Allemagne] | Is improvement in the quality of life after subthalamic nucleus stimulation in Parkinson's disease predictable? |
000280 |
Maria Milenkova [Allemagne, Bulgarie] ; Bahram Mohammadi [Allemagne] ; Katja Kollewe [Allemagne] ; Christoph Schrader [Allemagne] ; Anja Fellbrich [Allemagne] ; Matthias Wittfoth [Allemagne] ; Reinhard Dengler [Allemagne] ; Thomas F. Münte [Allemagne] | Intertemporal choice in Parkinson's disease |
000281 |
Nick H. G. Holford [Nouvelle-Zélande] ; John G. Nutt [États-Unis] | Interpreting the results of Parkinson's disease clinical trials: Time for a change |
000283 |
Sabine Skodda [Allemagne] ; Andrea Flasskamp [Allemagne] ; Uwe Schlegel [Allemagne] | Instability of syllable repetition as a marker of disease progression in Parkinson's disease: A longitudinal study |
000288 |
Meng-Ting Wang [République populaire de Chine] ; Pei-Wen Lian [République populaire de Chine] ; Chin-Bin Yeh [République populaire de Chine] ; Che-Hung Yen [République populaire de Chine] ; Kao-Hsing Ma [République populaire de Chine] ; Agnes L. F. Chan [République populaire de Chine] | Incidence, prescription patterns, and determinants of antipsychotic use in patients with Parkinson's disease |
000290 |
Angelo Antonini [Italie] ; Chiara Siri [Italie] ; Gabriella Santangelo [Italie] ; Roberto Cilia [Italie] ; Michele Poletti [Italie] ; Margherita Canesi [Italie] ; Alessandra Caporali [Italie] ; Francesca Mancini [Italie] ; Gianni Pezzoli [Italie] ; Roberto Ceravolo [Italie] ; Ubaldo Bonuccelli [Italie] ; Paolo Barone [Italie] | Impulsivity and compulsivity in drug‐naïve patients with Parkinson's disease |
000291 |
Polly Ambermoon [Australie] ; Adrian Carter [Australie] ; Wayne D. Hall [Australie] ; Nadeeka N. W. Dissanayaka [Australie] ; John D. O'Sullivan [Australie] | Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field |
000295 |
Toshiyuki Ishioka [Japon] ; Kazumi Hirayama [Japon] ; Yoshiyuki Hosokai [Japon] ; Atsushi Takeda [Japon] ; Kyoko Suzuki [Japon] ; Yoshiyuki Nishio [Japon] ; Yoichi Sawada [Japon] ; Shoki Takahashi [Japon] ; Hiroshi Fukuda [Japon] ; Yasuto Itoyama [Japon] ; Etsuro Mori [Japon] | Illusory misidentifications and cortical hypometabolism in Parkinson's disease |
000296 |
Maged M. Ragab [Égypte] ; Ehab S. Mohammed [Égypte] | Idiopathic Parkinson's disease patients at the urologic clinic |
000298 |
Ingrid De Chazeron [France] ; Pierre-Michel Llorca [France] ; Isabelle Chéreau-Boudet [France] ; Olivier Blanc [France] ; Jean Perriot [France] ; Lemlih Ouchchane [France] ; Miguel Ulla [France] ; Bérengère Debilly [France] ; Philippe Derost [France] ; Franck Durif [France] | Hypersexuality and pathological gambling in Parkinson's disease: A cross‐sectional case–control study |
000300 |
María Sierra [Espagne] ; Isabel González-Aramburu [Espagne] ; Pascual Sánchez-Juan [Espagne] ; Coro Sánchez-Quintana [Espagne] ; José Miguel Polo [Espagne] ; José Berciano [Espagne] ; Onofre Combarros [Espagne] ; Jon Infante [Espagne] | High frequency and reduced penetrance of lRRK2 g2019S mutation among Parkinson's disease patients in Cantabria (Spain) |
000302 |
Pablo Martinez-Martin [Espagne] ; Martine Jeukens-Visser [Pays-Bas] ; Kelly E. Lyons [États-Unis] ; C. Rodriguez-Blazquez [Espagne] ; Caroline Selai [Royaume-Uni] ; Andrew Siderowf [États-Unis] ; Mickie Welsh [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] ; Anette Schrag [Royaume-Uni] | Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations |
000303 |
Glenda M. Halliday [Australie] ; Claire H. Stevens [Australie] | Glia: Initiators and progressors of pathology in Parkinson's disease |
000305 |
Jeanne C. Latourelle [États-Unis] ; Audrey E. Hendricks [États-Unis] ; Nathan Pankratz [États-Unis] ; Jemma B. Wilk [États-Unis] ; Cheryl Halter [États-Unis] ; William C. Nichols [États-Unis] ; James F. Gusella [États-Unis] ; Anita L. Destefano [États-Unis] ; Richard H. Myers [États-Unis] ; Tatiana Foroud [États-Unis] | Genomewide linkage study of modifiers of LRRK2‐related Parkinson's disease |
000307 |
Owen A. Ross [États-Unis] ; Karen N. Conneely [États-Unis] ; Tao Wang [États-Unis] ; Carles Vilarino-Guell [États-Unis, Canada] ; Alexandra I. Soto-Ortolaza [États-Unis] ; Alex Rajput [Canada] ; Zbigniew K. Wszolek [États-Unis] ; Ryan J. Uitti [États-Unis] ; Elan D. Louis [États-Unis] ; Lorraine N. Clark [États-Unis] ; Matthew J. Farrer [États-Unis, Canada] ; Claudia M. Testa [États-Unis] | Genetic variants of α‐synuclein are not associated with essential tremor |
000308 |
Zhenyu Yue [États-Unis] ; M. Lenard Lachenmayer [États-Unis, Allemagne] | Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications |
000311 |
Tessel Boertien [Royaume-Uni, Pays-Bas] ; Ludvic Zrinzo [Royaume-Uni] ; Joshua Kahan [Royaume-Uni] ; Marjan Jahanshahi [Royaume-Uni] ; Marwan Hariz [Royaume-Uni] ; Laura Mancini [Royaume-Uni] ; Patricia Limousin [Royaume-Uni] ; Thomas Foltynie [Royaume-Uni] | Functional imaging of subthalamic nucleus deep brain stimulation in Parkinson's disease |
000312 |
Tao Wu [République populaire de Chine] ; Xiangyu Long [République populaire de Chine] ; Liang Wang [République populaire de Chine] ; Mark Hallett [États-Unis] ; Yufeng Zang [République populaire de Chine] ; Kuncheng Li [République populaire de Chine] ; Piu Chan [République populaire de Chine] | Functional connectivity of cortical motor areas in the resting state in Parkinson's disease |
000316 |
Armando Perrotta [Italie] ; Giorgio Sandrini [Italie] ; Mariano Serrao [Italie] ; Simona Buscone [Italie] ; Cristina Tassorelli [Italie] ; Michele Tinazzi [Italie] ; Roberta Zangaglia [Italie] ; Claudio Pacchetti [Italie] ; Michelangelo Bartolo [Italie] ; Francesco Pierelli [Italie] ; Emilia Martignoni [Italie] | Facilitated temporal summation of pain at spinal level in Parkinson's disease |
000317 |
Deborah A. Hall [États-Unis] ; Elizabeth Berry-Kravis [États-Unis] ; Wenting Zhang [États-Unis] ; Flora Tassone [États-Unis] ; Elaine Spector [États-Unis] ; Gary Zerbe [États-Unis] ; Paul J. Hagerman [États-Unis] ; Bichun Ouyang [États-Unis] ; Maureen A. Leehey [États-Unis] | FMR1 gray‐zone alleles: Association with Parkinson's disease in women? |
000318 |
Peter Jenner [Royaume-Uni] ; J. William Langston [États-Unis] | Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline |
000321 |
Mehrnaz Shoushtarian [Australie] ; Anna Murphy [Australie] ; Robert Iansek [Australie] | Examination of central gait control mechanisms in Parkinson's disease using movement‐related potentials |
000322 |
A. Kummer [Brésil] ; P. Scalzo [Brésil] ; F. Cardoso [Brésil] ; A. L. Teixeira [Brésil] | Evaluation of fatigue in Parkinson’s disease using the Brazilian version of Parkinson’s Fatigue Scale |
000324 |
Anthony H. Schapira [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Etiology and pathogenesis of Parkinson's disease |
000325 |
Charles. H. Adler [États-Unis] ; Holly A. Shill [États-Unis] ; Thomas G. Beach [États-Unis] | Essential tremor and Parkinson's disease: Lack of a link |
000327 |
David S. Goldstein ; Courtney Holmes ; Latoya Sewell ; Sandra Pechnik ; Irwin J. Kopin | Effects of Carbidopa and Entacapone on the Metabolic Fate of the Norepinephrine Prodrug L‐DOPS |
000333 |
Olivier Rascol [France] | Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release |
000334 |
Tomohiko Nakamura [Japon] ; Masaaki Hirayama [Japon] ; Takashi Hara [Japon] ; Tetsuo Hama [Japon] ; Hirohisa Watanabe [Japon] ; Gen Sobue [Japon] | Does cardiovascular autonomic dysfunction contribute to fatigue in Parkinson's disease? |
000336 |
Stewart A. Factor [États-Unis] ; N. Kyle Steenland [États-Unis] ; Donald S. Higgins [États-Unis] ; Eric S. Molho [États-Unis] ; Denise M. Kay [États-Unis] ; Jennifer Montimurro [États-Unis] ; Ami R. Rosen [États-Unis] ; Cyrus P. Zabetian [États-Unis] ; Haydeh Payami [États-Unis] | Disease‐related and genetic correlates of psychotic symptoms in Parkinson's disease |
000337 |
Thomas D. H Lbig [États-Unis, Allemagne] ; Stephanie Assuras [États-Unis] ; Judy Creighton [États-Unis] ; Joan C. Borod [États-Unis] ; Winona Tse [États-Unis] ; Pasquale G. Frisina [États-Unis] ; Andrei Voustianiouk [États-Unis] ; Jean-Michel Gracies [États-Unis] ; C. Warren Olanow [États-Unis] | Differential role of dopamine in emotional attention and memory: Evidence from Parkinson's disease |
000338 |
Alberto J. Espay [États-Unis] ; Joe P. Giuffrida [États-Unis] ; Robert Chen [Canada] ; Megan Payne [États-Unis] ; Filomena Mazzella [Canada] ; Emily Dunn [États-Unis] ; Jennifer E. Vaughan [États-Unis] ; Andrew P. Duker [États-Unis] ; Alok Sahay [États-Unis] ; Sang Jin Kim [Canada] ; Fredy J. Revilla [États-Unis] ; Dustin A. Heldman [États-Unis] | Differential response of speed, amplitude, and rhythm to dopaminergic medications in Parkinson's disease |
000339 |
Jee-Young Lee [Corée du Sud] ; Jinwhan Cho [Corée du Sud] ; Eun-Kyung Lee [Corée du Sud] ; Sung-Sup Park [Corée du Sud] ; Beom S. Jeon [Corée du Sud] | Differential genetic susceptibility in diphasic and peak‐dose dyskinesias in Parkinson's disease |
000342 |
Robert A. Hauser [États-Unis] ; Peggy Auinger [États-Unis] | Determination of minimal clinically important change in early and advanced Parkinson's disease |
000349 |
Robert A. Hauser [États-Unis] ; Aaron L. Ellenbogen [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Ann Hsu [États-Unis] ; Martin J. O'Connell [États-Unis] ; Nishit B. Modi [États-Unis] ; Hsuan-Ming Yao [États-Unis] ; Sherron H. Kell [États-Unis] ; Suneel K. Gupta [États-Unis] | Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease |
000355 |
Aristide Merola [Italie] ; Maurizio Zibetti [Italie] ; Serena Angrisano [Italie] ; Laura Rizzi [Italie] ; Michele Lanotte [Italie] ; Leonardo Lopiano [Italie] | Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease |
000356 |
Carmine Vitale [Italie] ; Gabriella Santangelo [Italie] ; Luigi Trojano [Italie] ; Francesca Verde [Italie] ; Mariangela Rocco [Italie] ; Dario Grossi [Italie] ; Paolo Barone [Italie] | Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson's disease |
000358 |
Sun Ju Chung [États-Unis, Corée du Sud] ; Sebastian M. Armasu [États-Unis] ; Joanna M. Biernacka [États-Unis] ; Timothy G. Lesnick [États-Unis] ; David N. Rider [États-Unis] ; Sarah J. Lincoln [États-Unis] ; Alexandra I. Ortolaza [États-Unis] ; Matthew J. Farrer [États-Unis] ; Julie M. Cunningham [États-Unis] ; Walter A. Rocca [États-Unis] ; Demetrius M. Maraganore [États-Unis] | Common variants in PARK loci and related genes and Parkinson's disease |
000359 |
Guangwei Du [États-Unis] ; Mechelle M. Lewis [États-Unis] ; Martin Styner [États-Unis] ; Michele L. Shaffer [États-Unis] ; Suman Sen [États-Unis] ; Qing X. Yang [États-Unis] ; Xuemei Huang [États-Unis] | Combined R2* and Diffusion Tensor Imaging Changes in the Substantia Nigra in Parkinson's Disease |
000361 |
Paolo Barone [Italie] ; Dag Aarsland [Norvège] ; David Burn [Royaume-Uni] ; Murat Emre [Turquie] ; Jaime Kulisevsky [Espagne] ; Daniel Weintraub [États-Unis] | Cognitive impairment in nondemented Parkinson's disease |
000362 |
Kolbjorn Bronnick [Norvège] ; Murat Emre [Turquie] ; Sibel Tekin [États-Unis] ; Siri B. Haugen [Norvège] ; Dag Aarsland [Norvège] | Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease |
000363 |
Stephanie M. Van Rooden [Pays-Bas] ; Fabrice Colas [Pays-Bas] ; Pablo Martínez-Martín [Espagne] ; Martine Visser [Pays-Bas] ; Dagmar Verbaan [Pays-Bas] ; Johan Marinus [Pays-Bas] ; Ray K. Chaudhuri [Royaume-Uni] ; Joost N. Kok [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas] | Clinical subtypes of Parkinson's disease |
000364 |
Oliver H. H. Gerlach [Pays-Bas] ; Ania Winogrodzka [Pays-Bas] ; Wim E. J. Weber [Pays-Bas] | Clinical problems in the hospitalized Parkinson's disease patient: Systematic review |
000365 |
Yun Ju Christine Song [Australie] ; Yue Huang [Australie] ; Glenda Margaret Halliday [Australie] | Clinical correlates of similar pathologies in parkinsonian syndromes |
000368 |
John C. Dalrymple-Alford [Nouvelle-Zélande] ; Leslie Livingston [Nouvelle-Zélande] ; Michael R. Macaskill [Nouvelle-Zélande] ; Charlotte Graham [Nouvelle-Zélande] ; Tracy R. Melzer [Nouvelle-Zélande] ; Richard J. Porter [Nouvelle-Zélande] ; Richard Watts [Nouvelle-Zélande] ; Tim J. Anderson [Nouvelle-Zélande] | Characterizing mild cognitive impairment in Parkinson's disease |
000371 |
M. B. Aerts [Pays-Bas] ; R. A. J. Esselink [Pays-Bas] ; B. R. Bloem [Pays-Bas] ; M. M. Verbeek [Pays-Bas] | Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome |
000373 |
Lucilla Parnetti [Italie] ; Davide Chiasserini [Italie] ; Gianni Bellomo [Italie] ; David Giannandrea [Italie] ; Claudia De Carlo [Italie] ; Mohamed M. Qureshi [Émirats arabes unis] ; Mustafa T. Ardah [Émirats arabes unis] ; Shiji Varghese [Émirats arabes unis] ; Laura Bonanni [Italie] ; Barbara Borroni [Italie] ; Nicola Tambasco [Italie] ; Paolo Eusebi [Italie] ; Aroldo Rossi [Italie] ; Marco Onofrj [Italie] ; Alessandro Padovani [Italie] ; Paolo Calabresi [Italie] ; Omar El-Agnaf [Émirats arabes unis] | Cerebrospinal fluid Tau/α‐synuclein ratio in Parkinson's disease and degenerative dementias |
000376 |
Ronald B. Postuma [Canada] ; Jacques Montplaisir [Canada] ; Paola Lanfranchi [Canada] ; Hélène Blais [Canada] ; Sylvie Rompré [Canada] ; Roberto Colombo [Italie] ; Jean-François Gagnon [Canada] | Cardiac autonomic denervation in Parkinson's disease is linked to REM sleep behavior disorder |
000378 |
Morinobu Seki [Japon] ; Kazushi Takahashi [Japon] ; Atsuo Koto [Japon] ; Ban Mihara [Japon] ; Yoko Morita [Japon] ; Kazuo Isozumi [Japon] ; Kouichi Ohta [Japon] ; Kazuhiro Muramatsu [Japon] ; Jun Gotoh [Japon] ; Keiji Yamaguchi [Japon] ; Yutaka Tomita [Japon] ; Hideki Sato [Japon] ; Yoshihiro Nihei [Japon] ; Satoko Iwasawa [Japon] ; Norihiro Suzuki [Japon] | Camptocormia in Japanese patients with Parkinson's disease: A multicenter study |
000379 |
Robert D. Altman [Canada] ; Anthony E. Lang [Canada] ; Ronald B. Postuma [Canada] | Caffeine in Parkinson's disease: A pilot open‐label, dose‐escalation study |
000380 |
Noriyuki Kimura [Japon] ; Syojirou Hanaki [Japon] ; Teruaki Masuda [Japon] ; Takuya Hanaoka [Japon] ; Yusuke Hazama [Japon] ; Toshio Okazaki [Japon] ; Ryuki Arakawa [Japon] ; Toshihide Kumamoto [Japon] | Brain perfusion differences in Parkinsonian disorders |
000381 |
Mélanie Vendette [Canada] ; Jean-François Gagnon [Canada] ; Jean-Paul Soucy [Canada] ; Nadia Gosselin [Canada] ; Ronald B. Postuma [Canada] ; Maria Tuineag [Canada] ; Isabelle Godin [Canada] ; Jacques Montplaisir [Canada] | Brain perfusion and markers of neurodegeneration in rapid eye movement sleep behavior disorder |
000384 |
Anna Prats París [Espagne] ; Heidi Guerra Saleta [Espagne] ; Maria De La Cruz Crespo Maraver [Espagne] ; Emmanuel Silvestre [États-Unis] ; Maite Garolera Freixa [Espagne] ; Cristina Petit Torrellas [Espagne] ; Silvia Alonso Pont [Espagne] ; Marc Fabra Nadal [Espagne] ; Sheila Alcaine Garcia [Espagne] ; Maria Victoria Perea Bartolomé [Espagne] ; Valentina Ladera Fernández [Espagne] ; Àngels Rusi Ol Bayés [Espagne] | Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease |
000386 |
Anke H. Snijders [Pays-Bas] ; Ivan Toni [Pays-Bas] ; Evžen Ruži Ka [République tchèque] ; Bastiaan R. Bloem [Pays-Bas] | Bicycling breaks the ice for freezers of gait |
000387 |
Maurizio Zibetti [Italie] ; Aristide Merola [Italie] ; Laura Rizzi [Italie] ; Valeria Ricchi [Italie] ; Serena Angrisano [Italie] ; Corrado Azzaro [Italie] ; Carlo Alberto Artusi [Italie] ; Nichy Arduino [Italie] ; Alice Marchisio [Italie] ; Michele Lanotte [Italie] ; Mario Rizzone [Italie] ; Leonardo Lopiano [Italie] | Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's disease |
000388 |
Natalie E. Allen [Australie] ; Catherine Sherrington [Australie] ; Serene S. Paul [Australie] ; Colleen G. Canning [Australie] | Balance and falls in Parkinson's disease: A meta‐analysis of the effect of exercise and motor training |
000390 |
Bernd Müller [Norvège] ; Jan Petter Larsen [Norvège] ; Tore Wentzel-Larsen [Norvège] ; Geir Olve Skeie [Norvège] ; Ole-Bj Rn Tysnes [Norvège] | Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: Frequent but mild |
000395 |
Francesca Assogna [Italie] ; Luca Cravello [Italie] ; Carlo Caltagirone [Italie] ; Gianfranco Spalletta [Italie] | Anhedonia in Parkinson's disease: A systematic review of the literature |
000400 |
Carsten Eggers [Allemagne] ; Deniz Kahraman [Allemagne] ; Gereon R. Fink [Allemagne] ; Matthias Schmidt [Allemagne] ; Lars Timmermann [Allemagne] | Akinetic‐rigid and tremor‐dominant Parkinson's disease patients show different patterns of FP‐CIT Single photon emission computed tomography |
000405 |
Maurizio Morelli [Italie] ; Gennarina Arabia [Italie] ; Maria Salsone [Italie] ; Fabiana Novellino [Italie] ; Laura Giofrè [Italie] ; Rosina Paletta [Italie] ; Demetrio Messina [Italie] ; Giuseppe Nicoletti [Italie] ; Francesca Condino [Italie] ; Olivier Gallo [Italie] ; Pierluigi Lanza [Italie] ; Aldo Quattrone [Italie] | Accuracy of magnetic resonance parkinsonism index for differentiation of progressive supranuclear palsy from probable or possible Parkinson disease |
000406 |
Chiung-Mei Chen [Taïwan] ; Chih-Hsin Lin [Taïwan] ; Hsueh-Fen Juan [Taïwan] ; Fen-Ju Hu [Taïwan] ; Ya-Chin Hsiao [Taïwan] ; Hsin-Yi Chang [Taïwan] ; Chih-Ying Chao [Taïwan] ; I-Cheng Chen [Taïwan] ; Li-Ching Lee [Taïwan] ; Tsu-Wei Wang [Taïwan] ; Ya-Tang Chen [Taïwan] ; Yi-Tsun Chen [Taïwan] ; Guey-Jen Lee-Chen [Taïwan] ; Yih-Ru Wu [Taïwan] | ATP13A2 variability in Taiwanese Parkinson's disease |
000411 |
Kitty K. Wong [Australie] ; Jane E. Alty [Australie] ; Amanda G. Goy [Australie] ; Sanjay Raghav [Australie] ; David C. Reutens [Australie] ; Peter A. Kempster [Australie] | A randomized, double‐blind, placebo‐controlled trial of levetiracetam for dyskinesia in Parkinson's disease |
000416 |
Anthony E. Lang [Canada] | A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials |
000417 |
Shearwood Mcclelland Iii [États-Unis] | A cost analysis of intraoperative microelectrode recording during subthalamic stimulation for Parkinson's disease |
000420 |
Monika Sobolak ; Przemysław Minta | Evaluation of chosen gait parameters in patients with the Parkinson's disease |
000490 |
David A. Gallagher [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Anette Schrag [Royaume-Uni] | What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? |
000492 |
Alessandra Nicoletti [Italie] ; Pierfrancesco Pugliese [Italie] ; Giuseppe Nicoletti [Italie] ; Gennarina Arabia [Italie] ; Grazia Annesi [Italie] ; Michele De Mari [Italie] ; Paolo Lamberti [Italie] ; Lucia Grasso [Italie] ; Roberto Marconi [Italie] ; Antonio Epifanio [Italie] ; Letterio Morgante [Italie] ; Autilia Cozzolino [Italie] ; Paolo Barone [Italie] ; Giusi Torchia [Italie] ; Aldo Quattrone [Italie] ; Mario Zappia [Italie] | Voluptuary habits and clinical subtypes of Parkinson's disease: The FRAGAMP case–control study |
000494 |
Akira Kurita [Japon] ; Maiko Murakami [Japon] ; Satoshi Takagi [Japon] ; Masato Matsushima [Japon] ; Masahiko Suzuki [Japon] | Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies |
000498 |
Chul Hyoung Lyoo [Corée du Sud] ; Young Hoon Ryu [Corée du Sud] ; Myung Sik Lee [Corée du Sud] | Topographical distribution of cerebral cortical thinning in patients with mild Parkinson's disease without dementia |
000500 |
Tanya Simuni [États-Unis] ; Emily Borushko [États-Unis] ; Michael J. Avram [États-Unis] ; Scott Miskevics [États-Unis] ; Audrey Martel [États-Unis] ; C. Zadikoff [États-Unis] ; Aleksandar Videnovic [États-Unis] ; Frances M. Weaver [États-Unis] ; Karen Williams [États-Unis] ; D. James Surmeier [États-Unis] | Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study |
000501 |
Charlotte A. Haaxma [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] ; Sebastiaan Overeem [Pays-Bas] ; George F. Borm [Pays-Bas] ; Martin W. I. M. Horstink [Pays-Bas] | Timed motor tests can detect subtle motor dysfunction in early Parkinson's disease |
000502 |
Ira Shoulson [États-Unis] | Therapeutic directions for Parkinson's disease |
000503 |
Maren Elisabeth Bodden [Allemagne] ; Richard Dodel [Allemagne] ; Elke Kalbe [Allemagne] | Theory of mind in Parkinson's disease and related basal ganglia disorders: A systematic review |
000504 |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates |
000512 |
Glenda Margaret Halliday [Australie] ; Heather Mccann [Australie] | The progression of pathology in Parkinson's disease |
000513 |
Hye Young Sung [Corée du Sud] ; Joong-Seok Kim [Corée du Sud] ; Kwang-Soo Lee [Corée du Sud] ; Yeong-In Kim [Corée du Sud] ; In-Uk Song [Corée du Sud] ; Sung-Woo Chung [Corée du Sud] ; Dong-Won Yang [Corée du Sud] ; Yu Kyung Cho [Corée du Sud] ; Jae Myung Park [Corée du Sud] ; In Seok Lee [Corée du Sud] ; Sang Woo Kim [Corée du Sud] ; In-Sik Chung [Corée du Sud] ; Myung-Gyu Choi [Corée du Sud] | The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson's disease |
000514 |
Kevin St. P. Mcnaught [États-Unis] ; Ruth Jnobaptiste [États-Unis] ; Tehone Jackson [États-Unis] ; Toni-Ann Jengelley [États-Unis] | The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease |
000515 |
Shen-Yang Lim [Canada, Malaisie] ; Anthony E. Lang [Canada] | The nonmotor symptoms of Parkinson's disease—An overview |
000516 |
K. Ray Chaudhuri [Royaume-Uni] ; Cristina Prieto-Jurcynska [Espagne] ; Yogini Naidu [Royaume-Uni] ; Tanya Mitra [Royaume-Uni] ; Belen Frades-Payo [Espagne] ; Susanne Tluk [Royaume-Uni] ; Anne Ruessmann [Allemagne] ; Per Odin [Allemagne] ; Graeme Macphee [Royaume-Uni] ; Fabrizio Stocchi [Italie] ; William Ondo [États-Unis] ; Kapil Sethi [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Juan Carlos Martinez Castrillo [Espagne] ; Pablo Martinez-Martin [Espagne] | The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire |
000520 |
Endre Pal [Hongrie] ; Ferenc Nagy [Hongrie] ; Zsuzsanna Aschermann [Hongrie] ; Eva Balazs [Hongrie] ; Norbert Kovacs [Hongrie] | The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: A randomized, double‐blind, placebo‐controlled study |
000521 |
Stephanie M. Van Rooden [Pays-Bas] ; Willem J. Heiser [Pays-Bas] ; Joost N. Kok [Pays-Bas] ; Dagmar Verbaan [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas] ; Johan Marinus [Pays-Bas] | The identification of Parkinson's disease subtypes using cluster analysis: A systematic review |
000523 |
William Dauer [États-Unis] ; Cherry Cheng-Ying Ho [États-Unis] | The biology and pathology of the familial Parkinson's disease protein LRRK2 |
000524 |
David J. Burn [Royaume-Uni] | The Treatment of Cognitive Impairment Associated with Parkinson's Disease |
000527 |
Daniel Harnack [Allemagne] ; Andreas Kupsch [Allemagne] | The Impact of Subthalamic Deep Brain Stimulation on Nigral Neuroprotection—Myth or Reality? |
000528 |
Dag Aarsland ; Martin Wilhelm Kurz [Norvège] | The Epidemiology of Dementia Associated with Parkinson's Disease |
000530 |
Carlo Colosimo [Italie] ; Pablo Martínez-Martín [Espagne] ; Giovanni Fabbrini [Italie] ; Robert A. Hauser [États-Unis] ; Marcelo Merello [Argentine] ; Janis Miyasaki [Canada] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Olivier Rascol [France] ; Glenn T. Stebbins [États-Unis] ; Anette Schrag [Royaume-Uni] ; Christopher G. Goetz [États-Unis] | Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations |
000532 |
Claire L. Tomlinson [Royaume-Uni] ; Rebecca Stowe [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Caroline Rick [Royaume-Uni] ; Richard Gray [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] | Systematic review of levodopa dose equivalency reporting in Parkinson's disease |
000535 |
Beate Ritz [États-Unis] ; Angelika D. Manthripragada [États-Unis] ; Lei Qian [États-Unis] ; Eva Schernhammer [États-Unis] ; Lene Wermuth [Danemark] ; Jorgen Olsen [Danemark] ; Soren Friis [Danemark] | Statin use and Parkinson's disease in Denmark |
000536 |
Jerrold L. Vitek [États-Unis] ; Kelly E. Lyons [États-Unis] ; Roy Bakay [États-Unis] ; Alim-Louis Benabid [France] ; Guenther Deuschl [Allemagne] ; Mark Hallett [États-Unis] ; Roger Kurlan [États-Unis] ; Joseph J. Pancrazio [États-Unis] ; Ali Rezai [États-Unis] ; Benjamin L. Walter [États-Unis] ; Anthony E. Lang [Canada] | Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS‐PD) |
000537 |
Fabian Klostermann [Allemagne] ; Michael Wahl [Allemagne] ; Frank Marzinzik [Allemagne] ; Jan Vesper [Allemagne] ; Werner Sommer [Allemagne] ; Gabriel Curio [Allemagne] | Speed effects of deep brain stimulation for Parkinson's disease |
000539 |
Joaquim J. Ferreira [Portugal] ; Dulce Neutel [Portugal] ; Tiago Mestre [Portugal] ; Miguel Coelho [Portugal] ; Mário M. Rosa [Portugal] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] | Skin cancer and Parkinson's disease |
000549 |
Karla Eggert [Allemagne] ; David Squillacote [États-Unis] ; Paolo Barone [Italie] ; Richard Dodel [Allemagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Olivier Rascol [France] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Claudia Trenkwalder [Allemagne] ; Marco Onofrj [Italie] ; Fabrizio Stocchi [Italie] ; Giuseppe Nappi [Italie] ; Vladimir Kostic [Serbie] ; Jagoda Potic [Serbie] ; Evzen Ruzicka [République tchèque] ; Wolfgang Oertel [Allemagne] | Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo‐controlled study |
000551 |
Kathrine Rugbjerg [Danemark] ; S Ren Friis [Danemark] ; Thomas L. J Rgensen [Danemark] ; Beate Ritz [États-Unis] ; Lise Korbo [Danemark] ; J Rgen H. Olsen [Danemark] | Risk for Parkinson's disease among patients with osteoarthritis: A Danish cohort study |
000552 |
Christine Daniels [Allemagne] ; Paul Krack [Allemagne] ; Jens Volkmann [Allemagne] ; Markus O. Pinsker [Allemagne] ; Martin Krause [Allemagne] ; Volker Tronnier [Allemagne] ; Manja Kloss [Allemagne] ; Alfons Schnitzler [Allemagne] ; Lars Wojtecki [Allemagne] ; Kai Bötzel [Allemagne] ; Adrian Danek [Allemagne] ; Rüdiger Hilker [Allemagne] ; Volker Sturm [Allemagne] ; Andreas Kupsch [Allemagne] ; Elfriede Karner [Autriche] ; Günther Deuschl [Allemagne] ; Karsten Witt [Allemagne] | Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson's disease |
000553 |
Atbin Djamshidian [Royaume-Uni, Autriche] ; Ashwani Jha [Royaume-Uni] ; Sean S. O'Sullivan [Royaume-Uni] ; Laura Silveira-Moriyama [Royaume-Uni] ; Clare Jacobson [Royaume-Uni] ; Peter Brown [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Bruno B. Averbeck [Royaume-Uni] | Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease |
000558 |
Xiang Gao [États-Unis] ; Michael A. Schwarzschild [États-Unis] ; Eilis J. O'Reilly [États-Unis] ; Hao Wang [États-Unis] ; Alberto Ascherio [États-Unis] | Restless legs syndrome and Parkinson's disease in men |
000564 |
Giuseppe Frazzitta [Italie] ; Roberto Maestri [Italie] ; Gabriella Bertotti [Italie] ; Davide Uccellini [Italie] ; Giacomo Bazzini [Italie] ; Paola Abelli [Italie] ; Roberto Aquilani [Italie] | Rehabilitation in Parkinson's disease: Assessing the outcome using objective metabolic measurements |
000566 |
Marcus M. Unger [Allemagne] ; Katja Hattemer [Allemagne] ; Jens C. Möller [Allemagne] ; Katrin Schmittinger [Allemagne] ; Katharina Mankel [Allemagne] ; Karla Eggert [Allemagne] ; Konstantin Strauch [Allemagne] ; Johannes J. Tebbe [Allemagne] ; Boris Keil [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Johannes T. Heverhagen [Allemagne] ; Susanne Knake [Allemagne] | Real‐time visualization of altered gastric motility by magnetic resonance imaging in patients with Parkinson's disease |
000567 |
Anthony H. V. Schapira [Royaume-Uni] ; Stefan Albrecht [Allemagne] ; Paolo Barone [Italie] ; Cynthia L. Comella [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Kenneth Marek [États-Unis] | Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study |
000568 |
Manabu Funayama [Japon] ; Hiroyuki Tomiyama [Japon] ; Ruey-Meei Wu [Taïwan] ; Kotaro Ogaki [Japon] ; Hiroyo Yoshino [Japon] ; Yoshikuni Mizuno [Japon] ; Nobutaka Hattori [Japon] | Rapid screening of ATP13A2 variant with high‐resolution melting analysis |
000569 |
Robert A. Hauser [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] ; Paolo Barone [Italie] ; Yoshikuni Mizuno [Japon] ; Laurence Salin [France] ; Monika Haaksma [Autriche] ; Nolwenn Juhel [France] ; Werner Poewe [Autriche] | Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease |
000571 |
David H. Benninger [Suisse, États-Unis] ; Jan Michel [Suisse] ; Daniel Waldvogel [Suisse] ; Victor Candia [Suisse] ; Rositsa Poryazova [Suisse] ; Hubertus J. A. Van Hedel [Suisse] ; Claudio L. Bassetti [Suisse] | REM sleep behavior disorder is not linked to postural instability and gait dysfunction in Parkinson |
000573 |
Hirohisa Watanabe [Japon] ; Mizuki Ito [Japon] ; Hiroshi Fukatsu [Japon] ; Jo Senda [Japon] ; Naoki Atsuta [Japon] ; Tomotsugu Kaga [Japon] ; Shigetaka Kato [Japon] ; Masahisa Katsuno [Japon] ; Fumiaki Tanaka [Japon] ; Masaaki Hirayama [Japon] ; Shinji Naganawa [Japon] ; Gen Sobue [Japon] | Putaminal magnetic resonance imaging features at various magnetic field strengths in multiple system atrophy |
000574 |
Francisco Javier Carod-Artal [Brésil] ; Luciola Da Silveira Ribeiro [Brésil] ; Wladimir Kummer [Brésil] ; Pablo Martinez-Martin [Espagne] | Psychometric properties of the SCOPA‐AUT Brazilian Portuguese version |
000577 |
Ying Jiao Zhao ; Hwee Lin Wee ; Yiong-Huak Chan ; Soo Hoon Seah ; Wing Lok Au ; Puay Ngoh Lau ; Emmanuel Camara Pica ; Shu Chuen Li [Australie] ; Nan Luo ; Louis C. S. Tan | Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times |
000579 |
G. Stennis Watson [États-Unis] ; James B. Leverenz [États-Unis] | Profile of Cognitive Impairment in Parkinson's Disease |
000581 |
Dagmar Verbaan [Pays-Bas] ; Stephanie M. Van Rooden [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas] ; Roselyne M. Rijsman [Pays-Bas] | Prevalence and clinical profile of restless legs syndrome in Parkinson's disease |
000582 |
Kayhan A. Tayarani-Binazir [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; Peter Jenner [Royaume-Uni] | Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP‐treated common marmosets |
000585 |
Raquel Duran [Espagne] ; Francisco J. Barrero [Espagne] ; Blas Morales [Espagne] ; Juan D. Luna [Espagne] ; Manuel Ramirez [Espagne] ; Francisco Vives [Espagne] | Plasma α‐synuclein in patients with Parkinson's disease with and without treatment |
000586 |
Avner Shahar [États-Unis, Israël] ; Kushang V. Patel [États-Unis] ; Richard D. Semba [États-Unis] ; Stefania Bandinelli [Italie] ; Danit R. Shahar [États-Unis, Israël] ; Louigi Ferrucci [États-Unis] ; Jack M. Guralnik [États-Unis] | Plasma selenium is positively related to performance in neurological tasks assessing coordination and motor speed |
000587 |
Sarah H. M. Robben [Pays-Bas] ; Monique J. M. Sleegers [Pays-Bas] ; Paul L. J. Dautzenberg [Pays-Bas] ; Floor S. Van Bergen [Pays-Bas] ; Jan-Pieter Ter Bruggen [Pays-Bas] ; Marcel G. M. Olde Rikkert [Pays-Bas] | Pilot study of a three‐step diagnostic pathway for young and old patients with Parkinson's disease dementia: screen, test and then diagnose |
000591 |
Javier Ruiz-Martínez [Espagne] ; Ana Gorostidi [Espagne] ; Berta Iba Ez [Espagne] ; Ainhoa Alzualde [Espagne] ; David Otaegui [Espagne] ; Fermin Moreno [Espagne] ; Adolfo L Pez De Munain [Espagne] ; Alberto Bergareche [Espagne] ; Juan Carlos G Mez-Esteban [Espagne] ; José F. Martí Mass [Espagne] | Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain) |
000597 |
Stanley Fahn [États-Unis] | Parkinson's disease: 10 years of progress, 1997–2007 |
000599 |
Kathy Dujardin [France] ; Bruno Dubois [France] ; François Tison [France] ; Franck Durif [France] ; Isabelle Bourdeix [France] ; Jean-Jacques Péré [France] ; Alain Duhamel [France] | Parkinson's disease dementia can be easily detected in routine clinical practice |
000601 |
Matthew B. Stern [États-Unis] ; Andrew Siderowf [États-Unis] | Parkinson's at risk syndrome: Can Parkinson's disease be predicted? |
000602 |
Daniela Frosini [Italie] ; Ilaria Pesaresi [Italie] ; Mirco Cosottini [Italie] ; Gina Belmonte [Italie] ; Carlo Rossi [Italie] ; Liliana Dell'Osso [Italie] ; Luigi Murri [Italie] ; Ubaldo Bonuccelli [Italie] ; Roberto Ceravolo [Italie] | Parkinson's Disease and pathological gambling: Results from a functional MRI study |
000603 |
Louisa Clare Johnston [Royaume-Uni] ; Michael John Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Andrew Christopher Mccreary [Pays-Bas] ; Peter Jenner [Royaume-Uni] | Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP‐treated common marmosets |
000605 |
Tiphaine Rouaud [France] ; Thibaut Dondaine [France] ; Sophie Drapier [France] ; Claire Haegelen [France] ; François Lallement [France] ; Julie Péron [France] ; Sylvie Raoul [France] ; Paul Sauleau [France] ; Marc Vérin [France] | Pallidal stimulation in advanced Parkinson's patients with contraindications for subthalamic stimulation |
000606 |
Blair Ford [États-Unis] | Pain in Parkinson's disease |
000610 |
Javier Pagonabarraga [Espagne] ; Jaime Kulisevsky [Espagne] ; Gisela Llebaria [Espagne] ; Carmen García-Sánchez [Espagne] ; Berta Pascual-Sedano [Espagne] ; Mercè Martinez-Corral [Espagne] ; Alexandre Gironell [Espagne] | PDD‐Short Screen: A brief cognitive test for screening dementia in Parkinson's disease |
000611 |
Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France] | Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study |
000612 |
Ray L. Watts [États-Unis] ; Kelly E. Lyons [États-Unis] ; Rajesh Pahwa [États-Unis] ; Kapil Sethi [États-Unis] ; Matthew Stern [États-Unis] ; Robert A. Hauser [États-Unis] ; Warren Olanow [États-Unis] ; Alex M. Gray [États-Unis] ; Bryan Adams [États-Unis] ; Nancy L. Earl [États-Unis] | Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease |
000617 |
Randolph Stephenson [États-Unis] ; David Houghton [États-Unis] ; Sri Sundarararjan [États-Unis] ; Richard L. Doty [États-Unis] ; Matthew Stern [États-Unis] ; Sharon X. Xie [États-Unis] ; Andrew Siderowf [États-Unis] | Odor identification deficits are associated with increased risk of neuropsychiatric complications in patients with Parkinson's disease |
000618 |
Anke H. Snijders [Pays-Bas] ; Vivian Weerdesteyn [Pays-Bas] ; Yolien J. Hagen [Pays-Bas] ; Jacques Duysens [Pays-Bas] ; Nir Giladi [Israël] ; Bastiaan R. Bloem [Pays-Bas] | Obstacle avoidance to elicit freezing of gait during treadmill walking |
000619 |
Arnaud Delval [France, Pays-Bas] ; Anke H. Snijders [Pays-Bas] ; Vivian Weerdesteyn [Pays-Bas] ; Jacques E. Duysens [Pays-Bas] ; Luc Defebvre [France] ; Nir Giladi [Israël] ; Bastiaan R. Bloem [Pays-Bas] | Objective detection of subtle freezing of gait episodes in Parkinson's disease |
000621 |
Jan O. Aasly [Norvège] ; Carles Vilari O-Güell [États-Unis] ; Justus C. Dachsel [États-Unis] ; Philip J. Webber [États-Unis] ; Andrew B. West [États-Unis] ; Kristoffer Haugarvoll [Norvège, États-Unis] ; Krisztina K. Johansen [Norvège] ; Mathias Toft [Norvège, États-Unis] ; John G. Nutt [États-Unis] ; Haydeh Payami [États-Unis] ; Jennifer M. Kachergus [États-Unis] ; Sarah J. Lincoln [États-Unis] ; Amela Felic [Norvège, États-Unis] ; Christian Wider [États-Unis] ; Alexandra I. Soto-Ortolaza [États-Unis] ; Stephanie A. Cobb [États-Unis] ; Linda R. White [Norvège] ; Owen A. Ross [États-Unis] ; Matthew J. Farrer [États-Unis] | Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease |
000622 |
Evangelos Evangelou [Grèce, Suisse] ; Demetrius M. Maraganore [États-Unis] ; Grazia Annesi [Italie] ; Laura Brighina [Italie] ; Alexis Brice [France] ; Alexis Elbaz [France] ; Carlo Ferrarese [Italie] ; Georgios M. Hadjigeorgiou [Grèce] ; Rejko Krueger [Allemagne] ; Jean-Charles Lambert [France] ; Suzanne Lesage [France] ; Katerina Markopoulou [Grèce] ; George D. Mellick [Australie] ; Bram Meeus [Belgique] ; Nancy L. Pedersen [Suède] ; Aldo Quattrone [Italie] ; Christine Van Broeckhoven [Belgique] ; Manu Sharma [Allemagne] ; Peter A. Silburn [Australie] ; Eng-King Tan [Singapour] ; Karin Wirdefeldt [Suède] ; John P. A. Ioannidis [Grèce, États-Unis] | Non‐replication of association for six polymorphisms from meta‐analysis of genome‐wide association studies of Parkinson's disease: Large‐scale collaborative study |
000623 |
Huijuan Li [République populaire de Chine] ; Meifen Zhang [République populaire de Chine] ; Ling Chen [République populaire de Chine] ; June Zhang [République populaire de Chine] ; Zhong Pei [République populaire de Chine] ; Ailing Hu [République populaire de Chine] ; Qing Wang [République populaire de Chine] | Nonmotor symptoms are independently associated with impaired health‐related quality of life in Chinese patients with Parkinson's disease |
000624 |
João Costa [Portugal, Espagne] ; Hernán A. González [Espagne] ; Francesc Valldeoriola [Espagne] ; Carles Gaig [Espagne] ; Eduardo Tolosa [Espagne] ; Josep Valls-Solé [Espagne] | Nonlinear dynamic analysis of oscillatory repetitive movements in Parkinson's disease and essential tremor |
000627 |
Christopher G. Goetz [États-Unis] | New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease |
000629 |
Gisela Llebaria [Espagne] ; Javier Pagonabarraga [Espagne] ; Mercè Martínez-Corral [Espagne] ; Carmen García-Sánchez [Espagne] ; Berta Pascual-Sedano [Espagne] ; Alexandre Gironell [Espagne] ; Jaime Kulisevsky [Espagne] | Neuropsychological correlates of mild to severe hallucinations in Parkinson's disease |
000632 |
Jennifer S. A. M. Reijnders [Pays-Bas] ; Bart Scholtissen [Pays-Bas] ; Wim E. J. Weber [Pays-Bas] ; Pauline Aalten [Pays-Bas] ; Frans R. J. Verhey [Pays-Bas] ; Albert F. G. Leentjens [Pays-Bas] | Neuroanatomical correlates of apathy in Parkinson's disease: A magnetic resonance imaging study using voxel‐based morphometry |
000633 |
Shalini Narayana [États-Unis] ; Peter T. Fox [États-Unis] ; Wei Zhang [États-Unis] ; Crystal Franklin [États-Unis] ; Donald A. Robin [États-Unis] ; Deanie Vogel [États-Unis] ; Lorraine O. Ramig [États-Unis] | Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance–correlation analysis |
000634 |
Simone Spuler [Allemagne] ; Henriette Krug [Allemagne] ; Christine Klein [Allemagne] ; Isabel Chaure Medialdea [Allemagne] ; Wibke Jakob [Allemagne] ; Georg Ebersbach [Allemagne] ; Doreen Gruber [Allemagne] ; Karl-Titus Hoffmann [Allemagne] ; Thomas Trottenberg [Allemagne] ; Andreas Kupsch [Allemagne] | Myopathy causing camptocormia in idiopathic Parkinson's disease: A multidisciplinary approach |
000635 |
Michele Tinazzi [Italie] ; Serena Recchia [Italie] ; Sara Simonetto [Italie] ; Stefano Tamburin [Italie] ; Giovanni Defazio ; Antonio Fiaschi [Italie] ; Giuseppe Moretto [Italie] ; Massimiliano Valeriani | Muscular pain in Parkinson's disease and nociceptive processing assessed with CO2 laser‐evoked potentials |
000637 |
Esther Cubo [Espagne] ; Pablo Martinez Martín [Espagne] ; Jesus A. Martin-Gonzalez [Espagne] ; Carmen Rodríguez-Blázquez [Espagne] ; Jaime Kulisevsky [Espagne] | Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease |
000638 |
Iria Cabo L Pez [Espagne] ; Pedro J. García Ruiz [Espagne] ; Silvia Vázquez Fernández Del Pozo [Espagne] ; Vicenta Sánchez Bernardos [Espagne] | Motor complications in Parkinson's disease: Ten year follow‐up study |
000640 |
Patrick Mcnamara [États-Unis] ; Karina Stavitsky [États-Unis] ; Erica Harris [États-Unis] ; Orsolya Szent-Imrey [États-Unis] ; Raymon Durso [États-Unis] | Mood, side of motor symptom onset and pain complaints in Parkinson's disease |
000642 |
Bobby Thomas [États-Unis] ; M. Flint Beal [États-Unis] | Mitochondrial therapies for Parkinson's disease |
000647 |
Marcos Serrano-Due As [Équateur] ; Belén Calero [Équateur] ; Soledad Serrano [Équateur] ; Maite Serrano [Équateur] ; Paulina Coronel [Équateur] | Metric properties of the mini‐mental Parkinson and SCOPA‐COG scales for rating cognitive deterioration in Parkinson's disease |
000648 |
Jean-Marc Taymans [États-Unis, Belgique] ; Mark R. Cookson [États-Unis] | Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau |
000652 |
Emanuele Cereda [Italie] ; Michela Barichella [Italie] ; Carlo Pedrolli [Italie] ; Gianni Pezzoli [Italie] | Low‐protein and protein‐redistribution diets for Parkinson's disease patients with motor fluctuations: A systematic review |
000653 |
Tomohiko Nakamura [Japon] ; Masaaki Hirayama [Japon] ; Fumitada Yamashita [Japon] ; Kei Uchida [Japon] ; Tetsuo Hama [Japon] ; Hirohisa Watanabe [Japon] ; Gen Sobue [Japon] | Lowered cardiac sympathetic nerve performance in response to exercise in Parkinson's disease |
000654 |
Asha Kishore [Inde] ; Ravimohan Rao [Inde] ; Syam Krishnan [Inde] ; Dilip Panikar [Inde] ; Gangadhara Sarma [Inde] ; Mathuranath Pavagada Sivasanakaran [Inde] ; Sankara Sarma [Inde] | Long‐term stability of effects of subthalamic stimulation in Parkinson's disease: Indian Experience |
000655 |
Elena Moro [Canada] ; Andres M. Lozano [Canada] ; Pierre Pollak [France] ; Yves Agid [France] ; Stig Rehncrona [Suède] ; Jens Volkmann [Allemagne] ; Jaime Kulisevsky [Espagne] ; Jose A. Obeso [Espagne] ; Alberto Albanese [Italie] ; Marwan I. Hariz [Royaume-Uni, Suède] ; Niall P. Quinn [Royaume-Uni] ; Jans D. Speelman [Pays-Bas] ; Alim-Louis Benabid [France] ; Valerie Fraix [France] ; Alexandre Mendes [France] ; Marie-Laure Welter [France] ; Jean-Luc Houeto [France] ; Philippe Cornu [France] ; Didier Dormont [France] ; Annalena L. Tornqvist [Suède] ; Ron Ekberg [Suède] ; Alfons Schnitzler [Allemagne] ; Lars Timmermann [Allemagne] ; Lars Wojtecki [Allemagne] ; Andres Gironell [Espagne] ; Maria C. Rodriguez-Oroz [Espagne] ; Jorge Guridi [Espagne] ; Anna R. Bentivoglio [Italie] ; Maria F. Contarino [Italie, Pays-Bas] ; Luigi Romito [Italie] ; Massimo Scerrati [Italie] ; Marc Janssens [Pays-Bas] ; Anthony E. Lang [Canada] | Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease |
000657 |
Elisabeth Wolf [Autriche] ; Klaus Seppi [Autriche] ; Regina Katzenschlager [Autriche] ; Guenter Hochschorner [Autriche] ; Gerhard Ransmayr [Autriche] ; Petra Schwingenschuh [Autriche] ; Erwin Ott [Autriche] ; Iris Kloiber [Autriche] ; Dietrich Haubenberger [Autriche] ; Eduard Auff [Autriche] ; Werner Poewe [Autriche] | Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease |
000659 |
Yaping Chu [États-Unis] ; Jeffrey H. Kordower [États-Unis] | Lewy body pathology in fetal grafts |
000661 |
Adam Zaidel [Israël] ; Hagai Bergman [Israël] ; Ya'Acov Ritov [Israël] ; Zvi Israel Md [Israël] | Levodopa and subthalamic deep brain stimulation responses are not congruent |
000662 |
Rachel Saunders-Pullman [États-Unis] ; Matthew J. Barrett [États-Unis] ; Kaili M. Stanley [États-Unis] ; Marta San Luciano [États-Unis] ; Vicki Shanker [États-Unis] ; Lawrence Severt [États-Unis] ; Ann Hunt [États-Unis] ; Deborah Raymond [États-Unis] ; Laurie J. Ozelius [États-Unis] ; Susan B. Bressman [États-Unis] | LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease |
000664 |
Marcelo Merello [Argentine] ; Natalia Fantacone [Argentine] ; Jorge Balej [Argentine] | Kinematic study of whole body center of mass position during gait in Parkinson's disease patients with and without festination |
000670 |
Janne Gierthmühlen [Allemagne] ; Philipp Arning [Allemagne] ; Andreas Binder [Allemagne] ; Jan Herzog [Allemagne] ; Günther Deuschl [Allemagne] ; Gunnar Wasner [Allemagne] ; Ralf Baron [Allemagne] | Influence of deep brain stimulation and levodopa on sensory signs in Parkinson's disease |
000671 |
Annu Aggarwal [Inde] ; Susanne A. Schneider [Allemagne, Royaume-Uni] ; Henry Houlden [Royaume-Uni] ; Monty Silverdale [Royaume-Uni] ; Reema Paudel [Royaume-Uni] ; Coro Paisan-Ruiz [Royaume-Uni] ; Shrinivas Desai [Inde] ; Mihir Munshi [Inde] ; Darshana Sanghvi [Inde] ; John Hardy [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni] ; Mohit Bhatt [Inde] | Indian‐subcontinent NBIA: Unusual phenotypes, novel PANK2 mutations, and undetermined genetic forms |
000673 |
E. Ray Dorsey [États-Unis] ; Lisa M. Deuel [États-Unis] ; Tiffini S. Voss [États-Unis] ; Kara Finnigan [États-Unis] ; Benjamin P. George [États-Unis] ; Sheelah Eason [États-Unis] ; David Miller [États-Unis] ; Jason I. Reminick [États-Unis] ; Anna Appler [États-Unis] ; Joyce Polanowicz [États-Unis] ; Lucy Viti [États-Unis] ; Sandy Smith [États-Unis] ; Anthony Joseph [États-Unis] ; Kevin M. Biglan [États-Unis] | Increasing access to specialty care: A pilot, randomized controlled trial of telemedicine for Parkinson's disease |
000674 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations |
000675 |
Charles H. Adler [États-Unis] ; Donald J. Connor [États-Unis] ; Joseph G. Hentz [États-Unis] ; Marwan N. Sabbagh [États-Unis] ; John N. Caviness [États-Unis] ; Holly A. Shill [États-Unis] ; Brie Noble [États-Unis] ; Thomas G. Beach [États-Unis] | Incidental Lewy body disease: Clinical comparison to a control cohort |
000676 |
Jan Linder [Suède] ; Hans Stenlund [Suède] ; Lars Forsgren [Suède] | Incidence of Parkinson's disease and parkinsonism in northern Sweden: A population‐based study |
000677 |
Yaroslav Winter [Allemagne] ; Yury Bezdolnyy [Russie] ; Elena Katunina [Russie] ; Gagik Avakjan [Russie] ; Jens P. Reese [Allemagne] ; Jens Klotsche [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Richard Dodel [Allemagne] ; Eugene Gusev [Russie] | Incidence of Parkinson's disease and atypical parkinsonism: Russian population‐based study |
000678 |
Russell C. Callaghan [Canada] ; James K. Cunningham [États-Unis] ; Gautam Sajeev [Canada] ; Stephen J. Kish [Canada] | Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders |
000682 |
Lena Kertelge [Allemagne] ; Norbert Brüggemann [Allemagne] ; Alexander Schmidt [Allemagne] ; Vera Tadic [Allemagne] ; Claudia Wisse [Allemagne] ; Sylwia Dankert [Allemagne] ; Laura Drude [Allemagne] ; Joyce Van Der Vegt [Allemagne] ; Hartwig Siebner [Allemagne] ; Heike Pawlack [Allemagne] ; Peter P. Pramstaller [Italie] ; Maria Isabel Behrens [Chili] ; Alfredo Ramirez [Allemagne] ; Dirk Reichel [Allemagne] ; Carsten Buhmann [Allemagne] ; Johann Hagenah [Allemagne] ; Christine Klein [Allemagne] ; Katja Lohmann [Allemagne] ; Meike Kasten [Allemagne] | Impaired sense of smell and color discrimination in monogenic and idiopathic Parkinson's disease |
000683 |
Myung Sik Lee [Corée du Sud] ; Chul Hyoung Lyoo [Corée du Sud] ; Myung Jun Lee [Corée du Sud] ; Jaeeun Sim [Corée du Sud] ; Hanna Cho [Corée du Sud] ; Yun Ho Choi [Corée du Sud] | Impaired finger dexterity in patients with parkinson's disease correlates with discriminative cutaneous sensory dysfunction |
000684 |
Rodger J. Elble [États-Unis] ; Oksana Suchowersky [Canada] ; Stephanie Shaftman [Canada, États-Unis] ; William J. Weiner [États-Unis] ; Peng Huang [États-Unis] ; Barbara Tilley [États-Unis] | Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease |
000685 |
Toshiharu Otaka [Japon] ; Hideki Oshima [Japon] ; Yoichi Katayama [Japon] ; Toshikazu Kano [Japon] ; Kazutaka Kobayashi [Japon] ; Yutaka Suzuki [Japon] ; Chikashi Fukaya [Japon] ; Takamitsu Yamamoto [Japon] | Impact of Subthalamic Nucleus Stimulation on Young‐Onset Parkinson's Disease |
000692 |
Seung Hun Lee [Corée du Sud] ; Mi Jung Kim [Corée du Sud] ; Beom-Jun Kim [Corée du Sud] ; Sung Reul Kim [Corée du Sud] ; Sail Chun [Corée du Sud] ; Jin Sook Ryu [Corée du Sud] ; Ghi Su Kim [Corée du Sud] ; Myoung Chong Lee [Corée du Sud] ; Jung-Min Koh [Corée du Sud] ; Sun Ju Chung [Corée du Sud] | Homocysteine‐lowering therapy or antioxidant therapy for bone loss in Parkinson's disease |
000695 |
Andrea Winquist [États-Unis] ; Kyle Steenland [États-Unis] ; Anoop Shankar [États-Unis] | Higher serum uric acid associated with decreased Parkinson's disease prevalence in a large community‐based survey |
000696 |
Inbal Maidan [Israël] ; Meir Plotnik [Israël] ; Anat Mirelman [Israël, États-Unis] ; Aner Weiss [Israël] ; Nir Giladi [Israël] ; Jeffrey M. Hausdorff [Israël, États-Unis] | Heart rate changes during freezing of gait in patients with Parkinson's disease |
000697 |
Turi O. Dalaker [États-Unis, Norvège] ; Robert Zivadinov [États-Unis] ; Jan P. Larsen [Norvège] ; Mona K. Beyer [Norvège] ; Jennifer L. Cox [États-Unis] ; Guido Alves [Norvège] ; Kolbjorn Bronnick [Norvège] ; Ole-Bjorn Tysnes [Norvège] ; Ronald Antulov [États-Unis, Croatie] ; Michael G. Dwyer [États-Unis] ; Dag Aarsland [Norvège] | Gray matter correlations of cognition in incident Parkinson's disease |
000700 |
Hyejin Hwang [États-Unis] ; Jianpeng Zhang [États-Unis] ; Kathryn A. Chung [États-Unis] ; James B. Leverenz [États-Unis] ; Cyrus P. Zabetian [États-Unis] ; Elaine R. Peskind [États-Unis] ; Joseph Jankovic [États-Unis] ; Zhen Su [États-Unis] ; Aneeka M. Hancock [États-Unis] ; Catherine Pan [États-Unis] ; Thomas J. Montine [États-Unis] ; Sheng Pan [États-Unis] ; John Nutt [États-Unis] ; Roger Albin [États-Unis] ; Marla Gearing [États-Unis] ; Richard P. Beyer [États-Unis] ; Min Shi [États-Unis] ; Jing Zhang [États-Unis] | Glycoproteomics in neurodegenerative diseases |
000701 |
Qi-Ying Sun [République populaire de Chine] ; Ji-Feng Guo [République populaire de Chine] ; Lei Wang [République populaire de Chine] ; Ren-He Yu [République populaire de Chine] ; Xing Zuo [République populaire de Chine] ; Ling-Yan Yao [République populaire de Chine] ; Qian Pan [République populaire de Chine] ; Kun Xia [République populaire de Chine] ; Bei-Sha Tang [République populaire de Chine] | Glucocerebrosidase Gene L444P mutation is a risk factor for Parkinson's disease in Chinese population |
000708 |
Rachel Saunders-Pullman [États-Unis] ; Johann Hagenah [Allemagne] ; Vijay Dhawan [États-Unis] ; Kaili Stanley [États-Unis] ; Gregory Pastores [États-Unis] ; Swati Sathe [États-Unis] ; Michele Tagliati [États-Unis] ; Kelly Condefer [États-Unis] ; Christina Palmese [États-Unis] ; Norbert Brüggemann [Allemagne] ; Christine Klein [Allemagne] ; Am Roe [États-Unis] ; Ruth Kornreich [États-Unis] ; Laurie Ozelius [États-Unis] ; Susan Bressman [États-Unis] | Gaucher disease ascertained through a Parkinson's center: Imaging and clinical characterization |
000710 |
Satoshi Kono [Japon] ; Yasuomi Ouchi [Japon] ; Tatsuhiro Terada [Japon] ; Hiroyuki Ida [Japon] ; Makiko Suzuki [Japon] ; Hiroaki Miyajima [Japon] | Functional brain imaging in glucocerebrosidase mutation carriers with and without Parkinsonism |
000711 |
Cristina Sanchez-Castaneda [Espagne] ; Ramon Rene [Espagne] ; Blanca Ramirez-Ruiz [Espagne] ; Jaume Campdelacreu [Espagne] ; Jordi Gascon [Espagne] ; Carles Falcon [Espagne] ; Matilde Calopa [Espagne] ; Serge Jauma [Espagne] ; Montserrat Juncadella [Espagne] ; Carme Junque [Espagne] | Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementia |
000712 |
Michelangelo Bartolo [Italie] ; Mariano Serrao [Italie] ; Cristina Tassorelli [Italie] ; Romildo Don [Italie] ; Alberto Ranavolo [Italie] ; Francesco Draicchio [Italie] ; Claudio Pacchetti [Italie] ; Simona Buscone [Italie] ; Armando Perrotta [Italie] ; Anna Furnari [Italie] ; Placido Bramanti [Italie] ; Luca Padua [Italie] ; Francesco Pierelli [Italie] ; Giorgio Sandrini [Italie] | Four‐week trunk‐specific rehabilitation treatment improves lateral trunk flexion in Parkinson's disease |
000714 |
Joseph H. Friedman [États-Unis] ; Guido Alves [Norvège] ; Peter Hagell [Suède] ; Johan Marinus [Pays-Bas] ; Laura Marsh [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn Stebbins [États-Unis] ; Anette Schrag [Royaume-Uni] | Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease |
000719 |
Michael Y. Shino [États-Unis] ; Valerie Mcguire [États-Unis] ; Stephen K. Van Den Eeden [États-Unis] ; Caroline M. Tanner [États-Unis] ; Rita Popat [États-Unis] ; Amethyst Leimpeter [États-Unis] ; Allan L. Bernstein [États-Unis] ; Lorene M. Nelson [États-Unis] | Familial aggregation of Parkinson's disease in a multiethnic community‐based case‐control study |
000720 |
Corey A. Lohnes [États-Unis] ; Gammon M. Earhart [États-Unis] | External validation of abbreviated versions of the activities‐specific balance confidence scale in Parkinson's disease |
000723 |
Ruksana Azhu Valappil [États-Unis] ; Jed E. Black [États-Unis] ; Meredith J. Broderick [États-Unis] ; Oscar Carrillo [États-Unis] ; Eric Frenette [Canada] ; Shannon S. Sullivan [États-Unis] ; Samuel M. Goldman [États-Unis] ; Caroline M. Tanner [États-Unis] ; James W. Langston [États-Unis] | Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease |
000725 |
David J. Brooks [Royaume-Uni] | Examining Braak's hypothesis by imaging Parkinson's disease |
000732 |
Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France] | Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease |
000735 |
Alberto J. Espay [États-Unis] ; Jennifer E. Vaughan [États-Unis] ; Connie Marras [Canada] ; Rob Fowler [Canada] ; Mark H. Eckman [États-Unis] | Early versus delayed bilateral subthalamic deep brain stimulation for parkinson's disease: A decision analysis |
000736 |
Bonnie P. Hersh [États-Unis] ; Nancy L. Earl [États-Unis] ; Robert A. Hauser [États-Unis] ; Mark Stacy [États-Unis] | Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations |
000738 |
Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas] | Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease |
000742 |
Vesna Sossi [Canada] ; Raul De La Fuente-Fernández [Canada] ; Ramachandiran Nandhagopal [Canada] ; Michael Schulzer [Canada] ; Jessamyn Mckenzie [Canada] ; Thomas J. Ruth [Canada] ; Jan O. Aasly [Norvège] ; Matthew J. Farrer [États-Unis] ; Zbigniew K. Wszolek [États-Unis] ; Jon A. Stoessl [Canada] | Dopamine turnover increases in asymptomatic LRRK2 mutations carriers |
000747 |
Nico J. Diederich [Luxembourg (pays)] ; Vannina Pieri [Luxembourg (pays)] ; Géraldine Hipp [Luxembourg (pays)] ; Olivier Rufra [Luxembourg (pays)] ; Sara Blyth [Luxembourg (pays)] ; Michel Vaillant [Luxembourg (pays)] | Discriminative power of different nonmotor signs in early Parkinson's disease. A case–control study |
000749 |
Gabriella Santangelo [Italie] ; Carmine Vitale [Italie] ; Luigi Trojano [Italie] ; Danilo De Gaspari [Italie] ; Leonilda Bilo [Italie] ; Angelo Antonini [Italie] ; Paolo Barone [Italie] | Differential neuropsychological profiles in Parkinsonian patients with or without vascular lesions |
000750 |
G. O. Skeie [Norvège] ; B. Muller [Norvège] ; K. Haugarvoll [Norvège] ; J. P. Larsen [Norvège] ; O. B. Tysnes [Norvège] | Differential effect of environmental risk factors on postural instability gait difficulties and tremor dominant Parkinson's disease |
000753 |
Anna Hussl [Autriche] ; Philipp Mahlknecht [Autriche] ; Christoph Scherfler [Autriche] ; Regina Esterhammer [Autriche] ; Michael Schocke [Autriche] ; Werner Poewe [Autriche] ; Klaus Seppi [Autriche] | Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain‐to‐pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy |
000754 |
Katsuji Kobayashi [Japon] ; Hisashi Sumiya [Japon] ; Hiroyuki Nakano [Japon] ; Noriko Akiyama [Japon] ; Katsumi Urata [Japon] ; Yoshifumi Koshino [Japon] | Detection of Lewy body disease in patients with late‐onset depression, anxiety and psychotic disorder with myocardial meta‐iodobenzylguanidine scintigraphy |
000756 |
Takeshi Inoue [Japon] ; Mayumi Kitagawa [Japon] ; Teruaki Tanaka [Japon] ; Shin Nakagawa [Japon] ; Tsukasa Koyama [Japon] | Depression and major depressive disorder in patients with Parkinson's disease |
000757 |
C. Warren Olanow [États-Unis, Italie] ; Karl Kieburtz [États-Unis] | Defining disease‐modifying therapies for PD—A road map for moving forward |
000759 |
Hengyi Rao [États-Unis, République populaire de Chine] ; Eugenia Mamikonyan [États-Unis] ; John A. Detre [États-Unis] ; Andrew D. Siderowf [États-Unis] ; Matthew B. Stern [États-Unis] ; Marc N. Potenza [États-Unis] ; Daniel Weintraub [États-Unis] | Decreased ventral striatal activity with impulse control disorders in Parkinson's disease |
000763 |
Ev De Marco [Italie] ; G. Annesi [Italie] ; P. Tarantino [Italie] ; G. Nicoletti [Italie] ; D. Civitelli [Italie] ; D. Messina [Italie] ; F. Annesi [Italie] ; G. Arabia [Italie] ; M. Salsone [Italie] ; F. Condino [Italie] ; F. Novellino [Italie] ; G. Provenzano [Italie] ; Fe Rocca [Italie] ; C. Colica [Italie] ; M. Morelli [Italie] ; V. Scornaienchi [Italie] ; V. Greco [Italie] ; L. Giofrè [Italie] ; A. Quattrone [Italie] | DJ‐1 is a Parkinson's disease susceptibility gene in southern Italy |
000765 |
Javier Virués-Ortega [Espagne] ; Carmen Rodríguez-Blázquez [Espagne] ; Federico Micheli [Argentine] ; Francisco Javier Carod-Artal [Brésil] ; Marcos Serrano-Due As [Équateur] ; Pablo Martínez-Martín [Espagne] | Cross‐cultural evaluation of the modified Parkinson Psychosis Rating Scale across disease stages |
000769 |
Pablo Arias [Espagne] ; Jamile Vivas [Espagne] ; Kenneth L. Grieve [Espagne, Royaume-Uni] ; Javier Cudeiro [Espagne] | Controlled trial on the effect of 10 days low‐frequency repetitive transcranial magnetic stimulation (rTMS) on motor signs in Parkinson's disease |
000770 |
Andrew H. Evans [Australie, Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Silke Appel Cresswell [Canada] ; Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Lees (neurologue) [Royaume-Uni] | Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti‐reward |
000771 |
Barbara Jasinska-Myga [États-Unis, Pologne] ; Jennifer Kachergus [États-Unis] ; Carles Vilari O-Güell [États-Unis] ; Christian Wider [États-Unis] ; Alexandra I. Soto-Ortolaza [États-Unis] ; Mounir Kefi [Tunisie] ; Lefkos T. Middleton [Royaume-Uni] ; Lianna Ishihara-Paul [Royaume-Uni] ; Rachel A. Gibson [Royaume-Uni] ; Rim Amouri [Tunisie] ; Samia Ben Yahmed [Tunisie] ; Samia Ben Sassi [Tunisie] ; Mourad Zouari [Tunisie] ; Ghada El Euch [Tunisie] ; Owen A. Ross [États-Unis] ; Faycal Hentati [Tunisie] ; Matthew J. Farrer [États-Unis] | Comprehensive sequencing of the LRRK2 gene in patients with familial Parkinson's disease from North Africa |
000772 |
Georg Ebersbach [Allemagne] ; Almut Ebersbach [Allemagne] ; Daniela Edler [Allemagne] ; Olaf Kaufhold [Allemagne] ; Matthias Kusch [Allemagne] ; Andreas Kupsch [Allemagne] ; Jörg Wissel [Allemagne] | Comparing exercise in Parkinson's disease—the Berlin BIG Study |
000773 |
Javier Rodríguez-Ferreiro [Espagne] ; Fernando Cuetos [Espagne] ; Elena Herrera [Espagne] ; Manuel Menéndez [Espagne] ; Renée Ribacoba [Espagne] | Cognitive impairment in Parkinson's disease without dementia |
000774 |
Karen Marder [États-Unis] | Cognitive impairment and dementia in Parkinson's disease |
000775 |
David Sulzer [États-Unis] | Clues to how alpha‐synuclein damages neurons in Parkinson's disease |
000778 |
Christian Wider [États-Unis] ; Tatiana Foroud [États-Unis] ; Zbigniew K. Wszolek [États-Unis] | Clinical implications of gene discovery in Parkinson's disease and parkinsonism |
000779 |
Marta San Luciano [États-Unis] ; Richard B. Lipton [États-Unis] ; Cuiling Wang [États-Unis] ; Mindy Katz [États-Unis] ; Molly E. Zimmerman [États-Unis] ; Amy E. Sanders [États-Unis] ; Laurie J. Ozelius [États-Unis] ; Susan B. Bressman [États-Unis] ; Rachel Saunders-Pullman [États-Unis] | Clinical expression of LRRK2 G2019S mutations in the elderly |
000782 |
Suk Yun Kang [États-Unis, Corée du Sud] ; Toshiaki Wasaka [États-Unis] ; Ejaz A. Shamim [États-Unis] ; Sungyoung Auh [États-Unis] ; Yoshino Ueki [États-Unis] ; Grisel J. Lopez [États-Unis] ; Tetsuo Kida [États-Unis] ; Seung-Hyun Jin [États-Unis] ; Nguyet Dang [États-Unis] ; Mark Hallett [États-Unis] | Characteristics of the sequence effect in Parkinson's disease |
000787 |
Mutsumi Iijima [Japon] ; Mikio Osawa [Japon] ; Mitsuru Momose [Japon] ; Tatsu Kobayakawa [Japon] ; Sachiko Saito [Japon] ; Makoto Iwata [Japon] ; Shinichiro Uchiyama [Japon] | Cardiac sympathetic degeneration correlates with olfactory function in Parkinson's disease |
000788 |
Ronald B. Postuma [Canada] ; Paola A. Lanfranchi [Canada] ; Helene Blais [Canada] ; Jean-Francois Gagnon [Canada] ; Jacques Y. Montplaisir [Canada] | Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder |
000790 |
Steven R. Schwid [États-Unis] ; Janice Bausch [États-Unis] ; David Oakes [États-Unis] ; Lynn Schuchter [États-Unis] ; Caroline Tanner [États-Unis] ; Misser Forrest [Danemark] ; Anthony E. Lang [Canada] ; Ira Shoulson [États-Unis] | Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease |
000792 |
Thomas J. Montine [États-Unis] ; Min Shi [États-Unis] ; Joseph F. Quinn [États-Unis] ; Elaine R. Peskind [États-Unis] ; Suzanne Craft [États-Unis] ; Carmen Ginghina [États-Unis] ; Kathryn A. Chung [États-Unis] ; Hojoong Kim [États-Unis] ; Douglas R. Galasko [États-Unis] ; Joseph Jankovic [États-Unis] ; Cyrus P. Zabetian [États-Unis] ; James B. Leverenz [États-Unis] ; Jing Zhang [États-Unis] | CSF Aβ42 and tau in Parkinson's disease with cognitive impairment |
000793 |
Matteo Marti [Italie] ; Silvio Sarubbo [Italie] ; Francesco Latini [Italie] ; Michele Cavallo [Italie] ; Roberto Eleopra [Italie] ; Sara Biguzzi [Italie] ; Christian Lettieri [Italie] ; Carlo Conti [Italie] ; Michele Simonato [Italie] ; Silvia Zucchini [Italie] ; Rocco Quatrale [Italie] ; Mariachiara Sensi [Italie] ; Sanzio Candeletti [Italie] ; Patrizia Romualdi [Italie] ; Michele Morari [Italie] | Brain Interstitial Nociceptin/Orphanin FQ Levels are Elevated in Parkinson's Disease |
000795 |
Janey Prodoehl [États-Unis] ; Mathew Spraker [États-Unis] ; Daniel Corcos [États-Unis] ; Cynthia Comella [États-Unis] ; David Vaillancourt [États-Unis] | Blood oxygenation level–dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's disease |
000796 |
Elisa Iacovelli [Italie] ; Francesca Gilio [Italie] ; Giuseppe Meco [Italie] ; Francesco Fattapposta [Italie] ; Nicola Vanacore [Italie] ; Livia Brusa [Italie] ; Elena Giacomelli [Italie] ; Maria Gabriele [Italie] ; Alfonso Rubino [Italie] ; Nicoletta Locuratolo [Italie] ; Cesare Iani [Italie] ; Floriana Pichiorri [Italie] ; Carlo Colosimo [Italie] ; Antonio Carbone [Italie] ; Giovanni Palleschi [Italie] ; Maurizio Inghilleri [Italie] | Bladder symptoms assessed with overactive bladder questionnaire in Parkinson's disease |
000800 |
Matthew B. Spraker [États-Unis] ; Janey Prodoehl [États-Unis] ; Daniel M. Corcos [États-Unis] ; Cynthia L. Comella [États-Unis] ; David E. Vaillancourt [États-Unis] | Basal ganglia hypoactivity during grip force in drug naïve Parkinson's disease |
000805 |
Emily Rosenthal [États-Unis] ; Laura Brennan [États-Unis] ; Sharon Xie [États-Unis] ; Howard Hurtig [États-Unis] ; Joshua Milber [États-Unis] ; Daniel Weintraub [États-Unis] ; Jason Karlawish [États-Unis] ; Andrew Siderowf [États-Unis] | Association between cognition and function in patients with Parkinson disease with and without dementia |
000807 |
Gabriella Constantinescu [Australie] ; Deborah Theodoros [Australie] ; Trevor Russell [Australie] ; Elizabeth Ward [Australie] ; Stephen Wilson [Australie] ; Richard Wootton [Royaume-Uni] | Assessing disordered speech and voice in Parkinson's disease: a telerehabilitation application |
000809 |
Petra Schwingenschuh [Royaume-Uni, Autriche] ; Petra Katschnig [Royaume-Uni, Autriche] ; Ronald Saurugg [Autriche] ; Erwin Ott [Autriche] ; Kailash P. Bhatia [Royaume-Uni] | Artistic profession: A potential risk factor for dopamine dysregulation syndrome in Parkinson's disease? |
000813 |
James H. Bower [États-Unis] ; Brandon R. Grossardt [États-Unis] ; Demetrius M. Maraganore [États-Unis] ; J. Eric Ahlskog [États-Unis] ; Robert C. Colligan [États-Unis] ; Yonas E. Geda [États-Unis] ; Terry M. Therneau [États-Unis] ; Walter A. Rocca [États-Unis] | Anxious personality predicts an increased risk of Parkinson's disease |
000814 |
Nadeeka N. W. Dissanayaka [Australie] ; Anna Sellbach [Australie] ; Sally Matheson [Australie] ; John D. O'Sullivan [Australie] ; Peter A. Silburn [Australie] ; Gerard J. Byrne [Australie] ; Rodney Marsh [Australie] ; George D. Mellick [Australie] | Anxiety disorders in Parkinson's disease: Prevalence and risk factors |
000816 |
Lorena De Mena [Espagne] ; Eliecer Coto [Espagne] ; Lucía F. Cardo [Espagne] ; Marta Díaz [Espagne] ; Marta Blázquez [Espagne] ; René Ribacoba [Espagne] ; Carlos Salvador [Espagne] ; Pau Pastor [Espagne] ; Lluis Samaranch [Espagne] ; Germán Moris [Espagne] ; Manuel Menéndez [Espagne] ; Ana I. Corao [Espagne] ; Victoria Alvarez [Espagne] | Analysis of the Micro‐RNA‐133 and PITX3 genes in Parkinson's disease |
000818 |
Gennarina Arabia [Italie] ; Maurizio Morelli [Italie] ; Sandra Paglionico [Italie] ; Fabiana Novellino [Italie] ; Maria Salsone [Italie] ; Laura Giofrè [Italie] ; Giusi Torchia [Italie] ; Giuseppe Nicoletti [Italie] ; Demetrio Messina [Italie] ; Francesca Condino [Italie] ; Pierluigi Lanza [Italie] ; Olivier Gallo [Italie] ; Aldo Quattrone [Italie] | An magnetic resonance imaging T2*‐weighted sequence at short echo time to detect putaminal hypointensity in Parkinsonisms |
000820 |
Erin R. Foster [États-Unis] ; Meghan C. Campbell [États-Unis] ; Michelle A. Burack [États-Unis] ; Johanna Hartlein [États-Unis] ; Hubert P. Flores [États-Unis] ; Nigel J. Cairns [États-Unis] ; Tamara Hershey [États-Unis] ; Joel S. Perlmutter [États-Unis] | Amyloid imaging of Lewy body‐associated disorders |
000823 |
Stephen Ku [États-Unis] ; Graham A. Glass [États-Unis] | Age of Parkinson's disease onset as a predictor for the development of dyskinesia |
000824 |
Caroline M. Tanner [États-Unis] | Advances in environmental epidemiology |
000833 |
Kelvin L. Chou [États-Unis] ; Melissa M. Amick [États-Unis] ; Jason Brandt [États-Unis] ; Richard Camicioli [Canada] ; Karen Frei [États-Unis] ; Darren Gitelman [États-Unis] ; Jennifer Goldman [États-Unis] ; John Growdon [États-Unis] ; Howard I. Hurtig [États-Unis] ; Bonnie Levin [États-Unis] ; Irene Litvan [États-Unis] ; Laura Marsh [États-Unis] ; Tanya Simuni [États-Unis] ; Alexander I. Tröster [États-Unis] ; Ergun Y. Uc [États-Unis] | A recommended scale for cognitive screening in clinical trials of Parkinson's disease |
000835 |
Michael D. Sage [Canada] ; Quincy J. Almeida [Canada] | A positive influence of vision on motor symptoms during sensory attention focused exercise for Parkinson's disease |
000838 |
Kerstin Ziegler [Allemagne] ; Frauke Schroeteler [Allemagne] ; Andres O. Ceballos-Baumann [Allemagne] ; Urban M. Fietzek [Allemagne] | A new rating instrument to assess festination and freezing gait in Parkinsonian patients |
000839 |
François Vacherot [France] ; Shahram Attarian [France] ; Marianne Vaugoyeau [France] ; Jean-Philippe Azulay [France] | A motor cortex excitability and gait analysis on Parkinsonian patients |
000840 |
C. Savio Chan [États-Unis] ; Tracy S. Gertler [États-Unis] ; D. James Surmeier [États-Unis] | A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease |
000846 |
E. Ray Dorsey [États-Unis] ; Tiffini S. Voss [États-Unis] ; David R. Shprecher [États-Unis] ; Lisa M. Deuel [États-Unis] ; Christopher A. Beck [États-Unis] ; Irenita F. Gardiner [États-Unis] ; Margaret A. Coles [États-Unis] ; Richard S. Burns [États-Unis] ; Frederick J. Marshall [États-Unis] ; Kevin M. Biglan [États-Unis] | A U.S. survey of patients with Parkinson's disease: Satisfaction with medical care and support groups |
000847 |
Young Seok Park ; Hae Yoo Kim ; Won Seok Chang ; Phil Hyu Lee [Corée du Sud] ; Young Ho Sohn [Corée du Sud] ; Jin Woo Chang | A Comparison of LEDD and Motor Scores Following STN‐DBS Treatment in Patient with Young Onset vs. Late Onset Parkinson's Disease |
000907 |
Balaji S. Srinivasan [États-Unis] ; Jaleh Doostzadeh [États-Unis] ; Farnaz Absalan [États-Unis] ; Sharareh Mohandessi [États-Unis] ; Roxana Jalili [États-Unis] ; Saharnaz Bigdeli [États-Unis] ; Justin Wang [États-Unis] ; Jaydev Mahadevan [États-Unis] ; Caroline L. G. Lee [Singapour] ; Ronald W. Davis [États-Unis] ; J. William Langston [États-Unis] ; Mostafa Ronaghi [États-Unis] | Whole genome survey of coding SNPs reveals a reproducible pathway determinant of Parkinson disease |
000908 |
Carles Gaig [Espagne] ; Eduardo Tolosa [Espagne] | When does Parkinson's disease begin? |
000909 |
Berend Arnold Ploeger [Pays-Bas] ; Nicholas H. G. Holford [Nouvelle-Zélande] | Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis |
000910 |
Cory L. Christiansen [États-Unis] ; Margaret L. Schenkman [États-Unis] ; Kim Mcfann [États-Unis] ; Pamela Wolfe [États-Unis] ; Wendy M. Kohrt [États-Unis] | Walking economy in people with Parkinson's disease |
000911 |
Simone Guglielmetti [Italie] ; Antonio Nardone [Italie] ; Alessandro Marco De Nunzio [Italie] ; Marco Godi [Italie] ; Marco Schieppati [Italie] | Walking along circular trajectories in Parkinson's disease |
000913 |
Zein M. Sammour [Brésil] ; Cristiano M. Gomes [Brésil] ; Egberto R. Barbosa ; Roberto I. Lopes [Brésil] ; Flávio S. Sallem ; Flavio E. Trigo-Rocha [Brésil] ; Homero Bruschini [Brésil] ; Miguel Srougi [Brésil] | Voiding dysfunction in patients with Parkinson's disease: Impact of neurological impairment and clinical parameters |
000914 |
James R. Williams [États-Unis] ; Laura Marsh [États-Unis] | Validity of the Cornell scale for depression in dementia in Parkinson's disease with and without cognitive impairment |
000915 |
Nir Giladi [Israël] ; Joseph Tal [Israël] ; Tali Azulay [Israël] ; Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Eldad Melamed [Israël] ; Wolfgang Oertel [Allemagne] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne] | Validation of the freezing of gait questionnaire in patients with Parkinson's disease |
000920 |
Leon Poltawski [Royaume-Uni] ; Hazel Edwards [Royaume-Uni] ; Amy Todd [Royaume-Uni] ; Tim Watson [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Cherry Ann James [Royaume-Uni] | Ultrasound treatment of cutaneous side‐effects of infused apomorphine: A randomized controlled pilot study |
000921 |
Madaline B. Harrison [États-Unis] ; Scott A. Wylie [États-Unis] ; Robert C. Frysinger [États-Unis] ; James T. Patrie [États-Unis] ; Diane S. Huss [États-Unis] ; Lillian J. Currie [États-Unis] ; G. Frederick Wooten [États-Unis] | UPDRS activity of daily living score as a marker of Parkinson's disease progression |
000922 |
Han-Joon Kim [Corée du Sud] ; Sun Ha Paek [Corée du Sud] ; Ji-Young Kim [Corée du Sud] ; Jee-Young Lee [Corée du Sud] ; Yong Hoon Lim [Corée du Sud] ; Dong Gyu Kim [Corée du Sud] ; Beom S. Jeon [Corée du Sud] | Two‐year follow‐up on the effect of unilateral subthalamic deep brain stimulation in highly asymmetric Parkinson's disease |
000926 |
Chen [États-Unis] ; Swope [États-Unis] ; Dashtipour [États-Unis] ; Lyons [États-Unis] | Transdermal Rotigotine: A Clinically Innovative Dopamine‐Receptor Agonist for the Management of Parkinson's Disease |
000930 |
Laura Silveira-Moriyama [Royaume-Uni] ; Aviva Petrie [Royaume-Uni] ; David R. Williams [Australie] ; Andrew Evans [Australie] ; Regina Katzenschlager [Autriche] ; Egberto R. Barbosa [Brésil] ; Andrew Lees (neurologue) [Royaume-Uni] | The use of a color coded probability scale to interpret smell tests in suspected parkinsonism |
000934 |
Matthew Menza [États-Unis] ; Roseanne Defronzo Dobkin [États-Unis] ; Humberto Marin [États-Unis] ; Margery H. Mark [États-Unis] ; Michael Gara [États-Unis] ; Steven Buyske [États-Unis] ; Karina Bienfait [États-Unis] ; Allison Dicke [États-Unis] | The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease |
000936 |
Patrick A. Lewis [Royaume-Uni] | The function of ROCO proteins in health and disease |
000938 |
Bernard Ravina [États-Unis] ; Jordan Elm [États-Unis] ; Richard Camicioli [Canada] ; Peter G. Como [États-Unis] ; Laura Marsh [États-Unis] ; Joseph Jankovic [États-Unis] ; Daniel Weintraub [États-Unis] | The course of depressive symptoms in early Parkinson's disease |
000939 |
Pablo Martínez-Martín [Espagne] ; Carmen Rodríguez-Blázquez [Espagne] ; Maria João Forjaz [Espagne] ; Jesús De Pedro [Espagne] | The clinical impression of severity index for Parkinson's disease: International validation study |
000942 |
Paolo Barone [Italie] ; Angelo Antonini [Italie] ; Carlo Colosimo [Italie] ; Roberto Marconi [Italie] ; Letterio Morgante [Italie] ; Tania P. Avarello [Italie] ; Eugenio Bottacchi [Italie] ; Antonino Cannas [Italie] ; Gabriella Ceravolo [Italie] ; Roberto Ceravolo [Italie] ; Giulio Cicarelli [Italie] ; Roberto M. Gaglio [Italie] ; Rosa M. Giglia [Italie] ; Francesco Iemolo [Italie] ; Michela Manfredi [Italie] ; Giuseppe Meco [Italie] ; Alessandra Nicoletti [Italie] ; Massimo Pederzoli [Italie] ; Alfredo Petrone [Italie] ; Antonio Pisani [Italie] ; Francesco E. Pontieri [Italie] ; Rocco Quatrale [Italie] ; Silvia Ramat [Italie] ; Rosanna Scala [Italie] ; Giuseppe Volpe [Italie] ; Salvatore Zappulla [Italie] ; Anna Rita Bentivoglio [Italie] ; Fabrizio Stocchi [Italie] ; Giorgio Trianni [Italie] ; Paolo Del Dotto [Italie] | The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease |
000944 |
Paolo Mazzone [Italie] ; Angelo Insola [Italie] ; Stefano Sposato ; Eugenio Scarnati [Italie] | The Deep Brain Stimulation of the Pedunculopontine Tegmental Nucleus |
000946 |
Kevin M. Biglan [États-Unis] ; Tiffini S. Voss [États-Unis] ; Lisa M. Deuel [États-Unis] ; David Miller [États-Unis] ; Sheelah Eason [États-Unis] ; Maria Fagnano [États-Unis] ; Benjamin P. George [États-Unis] ; Anna Appler [États-Unis] ; Joyce Polanowicz [États-Unis] ; Lucy Viti [États-Unis] ; Sandy Smith [États-Unis] ; Anthony Joseph [États-Unis] ; E. Ray Dorsey [États-Unis] | Telemedicine for the care of nursing home residents with Parkinson's disease |
000950 |
Michael D. Sage [Canada] ; Quincy J. Almeida [Canada] | Symptom and gait changes after sensory attention focused exercise vs aerobic training in Parkinson's disease |
000952 |
Daniel A. Nation [États-Unis] ; Heather L. Katzen [États-Unis] ; Spyridon Papapetropoulos [États-Unis] ; Blake K. Scanlon [États-Unis] ; Bonnie E. Levin [États-Unis] | Subthreshold depression in Parkinson's disease |
000954 |
David Weise [Allemagne] ; Reinhard Lorenz [Allemagne] ; Mira Schliesser [Allemagne] ; Andreas Schirbel [Allemagne] ; Karlheinz Reiners [Allemagne] ; Joseph Classen [Allemagne] | Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease |
000959 |
Addy [États-Unis] ; Assaid [États-Unis] ; Hreniuk [États-Unis] ; Stroh [États-Unis] ; Xu [États-Unis] ; Herring [États-Unis] ; Ellenbogen [États-Unis] ; Jinnah [États-Unis] ; Kirby [États-Unis] ; Leibowitz [États-Unis] ; Stewart [États-Unis] ; Tarsy [États-Unis] ; Tetrud [États-Unis] ; Stoch [États-Unis] ; Gottesdiener [États-Unis] ; Wagner [États-Unis] | Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease |
000962 |
Susan H. Fox [Canada] ; Rosalind Chuang [Canada] ; Jonathan M. Brotchie [Canada] | Serotonin and Parkinson's disease: On movement, mood, and madness |
000965 |
Xin Yang [Belgique] ; Birgit Mertens [Belgique] ; Enni Lehtonen [Belgique] ; Linda Vercammen [Belgique] ; Olivier Bockstael [Belgique] ; Abdelwahed Chtarto [Belgique] ; Marc Levivier [Belgique, Suisse] ; Jacques Brotchi [Belgique] ; Yvette Michotte [Belgique] ; Veerle Baekelandt [Belgique] ; Sophie Sarre [Belgique] ; Liliane Tenenbaum [Belgique] | Reversible neurochemical changes mediated by delayed intrastriatal glial cell line‐derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model |
000967 |
Nadège Limousin [France] ; Eric Konofal [France] ; Elias Karroum [France] ; Ebba Lohmann [France] ; Ioannis Theodorou [France] ; Alexandra Dürr [France] ; Isabelle Arnulf [France] | Restless legs syndrome, rapid eye movement sleep behavior disorder, and hypersomnia in patients with two parkin mutations |
000969 |
Kelly Claire Simon [États-Unis] ; Honglei Chen [États-Unis] ; Xiang Gao [États-Unis] ; Michael A. Schwarzschild [États-Unis] ; Alberto Ascherio [États-Unis] | Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease |
000970 |
Luigi M. Romito [Italie] ; Maria Fiorella Contarino [Italie] ; Nicola Vanacore [Italie] ; Anna Rita Bentivoglio [Italie] ; Massimo Scerrati [Italie] ; Alberto Albanese [Italie] | Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: Long‐term observation |
000971 |
Saša R. Filipovi [Royaume-Uni] ; John C. Rothwell [Royaume-Uni] ; Bart P. Van De Warrenburg [Royaume-Uni, Pays-Bas] ; Kailash Bhatia [Royaume-Uni] | Repetitive transcranial magnetic stimulation for levodopa‐induced dyskinesias in Parkinson's disease |
000972 |
Chengwu Yang [États-Unis] ; Elizabeth Garrett-Mayer [États-Unis] ; Jay S. Schneider [États-Unis] ; Stephen M. Gollomp [États-Unis] ; Barbara C. Tilley [États-Unis] | Repeatable battery for assessment of neuropsychological status in early Parkinson's disease |
000973 |
Linda Truong [Australie] ; Daniel Brooks [Australie] ; Fabricio Amaral [Australie] ; Jasmine M. Henderson [Australie] ; Glenda M. Halliday [Australie] | Relative preservation of thalamic centromedian nucleus in parkinsonian patients with dystonia |
000974 |
Giuseppe Frazzitta [Italie] ; Roberto Maestri [Italie] ; Davide Uccellini [Italie] ; Gabriella Bertotti [Italie] ; Paola Abelli [Italie] | Rehabilitation treatment of gait in patients with Parkinson's disease with freezing: A comparison between two physical therapy protocols using visual and auditory cues with or without treadmill training |
000976 |
Stephanie Louie [États-Unis] ; Mandy Miller Koop [États-Unis] ; Anna Frenklach [États-Unis] ; Helen Bronte-Stewart [États-Unis] | Quantitative lateralized measures of bradykinesia at different stages of Parkinson's disease: The role of the less affected side |
000977 |
Dagmar Verbaan [Pays-Bas] ; Stephanie M. Van Rooden [Pays-Bas] ; Martine Visser [Pays-Bas] ; Johan Marinus [Pays-Bas] ; Murat Emre [Turquie] ; Jacobus J. Van Hilten [Pays-Bas] | Psychotic and compulsive symptoms in Parkinson's disease |
000978 |
Florindo Stella [Brésil] ; Claudio E. M. Banzato [Brésil] ; Elizabeth M. A. Barasnevicius Quagliato [Brésil] ; Maura Aparecida Viana [Brésil] ; Gustavo Christofoletti [Brésil] | Psychopathological features in patients with Parkinson's disease and related caregivers' burden |
000979 |
Carmen Rodriguez-Blazquez [Espagne] ; Belen Frades-Payo [Espagne] ; Maria João Forjaz [Espagne] ; Jesus De Pedro-Cuesta [Espagne] ; Pablo Martinez-Martin [Espagne] | Psychometric attributes of the Hospital Anxiety and Depression Scale in Parkinson's disease |
000980 |
Eleanor J. Davison [Royaume-Uni] ; Kyla Pennington [Royaume-Uni] ; Chao-Chun Hung [Royaume-Uni] ; Jianhe Peng [Royaume-Uni] ; Rumana Rafiq [Royaume-Uni] ; Antje Ostareck-Lederer [Allemagne] ; Dirk H. Ostareck [Allemagne] ; Helen C. Ardley [Royaume-Uni] ; Rosamonde E. Banks [Royaume-Uni] ; Philip A. Robinson [Royaume-Uni] | Proteomic analysis of increased Parkin expression and its interactants provides evidence for a role in modulation of mitochondrial function |
000982 |
Sabine Skodda [Allemagne] ; Heiko Rinsche [Allemagne] ; Uwe Schlegel [Allemagne] | Progression of dysprosody in Parkinson's disease over time—A longitudinal study |
000988 |
Gregory M. Pontone [États-Unis] ; James R. Williams [États-Unis] ; Karen E. Anderson [États-Unis] ; Gary Chase [États-Unis] ; Susanne A. Goldstein [États-Unis] ; Stephen Grill [États-Unis] ; Elaina S. Hirsch [États-Unis] ; Susan Lehmann [États-Unis] ; John T. Little [États-Unis] ; Russell L. Margolis [États-Unis] ; Peter V. Rabins [États-Unis] ; Howard D. Weiss [États-Unis] ; Laura Marsh [États-Unis] | Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease |
000990 |
Norbert Schuff [États-Unis] | Potential role of high‐field MRI for studies in Parkinson's disease |
000993 |
William K. Gray [Royaume-Uni] ; Anthony Hildreth [Royaume-Uni] ; Julie A. Bilclough [Royaume-Uni] ; Brian H. Wood [Royaume-Uni] ; Katherine Baker [Royaume-Uni] ; Richard W. Walker [Royaume-Uni] | Physical assessment as a predictor of mortality in people with Parkinson's disease: A study over 7 years |
000996 |
David Devos [France] | Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease |
000997 |
Terri K. Pogoda [États-Unis] ; Irene E. Cramer [États-Unis] ; Mark Meterko [États-Unis] ; Hai Lin [États-Unis] ; Ann Hendricks [États-Unis] ; Robert G. Holloway [États-Unis] ; Martin P. Charns [États-Unis] | Patient and organizational factors related to education and support use by Veterans with Parkinson's disease |
000A00 |
Ichraf Kraoua [France] ; Jérôme Stirnemann [France] ; Maria João Ribeiro [France] ; Tiphaine Rouaud [France] ; Marc Verin [France] ; Agnès Annic [France] ; Christian Rose [France] ; Luc Defebvre [France] ; Liliane Réménieras [France] ; Michaël Schüpbach [France] ; Nadia Belmatoug [France] ; Marie Vidailhet [France] ; Frédéric Sedel [France] | Parkinsonism in Gaucher's disease type 1: Ten new cases and a review of the literature |
000A01 |
Vicky L. Marshall [Royaume-Uni] ; Cornelia B. Reininger [Allemagne] ; Moritz Marquardt [Allemagne] ; Jim Patterson [Royaume-Uni] ; Donald M. Hadley [Royaume-Uni] ; Wolfgang H. Oertel [Allemagne] ; Hani T. S. Benamer [Royaume-Uni] ; Paul Kemp [Royaume-Uni] ; David Burn [Royaume-Uni] ; Eduardo Tolosa [Espagne] ; Jamie Kulisevsky [Espagne] ; Luis Cunha [Portugal] ; Durval Costa [Portugal] ; Jan Booij [Pays-Bas] ; Klaus Tatsch [Allemagne] ; K. Ray Chaudhuri [Royaume-Uni] ; Gudrun Ulm [Allemagne] ; Oliver Pogarell [Allemagne] ; Helmut Höffken [Allemagne] ; Anja Gerstner [Allemagne] ; Donald G. Grosset [Royaume-Uni] | Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3‐year European multicenter study with repeat [123I]FP‐CIT SPECT |
000A02 |
Arja Mainio [Finlande] ; Kaisa Karvonen [Finlande] ; Helin Hakko [Finlande] ; Terttu S Rkioja [Finlande] ; Pirkko R S Nen [Finlande] | Parkinson's disease and suicide: a profile of suicide victims with Parkinson's disease in a population‐based study during the years 1988–2002 in Northern Finland |
000A03 |
Christopher H. Hawkes [Royaume-Uni] ; Kelly Del Tredici [Allemagne] ; Heiko Braak [Allemagne] | Parkinson's Disease |
000A04 |
Ingrid Pretzer-Aboff [États-Unis] ; Elizabeth Galik ; Barbara Resnick [États-Unis] | Parkinson's Disease: Barriers and Facilitators to Optimizing Function |
000A05 |
Marco D'Amelio [Italie] ; Paolo Ragonese [Italie] ; Gabriella Sconzo [Italie] ; Paolo Aridon [Italie] ; Giovanni Savettieri [Italie] | Parkinson's Disease and Cancer |
000A08 |
Clecio Godeiro-Junior [Brésil] ; Patricia M. De Carvalho-Aguiar [Brésil] ; Andre C. Felício [Brésil] ; Orlando G. P. Barsottini [Brésil] ; Sonia M. A. Silva [Brésil] ; Vanderci Borges [Brésil] ; Luiz Augusto F. Andrade [Brésil] ; Henrique Ballalai Ferraz [Brésil] | PINK1 mutations in a Brazilian cohort of early‐onset Parkinson's disease patients |
000A10 |
Maarit Matinolli [Finlande] ; Juha T. Korpelainen [Finlande] ; Raija Korpelainen [Finlande] ; Kyösti A. Sotaniemi [Finlande] ; Vilho V. Myllyl [Finlande] | Orthostatic hypotension, balance and falls in Parkinson's disease |
000A12 |
Alessandro Ferraris [Italie] ; Tamara Ialongo [Italie] ; Giulio Cesare Passali [Italie] ; Maria Teresa Pellecchia [Italie] ; Livia Brusa [Italie] ; Marianna Laruffa [Italie] ; Arianna Guidubaldi [Italie] ; Gaetano Paludetti [Italie] ; Alberto Albanese [Italie] ; Paolo Barone [Italie] ; Bruno Dallapiccola [Italie] ; Enza Maria Valente [Italie] ; Anna Rita Bentivoglio [Italie] | Olfactory dysfunction in Parkinsonism caused by PINK1 mutations |
000A13 |
Tomoyuki Miyamoto [Japon] ; Masayuki Miyamoto [Japon] ; Masaoki Iwanami [Japon] ; Keisuke Suzuki [Japon] ; Yuichi Inoue [Japon] ; Koichi Hirata [Japon] | Odor identification test as an indicator of idiopathic REM sleep behavior disorder |
000A14 |
Hiroki Takeuchi [Japon] ; Takashi Yanagida [Japon] ; Masatoshi Inden [Japon] ; Kazuyuki Takata [Japon] ; Yoshihisa Kitamura [Japon] ; Kentaro Yamakawa [Japon] ; Hideyuki Sawada [Japon] ; Yasuhiko Izumi [Japon] ; Noriyuki Yamamoto [Japon] ; Takeshi Kihara [Japon] ; Kengo Uemura [Japon] ; Haruhisa Inoue [Japon] ; Takashi Taniguchi [Japon] ; Akinori Akaike [Japon] ; Ryosuke Takahashi [Japon] ; Shun Shimohama [Japon] | Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone‐induced Parkinson's disease models |
000A17 |
Dag Aarsland [Norvège, Royaume-Uni] ; Laura Marsh [États-Unis] ; Anette Schrag [Royaume-Uni] | Neuropsychiatric symptoms in Parkinson's disease |
000A18 |
You-Joung Kim [Corée du Sud] ; Hyun-Jung Park [Corée du Sud] ; Gwang Lee [Corée du Sud] ; Oh Young Bang [Corée du Sud] ; Young Hwan Ahn [Corée du Sud] ; Eunhye Joe [Corée du Sud] ; Hyun Ok Kim [Corée du Sud] ; Phil Hyu Lee [Corée du Sud] | Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti‐inflammatory action |
000A19 |
Robert G. Hart [États-Unis] ; Lesly A. Pearce [États-Unis] ; Bernard M. Ravina [États-Unis] ; Toby C. Yaltho [États-Unis] ; John R. Marler [États-Unis] | Neuroprotection trials in Parkinson's disease: Systematic review |
000A23 |
Mélissa Tir [France] ; Christine Delmaire [France] ; Vianney Le Thuc [France] ; Alain Duhamel [France] ; Alain Destée [France] ; Jean-Pierre Pruvo [France] ; Luc Defebvre [France] | Motor‐related circuit dysfunction in MSA‐P: Usefulness of combined whole‐brain imaging analysis |
000A24 |
Stephanie M. Van Rooden [Pays-Bas] ; Martine Visser [Pays-Bas] ; Dagmar Verbaan [Pays-Bas] ; Johan Marinus [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas] | Motor patterns in Parkinson's disease: A data‐driven approach |
000A25 |
Sebastian Paus [Allemagne] ; Franziska Gadow [Allemagne] ; Michael Knapp [Allemagne] ; Christine Klein [Allemagne] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne] | Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism |
000A26 |
Horng-Huei Liou [Taïwan] ; Chia-Yun Wu ; Yueh-Hsia Chiu ; Amy Ming-Fang Yen ; Rong-Chi Chen [Taïwan] ; Ta-Fu Chen ; Chih-Chuan Chen [Taïwan] ; Yuarn-Chung Hwang [Taïwan] ; Ying-Rong Wen [Taïwan] ; Tony Hsiu-Hsi Chen [Taïwan] | Mortality of Parkinson's disease by Hoehn–Yahr stage from community‐based and clinic series [Keelung Community‐based Integrated Screening (KCIS) no. 17)] |
000A27 |
Anja Diem-Zangerl [Autriche] ; Klaus Seppi [Autriche] ; Gregor K. Wenning [Autriche] ; Eugen Trinka [Autriche] ; Gerhard Ransmayr [Autriche] ; Wilhelm Oberaigner [Autriche] ; Werner Poewe [Autriche] | Mortality in Parkinson's disease: A 20‐year follow‐up study |
000A28 |
Sarra Nazem [États-Unis] ; Andrew D. Siderowf [États-Unis] ; John E. Duda [États-Unis] ; Tom Ten Have [États-Unis] ; Amy Colcher [États-Unis] ; Stacy S. Horn [États-Unis] ; Paul J. Moberg [États-Unis] ; Jayne R. Wilkinson [États-Unis] ; Howard I. Hurtig [États-Unis] ; Matthew B. Stern [États-Unis] ; Daniel Weintraub [États-Unis] | Montreal Cognitive Assessment Performance in Patients with Parkinson's Disease with “Normal” Global Cognition According to Mini‐Mental State Examination Score |
000A32 |
Prachi Mehta [Australie] ; George D. Mellick [Australie] ; Dominic B. Rowe [Australie] ; Glenda M. Halliday [Australie] ; Michael M. Jones [Australie] ; Neil Manwaring [Australie] ; Himesha Vandebona [Australie] ; Peter A. Silburn [Australie] ; Jie Jin Wang [Australie] ; Paul Mitchell [Australie] ; Carolyn M. Sue [Australie] | Mitochondrial DNA haplogroups J and K are not protective for Parkinson's disease in the Australian community |
000A34 |
David Maltête [France] ; Nathalie Chastan [France] ; Stéphane Derrey [France] ; Bertrand Debono [France] ; Emmanuel Gérardin [France] ; Romain Lefaucheur [France] ; Bruno Mihout [France] ; Didier Hannequin [France] | Microsubthalamotomy effect at day 3: Screening for determinants |
000A36 |
Shigeki Hirano [États-Unis, Japon] ; Thomas Eckert [États-Unis, Allemagne] ; Toni Flanagan [États-Unis] ; David Eidelberg [États-Unis] | Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease |
000A37 |
Bart F. L. Van Nuenen [Pays-Bas, Allemagne] ; Thilo Van Eimeren [Canada] ; Joyce P. M. Van Der Vegt [Pays-Bas, Allemagne] ; Carsten Buhmann [Allemagne] ; Christine Klein [Allemagne] ; Bastiaan R. Bloem [Pays-Bas] ; Hartwig R. Siebner [Allemagne, Danemark] | Mapping preclinical compensation in Parkinson's disease: An imaging genomics approach |
000A39 |
Michela Barichella [Italie] ; Emanuele Cereda [Italie] ; Gianni Pezzoli [Italie] | Major nutritional issues in the management of Parkinson's disease |
000A40 |
Naroa Ibarretxe-Bilbao [Espagne] ; Eduardo Tolosa [Espagne] ; Carme Junque [Espagne] ; Maria-Jose Marti [Espagne] | MRI and cognitive impairment in Parkinson's disease |
000A41 |
Eun Joo Chung [Corée du Sud] ; Won Yong Lee [Corée du Sud] ; Won Tae Yoon [Corée du Sud] ; Byeong Joon Kim [Corée du Sud] ; Gyeong Han Lee [Corée du Sud] | MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism‐predominant multiple system atrophy |
000A43 |
Robert A. Hauser [États-Unis] ; Mark F. Lew [États-Unis] ; Howard I. Hurtig [États-Unis] ; William G. Ondo [États-Unis] ; Joanne Wojcieszek [États-Unis] ; Cheryl J. Fitzer-Attas [Israël] | Long‐term outcome of early versus delayed rasagiline treatment in early Parkinson's disease |
000A47 |
Robert A. Hauser [États-Unis] ; Peggy Auinger [États-Unis] ; David Oakes [États-Unis] | Levodopa response in early Parkinson's disease |
000A49 |
Payal N. Gandhi [États-Unis] ; Shu G. Chen [États-Unis] ; Amy L. Wilson-Delfosse [États-Unis] | Leucine‐rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease |
000A51 |
Jonathan Kimmelman [Canada, États-Unis] ; Alex John London [États-Unis] ; Bernard Ravina [États-Unis] ; Tim Ramsay [Canada] ; Mark Bernstein [Canada] ; Alan Fine [Canada] ; Frank W. Stahnisch [Canada] ; Marina Elena Emborg [États-Unis] | Launching invasive, first‐in‐human trials against Parkinson's disease: Ethical considerations |
000A55 |
Zijuan Zhang [République populaire de Chine] ; Jean-Marc Burgunder [République populaire de Chine, Suisse, Singapour] ; Xingkai An [République populaire de Chine] ; Yan Wu [République populaire de Chine] ; Wenjun Chen [République populaire de Chine] ; Jinhong Zhang [République populaire de Chine] ; Yingcheng Wang [République populaire de Chine] ; Yanming Xu [République populaire de Chine] ; Yingru Gou [République populaire de Chine] ; Guanggu Yuan [République populaire de Chine] ; Xueye Mao [République populaire de Chine] ; Rong Peng [République populaire de Chine] | LRRK2 R1628P variant is a risk factor of Parkinson's disease among Han‐Chinese from mainland China |
000A56 |
Roy Elbers [Pays-Bas] ; Erwin E. H. Van Wegen [Pays-Bas] ; Lynn Rochester [Royaume-Uni] ; Victoria Hetherington [Royaume-Uni] ; Alice Nieuwboer [Belgique] ; Anne-Marie Willems [Belgique] ; Diana Jones [Royaume-Uni] ; Gert Kwakkel [Pays-Bas] | Is impact of fatigue an independent factor associated with physical activity in patients with idiopathic Parkinson's disease? |
000A57 |
Michael Niehues [Allemagne] ; Hensel [Allemagne] | In‐vitro interaction of l‐dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability? |
000A58 |
Holger Honig [Allemagne] ; Angelo Antonini [Italie] ; Pablo Martinez-Martin [Espagne] ; Ian Forgacs [Royaume-Uni] ; Guy C. Faye [Royaume-Uni] ; Thomas Fox [Allemagne] ; Karen Fox [Allemagne] ; Francesca Mancini [Italie] ; Margherita Canesi [Italie] ; Per Odin [Allemagne] ; K. Ray Chaudhuri [Royaume-Uni] | Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life |
000A62 |
Andrew H. Evans [Australie] ; Antonio P. Strafella [Canada] ; Daniel Weintraub [États-Unis] ; Mark Stacy [États-Unis] | Impulsive and compulsive behaviors in Parkinson's disease |
000A63 |
Erik L. Johnsen [Danemark] ; Poul H. Mogensen [Danemark] ; Niels Aa. Sunde [Danemark] ; Karen Stergaard [Danemark] | Improved asymmetry of gait in Parkinson's disease with DBS: Gait and postural instability in Parkinson's disease treated with bilateral deep brain stimulation in the subthalamic nucleus |
000A65 |
Ronald B. Postuma [Canada] ; Jean-Francois Gagnon [Canada] ; Melanie Vendette [Canada] ; Jacques Y. Montplaisir [Canada] | Idiopathic REM sleep behavior disorder in the transition to degenerative disease |
000A66 |
Stefano Zoccolella [Italie] ; Claudia Dell'Aquila [Italie] ; Giovanni Abruzzese [Italie] ; Angelo Antonini [Italie] ; Ubaldo Bonuccelli [Italie] ; Margherita Canesi [Italie] ; Silvano Cristina [Italie] ; Roberta Marchese [Italie] ; Claudio Pacchetti [Italie] ; Roberto Zagaglia [Italie] ; Giancarlo Logroscino [Italie] ; Giovanni Defazio [Italie] ; Paolo Lamberti [Italie] ; Paolo Livrea [Italie] | Hyperhomocysteinemia in levodopa‐treated patients with Parkinson's disease dementia |
000A67 |
Thomas Müller [Allemagne] ; Wilfried Kuhn [Allemagne] | Homocysteine levels after acute levodopa intake in patients with Parkinson's disease |
000A68 |
Richard M. Camicioli ; Thomas P. Bouchard ; Martin J. Somerville [Canada] | Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients |
000A69 |
Maria C. Rodriguez-Oroz [Espagne] ; Pablo Martínez Lage [Espagne] ; Jose Sanchez-Mut [Espagne] ; Isabel Lamet [Espagne] ; Javier Pagonabarraga [Espagne] ; Jon B. Toledo [Espagne] ; David García-Garcia [Espagne] ; Pedro Clavero [Espagne] ; Lluis Samaranch [Espagne] ; Cecilia Irurzun [Espagne] ; Juan M. Matsubara [Espagne] ; Jaione Irigoien [Espagne] ; Emilia Bescos [Espagne] ; Jaime Kulisevsky [Espagne] ; Jordi Pérez-Tur [Espagne] ; Jose A. Obeso [Espagne] | Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study |
000A71 |
Greg T. Sutherland [Australie] ; Gerhard A. Siebert [Australie] ; Jeremy R. B. Newman [Australie] ; Peter A. Silburn [Australie] ; Richard S. Boyle [Australie] ; John D. O'Sullivan [Australie] ; George D. Mellick [Australie] | Haplotype analysis of the PARK 11 gene, GIGYF2, in sporadic Parkinson's disease |
000A72 |
Jan Štochl [République tchèque] ; Knut A. Hagtvet [Norvège] ; Hana Brožová [République tchèque] ; Ji Klempí [République tchèque] ; Jan Roth [République tchèque] ; Evžen Růži Ka [République tchèque] | Handedness does not predict side of onset of motor symptoms in Parkinson's disease |
000A74 |
Edward J. Newman [Royaume-Uni] ; Katherine A. Grosset [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] | Geographical difference in Parkinson's disease prevalence within West Scotland |
000A75 |
Maria G. Macedo [Pays-Bas] ; Dagmar Verbaan [Pays-Bas] ; Yue Fang [Pays-Bas] ; Stephanie M. Van Rooden [Pays-Bas] ; Martine Visser [Pays-Bas] ; Burcu Anar [Pays-Bas] ; Antonella Uras [Pays-Bas] ; Justus L. Groen [Pays-Bas] ; Patrizia Rizzu [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas] ; Peter Heutink [Pays-Bas] | Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease |
000A76 |
Ming-Jen Lee [Taïwan] ; Ignacio F. Mata [États-Unis] ; Chin-Hsien Lin [Taïwan] ; Kai-Yuan Tzen [Taïwan] ; Sarah J. Lincoln [États-Unis] ; Rebecca Bounds [États-Unis] ; Paul J. Lockhart [Australie] ; Mary M. Hulihan [États-Unis] ; Matthew J. Farrer [États-Unis] ; Ruey-Meei Wu [Taïwan] | Genotype–phenotype correlates in Taiwanese patients with early‐onset recessive parkinsonism |
000A78 |
Yumi Sakakibara [Japon] ; Masato Asahina [Japon] ; Atsuya Suzuki [Japon] ; Takamichi Hattori [Japon] | Gastric myoelectrical differences between Parkinson's disease and multiple system atrophy |
000A79 |
Nathalie Chastan [France] ; Manh Cuong Do [France] ; Fabrice Bonneville [France] ; Frédéric Torny [France] ; Frédéric Bloch [France] ; G. W. Max Westby [France] ; Didier Dormont [France] ; Yves Agid [France] ; Marie-Laure Welter [France] | Gait and balance disorders in Parkinson's disease: Impaired active braking of the fall of centre of gravity |
000A81 |
Stephanie A. Cobb [États-Unis] ; Christian Wider [États-Unis] ; Owen A. Ross [États-Unis] ; Ignacio F. Mata [États-Unis] ; Charles H. Adler [États-Unis] ; Alex Rajput [Canada] ; Ali H. Rajput [Canada] ; Ruey-Meei Wu [Taïwan] ; Robert Hauser [États-Unis] ; Keith A. Josephs [États-Unis] ; Jonathan Carr [Afrique du Sud] ; Katrina Gwinn [États-Unis] ; Michael G. Heckman [États-Unis] ; Jan O. Aasly [Norvège] ; Timothy Lynch [Irlande (pays)] ; Ryan J. Uitti [États-Unis] ; Zbigniew K. Wszolek [États-Unis] ; Gregory Kapatos [États-Unis] ; Matthew J. Farrer [États-Unis] | GCH1 in early‐onset Parkinson's disease |
000A85 |
Yasuyuki Okuma [Japon] ; Satoshi Kamei [Japon] ; Akihiko Morita [Japon] ; Fumihito Yoshii [Japon] ; Toshimasa Yamamoto [Japon] ; Shiori Hashimoto [Japon] ; Hiroya Utsumi [Japon] ; Taku Hatano [Japon] ; Nobutaka Hattori [Japon] ; Miyuki Matsumura [Japon] ; Kazushi Takahashi [Japon] ; Shigeru Nogawa [Japon] ; Yuka Watanabe [Japon] ; Tomoyuki Miyamoto [Japon] ; Masayuki Miyamoto [Japon] ; Koichi Hirata [Japon] | Fatigue in Japanese patients with Parkinson's disease: A study using Parkinson fatigue scale |
000A88 |
Christian Wider [États-Unis] ; Justus C. Dachsel [États-Unis] ; Alexandra I. Soto [États-Unis] ; Michael G. Heckman [États-Unis] ; Nancy N. Diehl [États-Unis] ; Mei Yue [États-Unis] ; Sarah Lincoln [États-Unis] ; Jan O. Aasly [Norvège] ; Kristoffer Haugarvoll [États-Unis, Norvège] ; John Q. Trojanowski [États-Unis] ; Spiridon Papapetropoulos [États-Unis] ; Deborah Mash [États-Unis] ; Alex Rajput [Canada] ; Ali H. Rajput [Canada] ; J. Mark Gibson [Irlande (pays)] ; Timothy Lynch [Irlande (pays)] ; Dennis W. Dickson [États-Unis] ; Ryan J. Uitti [États-Unis] ; Zbigniew K. Wszolek [États-Unis] ; Matthew J. Farrer [États-Unis] ; Owen A. Ross [États-Unis] | FGF20 and Parkinson's disease: No evidence of association or pathogenicity via α‐synuclein expression |
000A89 |
Sanne Boesveldt [Pays-Bas] ; Robert-Jan O. De Muinck Keizer [Pays-Bas] ; Dirk L. Knol [Pays-Bas] ; Erik Ch. Wolters [Pays-Bas] ; Henk W. Berendse [Pays-Bas] | Extended testing across, not within, tasks raises diagnostic accuracy of smell testing in Parkinson's disease |
000A90 |
Lina Shehadeh [États-Unis] ; Georgia Mitsi [États-Unis] ; Nikhil Adi [États-Unis] ; Nanette Bishopric [États-Unis] ; Spyridon Papapetropoulos [États-Unis] | Expression of Lewy body protein septin 4 in postmortem brain of Parkinson's disease and control subjects |
000A91 |
Kenya Nishioka [Japon, États-Unis] ; Owen A. Ross [États-Unis] ; Kenji Ishii [Japon] ; Jennifer M. Kachergus [États-Unis] ; Kiichi Ishiwata [Japon] ; Mayumi Kitagawa [Japon] ; Satoshi Kono [Japon] ; Tomokazu Obi [Japon] ; Koichi Mizoguchi [Japon] ; Yuichi Inoue [Japon] ; Hisamasa Imai [Japon] ; Masashi Takanashi [Japon] ; Yoshikuni Mizuno [Japon] ; Matthew J. Farrer [États-Unis] ; Nobutaka Hattori [Japon] | Expanding the clinical phenotype of SNCA duplication carriers |
000A93 |
Laura B. Zahodne [États-Unis] ; Shamar Young [États-Unis] ; Lindsey Kirsch-Darrow [États-Unis] ; Anne Nisenzon [États-Unis] ; Hubert H. Fernandez [États-Unis] ; Michael S. Okun [États-Unis] ; Dawn Bowers [États-Unis] | Examination of the Lille Apathy Rating Scale in Parkinson disease |
000A95 |
Amir Glik [Israël] ; Magdalena Masarwa [Israël] ; Amin Abuful [Israël] ; Amar Deeb [Israël] ; Rosa Strugatsky [Israël] ; Lindsay A. Farrer [États-Unis] ; Robert P. Friedland [États-Unis] ; Rivka Inzelberg [Israël] | Essential tremor might be less frequent than Parkinson's disease in North Israel Arab villages |
000A96 |
Cleanthe Spanaki [Grèce] ; Andreas Plaitakis [Grèce] | Essential tremor in Parkinson's disease kindreds from a population of similar genetic background |
000B03 |
Behzad Elahi [Canada] ; Behrad Elahi [Iran] ; Robert Chen [Canada] | Effect of transcranial magnetic stimulation on Parkinson motor function—Systematic review of controlled clinical trials |
000B06 |
Marian L. Evatt [États-Unis] ; K. Ray Chaudhuri [Royaume-Uni] ; Kelvin L. Chou [États-Unis] ; Ester Cubo [Espagne] ; Vanessa Hinson [États-Unis] ; Katie Kompoliti [États-Unis] ; Chengwu Yang [États-Unis] ; Werner Poewe [États-Unis] ; Olivier Rascol [Autriche] ; Cristina Sampaio [France, Portugal] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] | Dysautonomia rating scales in Parkinson's disease: Sialorrhea, dysphagia, and constipation—Critique and recommendations by movement disorders task force on rating scales for Parkinson's disease |
000B07 |
Robert A. Hauser [États-Unis] ; Michel Panisset [Canada] ; Giovanni Abbruzzese [Italie] ; Linda Mancione [États-Unis] ; Nalina Dronamraju [États-Unis] ; Algirdas Kakarieka [Suisse] | Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease |
000B11 |
Greg T. Sutherland [Australie] ; Glenda M. Halliday [Australie] ; Peter A. Silburn [Australie] ; Frank L. Mastaglia [Australie] ; Dominic B. Rowe [Australie] ; Richard S. Boyle [Australie] ; John D. O'Sullivan [Australie] ; Tina Ly [Australie] ; Steve D. Wilton [Australie] ; George D. Mellick [Australie] | Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease? |
000B13 |
Yoshiyuki Hosokai [Japon] ; Yoshiyuki Nishio [Japon] ; Kazumi Hirayama [Japon] ; Atsushi Takeda [Japon] ; Toshiyuki Ishioka [Japon] ; Yoichi Sawada [Japon] ; Kyoko Suzuki [Japon] ; Yasuto Itoyama [Japon] ; Shoki Takahashi [Japon] ; Hiroshi Fukuda [Japon] ; Etsuro Mori [Japon] | Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment |
000B15 |
Nadja Van Camp [Belgique, France] ; Ines Blockx [Belgique] ; Marleen Verhoye [Belgique] ; Cindy Casteels [Belgique] ; Frea Coun [Belgique] ; Alexander Leemans [Royaume-Uni, Pays-Bas] ; Jan Sijbers [Belgique] ; Veerle Baekelandt [Belgique] ; Koen Van Laere [Belgique] ; Annemie Van Der Linden [Belgique] | Diffusion tensor imaging in a rat model of Parkinson's disease after lesioning of the nigrostriatal tract |
000B19 |
Susan Howell [Royaume-Uni] ; Elina Tripoliti [Royaume-Uni] ; Tim Pring [Royaume-Uni] | Delivering the Lee Silverman Voice Treatment (LSVT) by web camera: a feasibility study |
000B20 |
Adam Zaidel [Israël] ; Alexander Spivak [Israël] ; Lavi Shpigelman [Israël] ; Hagai Bergman [Israël] ; Zvi Israel [Israël] | Delimiting subterritories of the human subthalamic nucleus by means of microelectrode recordings and a Hidden Markov Model |
000B22 |
Jeffrey M. Hausdorff [Israël, États-Unis] ; Leor Gruendlinger [Israël] ; Lisa Scollins [États-Unis] ; Siobhan O'Herron [États-Unis] ; Daniel Tarsy [États-Unis] | Deep brain stimulation effects on gait variability in Parkinson's disease |
000B23 |
Roberta Zangaglia [Italie] ; Claudio Pacchetti [Italie] ; Chiara Pasotti [Italie] ; Francesca Mancini [Italie] ; Domenico Servello [Italie] ; Elena Sinforiani [Italie] ; Silvano Cristina [Italie] ; Marco Sassi [Italie] ; Giuseppe Nappi [Italie] | Deep brain stimulation and cognitive functions in Parkinson's disease: A three‐year controlled study |
000B24 |
Yasushi Osaki [Japon] ; Yukari Morita [Japon] ; Mitsutaka Fukumoto [Japon] ; Naoki Akagi [Japon] ; Shoji Yoshida [Japon] ; Yoshinori Doi [Japon] | Cross‐sectional and longitudinal studies of three‐dimensional stereotactic surface projection SPECT analysis in Parkinson's disease |
000B26 |
Inga Liepelt [Allemagne] ; Matthias Reimold [Allemagne] ; Walter Maetzler [Allemagne] ; Jana Godau [Allemagne] ; Gerald Reischl [Allemagne] ; Alexandra Gaenslen [Allemagne] ; Heinz Herbst [Allemagne] ; Daniela Berg [Allemagne] | Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration—[18F]FDG‐PET |
000B28 |
Zhen Qi [États-Unis] ; Gary W. Miller [États-Unis] ; Eberhard O. Voit [États-Unis] | Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals |
000B32 |
Gabriel Robert [France] ; Dominique Drapier [France] ; Marc Verin [France] ; Bruno Millet [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] | Cognitive impulsivity in Parkinson's disease patients: Assessment and pathophysiology |
000B33 |
Jaime Kulisevsky [Espagne] ; Javier Pagonabarraga [Espagne] | Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment |
000B35 |
Gabriella Santangelo [Italie] ; Carmine Vitale [Italie] ; Luigi Trojano [Italie] ; Francesca Verde [Italie] ; Dario Grossi [Italie] ; Paolo Barone [Italie] | Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease |
000B36 |
Nagaendran Kandiah [Singapour] ; Kaavya Narasimhalu [Singapour] ; Puay-Ngoh Lau [Singapour] ; Soo-Hoon Seah [Singapour] ; Wing Lok Au [Singapour] ; Louis C. S. Tan [Singapour] | Cognitive decline in early Parkinson's disease |
000B37 |
Casey H. Halpern [États-Unis] ; Jacqueline H. Rick [États-Unis] ; Shabbar F. Danish [États-Unis] ; Murray Grossman [États-Unis] ; Gordon H. Baltuch [États-Unis] | Cognition following bilateral deep brain stimulation surgery of the subthalamic nucleus for Parkinson's disease |
000B41 |
Werner Poewe [Autriche] | Clinical measures of progression in Parkinson's disease |
000B45 |
Yaroslau Compta [Espagne] ; María J. Martí [Espagne] ; Naroa Ibarretxe-Bilbao [Espagne] ; Carme Junqué [Espagne] ; Francesc Valldeoriola [Espagne] ; Esteban Mu Oz [Espagne] ; Mario Ezquerra [Espagne] ; Jose Ríos [Espagne] ; Eduardo Tolosa [Espagne] | Cerebrospinal tau, phospho‐tau, and beta‐amyloid and neuropsychological functions in Parkinson's disease |
000B52 |
Turi O. Dalaker [États-Unis, Norvège] ; Jan P. Larsen [Norvège] ; Niels Bergsland [États-Unis] ; Mona K. Beyer [Norvège] ; Guido Alves [Norvège] ; Michael G. Dwyer [États-Unis] ; Ole-Bjorn Tysnes [Norvège] ; Ralph H. B. Benedict [États-Unis] ; Arpad Kelemen [États-Unis] ; Kolbjorn Bronnick [Norvège] ; Robert Zivadinov [États-Unis] | Brain atrophy and white matter hyperintensities in early Parkinson's disease |
000B53 |
Helen Petrovitch [États-Unis] ; Robert D. Abbott [États-Unis, Japon] ; G. Webster Ross [États-Unis] ; James Nelson [États-Unis] ; Kamal H. Masaki [États-Unis] ; Caroline M. Tanner [États-Unis] ; Lenore J. Launer [États-Unis] ; Lon R. White [États-Unis] | Bowel movement frequency in late‐life and substantia nigra neuron density at death |
000B56 |
Gráinne C. O Eeffe [Royaume-Uni] ; Andrew W. Michell [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] | Biomarkers in Huntington's and Parkinson's Disease |
000B57 |
Karin D. Van Dijk [Pays-Bas] ; Els I. S. M St [Pays-Bas] ; Eus J. W. Van Someren [Pays-Bas] ; Henk W. Berendse [Pays-Bas] ; Ysbrand D. Van Der Werf [Pays-Bas] | Beneficial effect of transcranial magnetic stimulation on sleep in Parkinson's disease |
000B58 |
Rodolfo Savica [États-Unis] ; James H. Bower [États-Unis] ; Demetrius M. Maraganore [États-Unis] ; Brandon R. Grossardt [États-Unis] ; Walter A. Rocca [États-Unis] | Bell's palsy preceding Parkinson's disease: A case‐control study |
000B59 |
Madeleine E. Hackney [États-Unis] ; Gammon M. Earhart [États-Unis] | Backward walking in Parkinson's disease |
000B60 |
F. R. Guerini [Italie] ; E. Beghi [Italie] ; G. Riboldazzi ; R. Zangaglia ; C. Pianezzola ; G. Bono ; C. Casali [Italie] ; C. Di Lorenzo [Italie] ; C. Agliardi [Italie] ; G. Nappi [Italie] ; M. Clerici [Italie] ; E. Martignoni [Italie] | BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson’s disease |
000B61 |
Laura Marsh [États-Unis] ; Kevin Biglan [États-Unis] ; Melissa Gerstenhaber [États-Unis] ; James R. Williams [États-Unis] | Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label study |
000B63 |
Jee-Young Lee [Corée du Sud] ; Eun Kyung Lee [Corée du Sud] ; Sung Sup Park [Corée du Sud] ; Ji-Yeon Lim [Corée du Sud] ; Hee Jin Kim [Corée du Sud] ; Ji Sun Kim [Corée du Sud] ; Beom S. Jeon [Corée du Sud] | Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease |
000B68 |
Flavio Nobili [Italie] ; Giovanni Abbruzzese [Italie] ; Silvia Morbelli [Italie] ; Roberta Marchese [Italie] ; Nicola Girtler [Italie] ; Barbara Dessi [Italie] ; Andrea Brugnolo [Italie] ; Cinzia Canepa [Italie] ; Giorgos Chr. Drosos [Italie] ; Gianmario Sambuceti [Italie] ; Guido Rodriguez [Italie] | Amnestic mild cognitive impairment in Parkinson's disease: A brain perfusion SPECT study |
000B69 |
Nathan Pankratz [États-Unis] ; William C. Nichols [États-Unis] ; Veronika E. Elsaesser [États-Unis] ; Michael W. Pauciulo [États-Unis] ; Diane K. Marek [États-Unis] ; Cheryl A. Halter [États-Unis] ; Joanne Wojcieszek [États-Unis] ; Alice Rudolph [États-Unis] ; Ronald F. Pfeiffer [États-Unis] ; Tatiana Foroud [États-Unis] | Alpha‐synuclein and familial Parkinson's disease |
000B70 |
Maarten J. Nijkrake [Pays-Bas] ; Samyra H. J. Keus [Pays-Bas] ; Rob A. B. Oostendorp [Pays-Bas] ; Sebastiaan Overeem [Pays-Bas] ; Wim Mulleners [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] ; Marten Munneke [Pays-Bas] | Allied health care in Parkinson's disease: Referral, consultation, and professional expertise |
000B72 |
Donald Grosset [Royaume-Uni] ; Angelo Antonini [Italie] ; Margherita Canesi [Italie] ; Gianni Pezzoli [Italie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Karen Shaw [Royaume-Uni] ; Esther Cubo [Espagne] ; Pablo Martinez-Martin [Espagne] ; Olivier Rascol [France] ; Laurence Negre-Pages [France] ; Ana Senard [France] ; Johannes Schwarz [Allemagne] ; Karl Strecker [Allemagne] ; Heinz Reichmann [Allemagne] ; Alexander Storch [Allemagne] ; Matthias Löhle [Allemagne] ; Fabrizio Stocchi [Italie] ; Katherine Grosset [Royaume-Uni] | Adherence to antiparkinson medication in a multicenter European study |
000B75 |
Laura Silveira-Moriyama [Royaume-Uni] ; Dharshana Sirisena [Sri Lanka] ; Pasan Gamage [Sri Lanka] ; Ranjanie Gamage [Sri Lanka] ; Rohan De Silva [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Adapting the Sniffin' Sticks to diagnose Parkinson's disease in Sri Lanka |
000B76 |
Edward J. Newman [Royaume-Uni] ; Kieran Breen [Royaume-Uni] ; Jim Patterson [Royaume-Uni] ; Donald M. Hadley [Royaume-Uni] ; Katherine A. Grosset [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] | Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland |
000B77 |
Meg E. Morris [Australie] ; Robert Iansek [Australie] ; Beth Kirkwood [Australie] | A randomized controlled trial of movement strategies compared with exercise for people with Parkinson's disease |
000B78 |
Bernard Ravina [États-Unis] ; Caroline Tanner [États-Unis] ; Diane Dieuliis [États-Unis] ; Shirley Eberly [États-Unis] ; Emily Flagg [États-Unis] ; Wendy R. Galpern [États-Unis] ; Stanley Fahn [États-Unis] ; Christopher G. Goetz [États-Unis] ; Stephen Grate [États-Unis] ; Roger Kurlan [États-Unis] ; Anthony E. Lang [Canada] ; Kenneth Marek [États-Unis] ; Karl Kieburtz [États-Unis] ; David Oakes [États-Unis] ; Robin Elliott [États-Unis] ; Ira Shoulson [États-Unis] | A longitudinal program for biomarker development in Parkinson's disease: A feasibility study |
000B79 |
Anna Brück [Finlande] ; Sargo Aalto [Finlande] ; Elina Rauhala [Finlande] ; Jörgen Bergman [Finlande] ; Reijo Marttila [Finlande] ; Juha O. Rinne [Finlande] | A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen |
000B80 |
Connie Marras [Canada] ; Anthony E. Lang [Canada] ; Shirley W. Eberly [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Steven R. Schwid [États-Unis] ; Christopher Hyson [Canada] ; Ira Shoulson [États-Unis] | A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts |
000B83 |
Olivier Rascol [France] ; Ludwig Schelosky [Suisse] | 123I‐metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders |
000C22 |
Helene Plun-Favreau [Royaume-Uni] ; Sonia Gandhi [Royaume-Uni] ; Alison Wood-Kaczmar [Royaume-Uni] ; Emma Deas [Royaume-Uni] ; Zhi Yao [Royaume-Uni] ; Nicholas W. Wood [Royaume-Uni] | What Have PINK1 and HtrA2 Genes Told Us about the Role of Mitochondria in Parkinson's Disease? |
000C24 |
Anne Marthe Meppelink [Pays-Bas] ; Janneke Koerts [Pays-Bas] ; Maarten Borg [Pays-Bas] ; Klaus Leonard Leenders [Pays-Bas] ; Teus Van Laar [Pays-Bas] | Visual object recognition and attention in Parkinson's disease patients with visual hallucinations |
000C27 |
Pablo Martinez-Martin [Espagne] ; Eduardo Tolosa [Espagne] ; Basilio Hernandez [Espagne] ; Xavier Badia [Espagne] | Validation of the “QUICK” questionnaire—A tool for diagnosis of “wearing‐off” in patients with Parkinson's disease |
000C29 |
Ilana Schlesinger [Israël] ; Naomi Schlesinger [États-Unis] | Uric acid in Parkinson's disease |
000C37 |
Olalla Bello [Espagne] ; Jose Andres Sanchez [Espagne] ; Miguel Fernandez-Del-Olmo [Espagne] | Treadmill walking in Parkinson's disease patients: Adaptation and generalization effect |
000C39 |
Laura Silveira-Moriyama [Royaume-Uni] ; Margarete De Jesus Carvalho [Brésil] ; Regina Katzenschlager [Autriche] ; Aviva Petrie [Royaume-Uni] ; Ronald Ranvaud [Brésil] ; Egberto Reis Barbosa [Brésil] ; Andrew Lees (neurologue) [Royaume-Uni] | The use of smell identification tests in the diagnosis of Parkinson's disease in Brazil |
000C41 |
Meir Plotnik [Israël] ; Jeffrey M. Hausdorff [Israël, États-Unis] | The role of gait rhythmicity and bilateral coordination of stepping in the pathophysiology of freezing of gait in Parkinson's disease |
000C42 |
Ioannis U. Isaias [Italie] ; Chiara Siri [Italie] ; Roberto Cilia [Italie] ; Danilo De Gaspari [Italie] ; Gianni Pezzoli [Italie] ; Angelo Antonini [Italie] | The relationship between impulsivity and impulse control disorders in Parkinson's disease |
000C43 |
Christopher H. Hawkes [Royaume-Uni] | The prodromal phase of sporadic Parkinson's disease: Does it exist and if so how long is it? |
000C46 |
Lisa M. Shulman [États-Unis] ; Ann L. Gruber-Baldini [États-Unis] ; Karen E. Anderson [États-Unis] ; Christopher G. Vaughan [États-Unis] ; Stephen G. Reich [États-Unis] ; Paul S. Fishman [États-Unis] ; William J. Weiner [États-Unis] | The evolution of disability in Parkinson disease |
000C47 |
M. E. Kalaitzakis [Royaume-Uni] ; M. B. Graeber [Royaume-Uni] ; S. M. Gentleman [Royaume-Uni] ; R. K. B. Pearce [Royaume-Uni] | The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of α‐synuclein staging |
000C49 |
Yasuyuki Okuma [Japon] ; Nobuo Yanagisawa [Japon] | The clinical spectrum of freezing of gait in Parkinson's disease |
000C50 |
Anthony H. V. Schapira [Royaume-Uni] | The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease |
000C53 |
Mariese A. Hely [Australie] ; Wayne G. J. Reid [Australie] ; Michael A. Adena [Australie] ; Glenda M. Halliday [Australie] ; John G. L. Morris [Australie] | The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years |
000C54 |
Payal N. Gandhi [États-Unis] ; Xinglong Wang [États-Unis] ; Xiongwei Zhu [États-Unis] ; Shu G. Chen [États-Unis] ; Amy L. Wilson-Delfosse [États-Unis] | The Roc domain of leucine‐rich repeat kinase 2 is sufficient for interaction with microtubules |
000C56 |
Renato P. Munhoz [Brésil] ; Yosuke Wakutani [Canada] ; Connie Marras [Canada] ; Helio A. Teive [Brésil] ; Salmo Raskin [Brésil] ; Lineu C. Werneck [Brésil] ; Danielle Moreno [Canada] ; Christine Sato [Canada] ; Anthony E. Lang [Canada] ; Ekaterina Rogaeva [Canada] | The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: Phenotype in monozygotic twins |
000C60 |
Sarra Nazem [États-Unis] ; Andrew D. Siderowf [États-Unis] ; John E. Duda [États-Unis] ; Gregory K. Brown [États-Unis] ; Tom Ten Have [États-Unis] ; Matthew B. Stern [États-Unis] ; Daniel Weintraub [États-Unis] | Suicidal and death ideation in Parkinson's disease |
000C63 |
Robert A. Hauser [États-Unis] ; Lisa M. Shulman [États-Unis] ; Joel M. Trugman [États-Unis] ; John W. Roberts [États-Unis] ; Akihisa Mori [Japon] ; Rocco Ballerini [États-Unis] ; Neil M. Sussman [États-Unis] | Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations |
000C65 |
Irena Rektorova [République tchèque] ; Hana Srovnalova [République tchèque] ; Radka Kubikova [République tchèque] ; Jiri Prasek [République tchèque] | Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease |
000C66 |
Yoland Smith [États-Unis] ; Rosa Villalba [États-Unis] | Striatal and extrastriatal dopamine in the basal ganglia: An overview of its anatomical organization in normal and Parkinsonian brains |
000C71 |
Sabine Skodda [Allemagne] ; Uwe Schlegel [Allemagne] | Speech rate and rhythm in Parkinson's disease |
000C76 |
Pablo Martinez-Martin [Espagne] ; Martine Visser [Pays-Bas] ; Carmen Rodriguez-Blazquez [Espagne] ; Johan Marinus [Pays-Bas] ; K. Ray Chaudhuri [Royaume-Uni] ; Jacobus J. Van Hilten [Pays-Bas] | SCOPA‐sleep and PDSS: Two scales for assessment of sleep disorder in Parkinson's disease |
000C78 |
Carola Schiesling ; Nicole Kieper ; Kay Seidel [Allemagne] ; Rejko Krüger | Review: Familial Parkinson's disease – genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease |
000C79 |
Genevieve Bureau [Canada] ; Fanny Longpré [Canada] ; M. Martinoli [Canada] | Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation |
000C81 |
H. Randall Griffith [États-Unis] ; Ozioma C. Okonkwo [États-Unis] ; Timothy O'Brien [États-Unis] ; Jan A. Den Hollander [États-Unis] | Reduced brain glutamate in patients with Parkinson's disease |
000C82 |
Evan L. Thacker [États-Unis] ; Honglei Chen [États-Unis] ; Alpa V. Patel [États-Unis] ; Marjorie L. Mccullough [États-Unis] ; Eugenia E. Calle [États-Unis] ; Michael J. Thun [États-Unis] ; Michael A. Schwarzschild [États-Unis] ; Alberto Ascherio [États-Unis] | Recreational physical activity and risk of Parkinson's disease |
000C85 |
Elena Sinforiani [Italie] ; Claudio Pacchetti [Italie] ; Roberta Zangaglia [Italie] ; Chiara Pasotti [Italie] ; Raffaele Manni [Italie] ; Giuseppe Nappi [Italie] | REM behavior disorder, hallucinations and cognitive impairment in Parkinson's disease: A two‐year follow up |
000C88 |
Peter Valkovi ; Hana Brožová [République tchèque] ; Kai Bötzel [Allemagne] ; Evžen Růži Ka [République tchèque] ; Ján Benetin | Push and release test predicts better Parkinson fallers and nonfallers than the pull test: Comparison in OFF and ON medication states |
000C90 |
Francisco Javier Carod-Artal [Brésil] ; Pablo Martínez-Martin [Espagne] ; Wladimir Kummer [Brésil] ; Luciola Da Silveira Ribeiro [Brésil] | Psychometric attributes of the SCOPA‐COG Brazilian version |
000D01 |
Connie Marras [Canada] ; Michael P. Mcdermott [États-Unis] ; Paula A. Rochon [Canada] ; Caroline M. Tanner [États-Unis] ; Gary Naglie [Canada] ; Anthony E. Lang [Canada] | Predictors of deterioration in health‐related quality of life in Parkinson's disease: Results from the DATATOP trial |
000D02 |
Elin Bjelland Forsaa [Norvège] ; Jan Petter Larsen [Norvège] ; Tore Wentzel-Larsen [Norvège] ; Karen Herlofson [Norvège] ; Guido Alves [Norvège] | Predictors and course of health‐related quality of life in Parkinson's disease |
000D03 |
Roberto Ceravolo [Italie] ; Angelo Antonini [Italie] ; Duccio Volterrani [Italie] ; Carlo Rossi [Italie] ; Lorenzo Kiferle [Italie] ; Daniela Frosini [Italie] ; Claudio Lucetti [Italie] ; Ioannis U. Isaias [Italie] ; Riccardo Benti [Italie] ; Luigi Murri [Italie] ; Ubaldo Bonuccelli [Italie] | Predictive value of nigrostriatal dysfunction in isolated tremor: A clinical and SPECT study |
000D06 |
Andreas Gebhardt [Suisse] ; Tim Vanbellingen [Suisse] ; Fabio Baronti [Suisse] ; Bernd Kersten [Suisse] ; Stephan Bohlhalter [Suisse] | Poor dopaminergic response of impaired dexterity in Parkinson's disease: Bradykinesia or limb kinetic apraxia? |
000D08 |
Christopher G. Goetz [États-Unis] ; Joanne Wuu [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Charles H. Adler [États-Unis] ; Stanley Fahn [États-Unis] ; Curt R. Freed [États-Unis] ; Robert A. Hauser [États-Unis] ; Warren C. Olanow [États-Unis] ; Ira Shoulson [États-Unis] ; P. K. Tandon [États-Unis] ; Sue Leurgans [États-Unis] | Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions |
000D11 |
Eng-King Tan [Singapour] ; Hui-Qin Lim [Singapour] ; Yih Yuen [Singapour] ; Yi Zhao [Singapour] | Pathogenicity of LRRK2 P755L variant in Parkinson's disease |
000D13 |
Javier Pagonabarraga [Espagne] ; Jaime Kulisevsky [Espagne] ; Gisela Llebaria [Espagne] ; Carmen García-Sánchez [Espagne] ; Berta Pascual-Sedano [Espagne] ; Alexandre Gironell [Espagne] | Parkinson's disease‐cognitive rating scale: A new cognitive scale specific for Parkinson's disease |
000D14 |
Hani T. S. Benamer [Royaume-Uni] ; Rajith De Silva [Royaume-Uni] ; Khurram A. Siddiqui ; Donald G. Grosset [Royaume-Uni] | Parkinson's disease in Arabs: A systematic review |
000D16 |
Michael J. Falvo [États-Unis] ; Brian K. Schilling [États-Unis] ; Gammon M. Earhart [États-Unis] | Parkinson's disease and resistive exercise: Rationale, review, and recommendations |
000D17 |
Christopher H. Hawkes | Parkinson's disease and aging: Same or different process? |
000D18 |
Paul S. Fishman [États-Unis] | Paradoxical aspects of parkinsonian tremor |
000D19 |
Peter Brown [Royaume-Uni] ; Alexandre Eusebio [Royaume-Uni] | Paradoxes of functional neurosurgery: Clues from basal ganglia recordings |
000D21 |
Chun Zhou ; Yong Huang ; Serge Przedborski [États-Unis] | Oxidative Stress in Parkinson's Disease |
000D26 |
Frank J. M. Van Eijkeren [Pays-Bas] ; Ruud S. J. Reijmers [Pays-Bas] ; Mirjam J. Kleinveld [Pays-Bas] ; Angret Minten [Pays-Bas] ; Jan Pieter Ter Bruggen [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] | Nordic walking improves mobility in Parkinson's disease |
000D30 |
Dagmar Verbaan [Pays-Bas] ; Stephanie M. Van Rooden [Pays-Bas] ; Martine Visser [Pays-Bas] ; Johan Marinus [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas] | Nighttime sleep problems and daytime sleepiness in Parkinson's disease |
000D33 |
Cory Toth [Canada] ; Martin Sutton Brown [Canada] ; Sarah Furtado [Canada] ; Oksana Suchowersky [Canada] ; Douglas Zochodne [Canada] | Neuropathy as a potential complication of levodopa use in Parkinson's disease |
000D34 |
Chelsea Stamper [États-Unis] ; Andrew Siegel [États-Unis] ; Winnie S. Liang [États-Unis] ; John V. Pearson [États-Unis] ; Dietrich A. Stephan [États-Unis] ; Holly Shill [États-Unis] ; Don Connor [États-Unis] ; John N. Caviness [États-Unis] ; Marwan Sabbagh [États-Unis] ; Thomas G. Beach [États-Unis] ; Charles H. Adler [États-Unis] ; Travis Dunckley [États-Unis] | Neuronal gene expression correlates of Parkinson's disease with dementia |
000D42 |
Claire Henchcliffe [États-Unis] ; Dikoma C. Shungu [États-Unis] ; Xiangling Mao [États-Unis] ; Chaorui Huang [États-Unis] ; Melissa J. Nirenberg [États-Unis] ; Bruce G. Jenkins [États-Unis] ; M. Flint Beal [États-Unis] | Multinuclear Magnetic Resonance Spectroscopy for in Vivo Assessment of Mitochondrial Dysfunction in Parkinson's Disease |
000D43 |
Marwan I. Hariz [Royaume-Uni, Suède] ; Stig Rehncrona [Suède] ; Niall P. Quinn [Royaume-Uni] ; Johannes D. Speelman [Pays-Bas] ; Carin Wensing [Pays-Bas] | Multicenter study on deep brain stimulation in Parkinson's disease: An independent assessment of reported adverse events at 4 years |
000D46 |
Yi Wei Lu [Singapour] ; Eng-King Tan [Singapour] | Molecular biology changes associated with LRRK2 mutations in Parkinson's disease |
000D47 |
Rajnish K. Chaturvedi [États-Unis] ; M. Flint Beal [États-Unis] | Mitochondrial Approaches for Neuroprotection |
000D50 |
Ji-Young Park [Corée du Sud] ; Seung R. Paik [Corée du Sud] ; Ilo Jou [Corée du Sud] ; Sang Myun Park [Corée du Sud] | Microglial phagocytosis is enhanced by monomeric α‐synuclein, not aggregated α‐synuclein: Implications for Parkinson's disease |
000D51 |
Riccardo Ruffoli [Italie] ; Paola Soldani [Italie] ; Livia Pasquali [Italie] ; Stefano Ruggieri [Italie] ; Antonio Paparelli [Italie] ; Francesco Fornai [Italie] | Methamphetamine Fails to Alter the Noradrenergic Integrity of the Heart |
000D54 |
Nir Giladi [Israël] | Medical treatment of freezing of gait |
000D55 |
Roy C. Martin [États-Unis] ; Ozioma C. Okonkwo [États-Unis] ; Joni Hill [États-Unis] ; H. Randall Griffith [États-Unis] ; Kristen Triebel [États-Unis] ; Alfred Bartolucci [États-Unis] ; Anthony P. Nicholas [États-Unis] ; Ray L. Watts [États-Unis] ; Natividad Stover [États-Unis] ; Lindy E. Harrell [États-Unis] ; David Clark [États-Unis] ; Daniel C. Marson [États-Unis] | Medical decision‐making capacity in cognitively impaired Parkinson's disease patients without dementia |
000D57 |
Lauren I. Wallis [Royaume-Uni] ; Martyn N. J. Paley [Royaume-Uni] ; Jacqueline M. Graham [Royaume-Uni] ; Richard A. Grünewald [Royaume-Uni] ; Emma L. Wignall [Royaume-Uni] ; Harriet M. Joy [Royaume-Uni] ; Paul D. Griffiths [Royaume-Uni] | MRI assessment of basal ganglia iron deposition in Parkinson's disease |
000D58 |
Xuemei Huang [États-Unis] ; Robert D. Abbott [États-Unis, Japon] ; Helen Petrovitch [États-Unis] ; Richard B. Mailman [États-Unis] ; G. Webster Ross [États-Unis] | Low LDL cholesterol and increased risk of Parkinson's disease: Prospective results from Honolulu‐Asia Aging Study |
000D60 |
Eugenia Mamikonyan [États-Unis] ; Andrew D. Siderowf [États-Unis] ; John E. Duda [États-Unis] ; Marc N. Potenza [États-Unis] ; Stacy Horn [États-Unis] ; Matthew B. Stern [États-Unis] ; Daniel Weintraub [États-Unis] | Long‐term follow‐up of impulse control disorders in Parkinson's disease |
000D61 |
C. Warren Olanow [États-Unis] | Levodopa/dopamine replacement strategies in Parkinson's disease—Future directions |
000D64 |
Vania Gelmetti [Italie] ; Alessandro Ferraris [Italie] ; Livia Brusa [Italie] ; Francesca Romano [Italie] ; Federica Lombardi [Italie] ; Chiara Barzaghi [Italie] ; Paolo Stanzione [Italie] ; Barbara Garavaglia [Italie] ; Bruno Dallapiccola [Italie] ; Enza Maria Valente [Italie] | Late onset sporadic Parkinson's disease caused by PINK1 mutations: Clinical and functional study |
000D66 |
J. Alegre-Abarrategui ; O. Ansorge [Royaume-Uni] ; M. Esiri [Royaume-Uni] ; R. Wade-Martins | LRRK2 is a component of granular alpha‐synuclein pathology in the brainstem of Parkinson's disease |
000D68 |
Rocco Agostino [Italie] ; Loredana Dinapoli [Italie] ; Nicola Modugno [Italie] ; Ennio Iezzi [Italie] ; Bruno Gregori [Italie] ; Vincenzo Esposito [Italie] ; Pantaleo Romanelli [Italie] ; Alfredo Berardelli [Italie] | Ipsilateral sequential arm movements after unilateral subthalamic deep‐brain stimulation in patients with Parkinson's disease |
000D72 |
Shen-Yang Lim [Canada] ; Andrew H. Evans [Australie] ; Janis M. Miyasaki [Canada] | Impulse Control and Related Disorders in Parkinson's Disease |
000D73 |
Andrew B. Knott [États-Unis] ; Ella Bossy-Wetzel [États-Unis] | Impairing the Mitochondrial Fission and Fusion Balance: A New Mechanism of Neurodegeneration |
000D75 |
Yasin Temel [Pays-Bas] ; Taco Prinsenberg [Pays-Bas] ; Veerle Visser-Vandewalle [Pays-Bas] | Imaging of the Subthalamic Nucleus for Deep Brain Stimulation: A Systematic Review |
000D76 |
Efstathia Kitsou [États-Unis] ; Sheng Pan [États-Unis] ; Jianpeng Zhang [États-Unis] ; Min Shi [États-Unis] ; Aram Zabeti [États-Unis] ; Dennis W. Dickson [États-Unis] ; Roger Albin [États-Unis] ; Marla Gearing [États-Unis] ; Daniel T. Kashima [États-Unis] ; Yan Wang [États-Unis] ; Richard P. Beyer [États-Unis] ; Yong Zhou [États-Unis] ; Catherine Pan [États-Unis] ; W. Michael Caudle [États-Unis] ; Jing Zhang [États-Unis] | Identification of proteins in human substantia nigra |
000D77 |
Christopher F. Mcnicoll [États-Unis] ; Jeanne C. Latourelle [États-Unis] ; Marcy E. Macdonald [États-Unis] ; Mark F. Lew [États-Unis] ; Oksana Suchowersky [Canada] ; Christine Klein [Allemagne] ; Lawrence I. Golbe [États-Unis] ; Margery H. Mark [États-Unis] ; John H. Growdon [États-Unis] ; G. Frederick Wooten [États-Unis] ; Ray L. Watts [États-Unis] ; Mark Guttman [Canada] ; Brad A. Racette [États-Unis] ; Joel S. Perlmutter [États-Unis] ; Anwar Ahmed [États-Unis] ; Holly A. Shill [États-Unis] ; Carlos Singer [États-Unis] ; Marie H. Saint-Hilaire [États-Unis] ; Tiffany Massood [États-Unis] ; Karen W. Huskey [États-Unis] ; Anita L. Destefano [États-Unis] ; Tammy Gillis [États-Unis] ; Jayalakshmi Mysore [États-Unis] ; Stefano Goldwurm [Italie] ; Gianni Pezzoli [Italie] ; Kenneth B. Baker [États-Unis] ; Ilia Itin [États-Unis] ; Irene Litvan [États-Unis] ; Garth Nicholson [Australie] ; Alastair Corbett [Australie] ; Martha Nance [États-Unis] ; Edward Drasby [États-Unis] ; Stuart Isaacson [États-Unis] ; David J. Burn [Royaume-Uni] ; Patrick F. Chinnery [Royaume-Uni] ; Peter P. Pramstaller [Italie] ; Jomana Al-Hinti [États-Unis] ; Anette T. Moller [Danemark] ; Karen Ostergaard [Danemark] ; Scott J. Sherman [États-Unis] ; Richard Roxburgh [Nouvelle-Zélande] ; Barry Snow [Nouvelle-Zélande] ; John T. Slevin [États-Unis] ; Franca Cambi [États-Unis] ; James F. Gusella [États-Unis] ; Richard H. Myers [États-Unis] | Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The GenePD study |
000D80 |
Masashi Hamada [Japon] ; Yoshikazu Ugawa [Japon] ; Sadatoshi Tsuji [Japon] | High‐frequency rTMS over the supplementary motor area for treatment of Parkinson's disease |
000D83 |
Won Yong Lee [Corée du Sud] ; Won Tae Yoon [Corée du Sud] ; Hee Young Shin [Corée du Sud] ; Seong Hee Jeon [Corée du Sud] ; Poong-Lyul Rhee [Corée du Sud] | Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease |
000D86 |
Greg Sutherland [Australie] ; George Mellick [Australie] ; Jeremy Newman [Australie] ; Kay L. Double [Australie] ; Julia Stevens [Australie] ; Linda Lee [Australie] ; Dominic Rowe [Australie] ; Peter Silburn [Australie] ; Glenda M. Halliday [Australie] | Haplotype analysis of the IGF2‐INS‐TH gene cluster in Parkinson's disease |
000D92 |
Patricia De Carvalho Aguiar [Brésil] ; Patricia Silva Lessa [Brésil] ; Clecio Godeiro Junior [Brésil] ; Orlando Barsottini [Brésil] ; Andre Carvalho Felício [Brésil] ; Vanderci Borges [Brésil] ; Sonia Maria De Azevedo Silva [Brésil] ; Roberta Arb Saba [Brésil] ; Henrique Ballalai Ferraz [Brésil] ; Carlos A. Moreira-Filho [Brésil] ; Luiz Augusto F. Andrade [Brésil] | Genetic and environmental findings in early‐onset Parkinson's disease Brazilian patients |
000D93 |
Yehonatan Sharabi [États-Unis] ; Richard Imrich [États-Unis] ; Courtney Holmes [États-Unis] ; Sandra Pechnik [États-Unis] ; David S. Goldstein [États-Unis] | Generalized and neurotransmitter‐selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension |
000D94 |
Meg E. Morris [Australie] ; Robert Iansek [Australie] ; Brook Galna [Australie] | Gait festination and freezing in Parkinson's disease: Pathogenesis and rehabilitation |
000D97 |
Aileen K. Ho [Royaume-Uni] ; John L. Bradshaw [Australie] ; Robert Iansek [Australie] | For better or worse: The effect of levodopa on speech in Parkinson's disease |
000D98 |
Frances Huxham [Australie] ; Richard Baker [Australie] ; Meg E. Morris [Australie] ; Robert Iansek [Australie] | Footstep adjustments used to turn during walking in Parkinson's disease |
000E00 |
Evan L. Thacker [États-Unis] ; Alberto Ascherio [États-Unis] | Familial aggregation of Parkinson's disease: A meta‐analysis |
000E05 |
Eng-King Tan [Singapour] ; Seng-Swim Lee [Singapour] ; Fook-Chong S. [Singapour] ; Sau-Ying Lum [Singapour] | Evidence of increased odds of essential tremor in Parkinson's disease |
000E06 |
Samuel A. Frank [États-Unis] ; Renee Wilson [États-Unis] ; Robert G. Holloway [États-Unis] ; Carol Zimmerman [États-Unis] ; Derick R. Peterson [États-Unis] ; Karl Kieburtz [États-Unis] ; Scott Y. H. Kim [États-Unis] | Ethics of sham surgery: Perspective of patients |
000E08 |
Pedro J. García Ruiz [Espagne] ; Ángel Sesar Ignacio [Espagne] ; Bego A Ares Pensado [Espagne] ; Alfonso Castro García [Espagne] ; Fernando Alonso Frech [Espagne] ; Mercedes Álvarez L Pez [Espagne] ; José Arbelo González [Espagne] ; Joan Baiges Octavio [Espagne] ; Juan Andrés Burguera Hernández [Espagne] ; Matilde Calopa Garriga [Espagne] ; Dulce Campos Blanco [Espagne] ; Belén Casta O García [Espagne] ; Manuel Carballo Cordero [Espagne] ; José Chac N Pe A [Espagne] ; Anna Espino Ibá Ez [Espagne] ; Aránzazu Gorospe Onisalde [Espagne] ; Santiago Giménez-Roldán [Espagne] ; Pilar Granés Ibá Ez [Espagne] ; Jorge Hernández Vara [Espagne] ; Ram N Ibá Ez Alonso [Espagne] ; Félix Javier Jiménez Jiménez [Espagne] ; Jerzy Krupinski [Espagne] ; Jaime Kulisevsky Bojarsky [Espagne] ; Inés Legarda Ramírez [Espagne] ; Elena Lezcano García [Espagne] ; Juan Carlos Martínez-Castrillo [Espagne] ; Dolores Mateo González [Espagne] ; Francesc Miquel Rodríguez [Espagne] ; Pablo Mir [Espagne] ; Elena Mu Oz Fargas [Espagne] ; José Obeso Inchausti [Espagne] ; Jesús Olivares Romero [Espagne] ; José Olivé Plana [Espagne] ; Pilar Otermin Vallejo [Espagne] ; Berta Pascual Sedano [Espagne] ; Víctor Pérez De Colosía Rama [Espagne] ; Isabel Pérez L Pez-Fraile [Espagne] ; Albert Planas Comes [Espagne] ; Víctor Puente Periz [Espagne] ; María Cruz Rodríguez Oroz [Espagne] ; Dolores Sevillano García [Espagne] ; Pilar Solís Pérez [Espagne] ; José Suárez Mu Oz [Espagne] ; Julia Vaamonde Gamo [Espagne] ; Caridad Valero Merino [Espagne] ; Francesc Valldeoriola Serra [Espagne] ; José Miguel Velázquez Pérez [Espagne] ; Rosa Yá Ez Ba A [Espagne] ; Ivana Zamarbide Capdepon [Espagne] | Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study |
000E10 |
Myeong Soo Lee [Royaume-Uni, Corée du Sud] ; Byung-Cheul Shin [Corée du Sud] ; Jae Cheol Kong [Corée du Sud] ; Edzard Ernst [Royaume-Uni] | Effectiveness of acupuncture for Parkinson's disease: A systematic review |
000E12 |
Thomas A. Buckley [États-Unis] ; Chris Pitsikoulis [États-Unis] ; Chris J. Hass [États-Unis] | Dynamic postural stability during sit‐to‐walk transitions in Parkinson disease patients |
000E14 |
Richard Cordell [Australie] ; Hoe C. Lee [Australie] ; Andrew Granger [Australie] ; Barry Vieira [Australie] ; Andy H. Lee [Australie] | Driving assessment in Parkinson's disease—A novel predictor of performance? |
000E15 |
Masaki Wakamatsu [Japon] ; Shingo Iwata [Japon] ; Takeo Funakoshi [Japon] ; Makoto Yoshimoto [Japon] | Dopamine receptor agonists reverse behavioral abnormalities of α‐synuclein transgenic mouse, a new model of Parkinson's disease |
000E18 |
Shen-Yang Lim [Australie] ; Michael J. Farrell [Australie] ; Stephen J. Gibson [Australie] ; Robert D. Helme [Australie] ; Anthony E. Lang [Canada] ; Andrew H. Evans [Australie] | Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease? |
000E20 |
Lars Timmermann [Allemagne] ; Martin Braun [Allemagne] ; Stefan Groiss [Allemagne] ; Lars Wojtecki [Allemagne] ; Stefan Ostrowski [Allemagne] ; Holger Krause [Allemagne] ; Bettina Pollok [Allemagne] ; Martin Südmeyer [Allemagne] ; Markus Ploner [Allemagne] ; Joachim Gross [Allemagne] ; Mohammad Maarouf [Allemagne] ; Jürgen Voges [Allemagne] ; Volker Sturm [Allemagne] ; Alfons Schnitzler [Allemagne] | Differential effects of levodopa and subthalamic nucleus deep brain stimulation on bradykinesia in Parkinson's disease |
000E25 |
Michael Hutchinson [États-Unis] ; Ulrich Raff [Chili] | Detection of Parkinson's disease by MRI: Spin‐lattice distribution imaging |
000E27 |
S. E. P Lhagen [Suède] ; M. Carlsson [Suède] ; E. Curman [Suède] ; J. W Linder [Suède] ; A. Granérus [Suède] | Depressive illness in Parkinson’s disease – indication of a more advanced and widespread neurodegenerative process? |
000E28 |
Aleksandar Videnovic [États-Unis] ; Leo Verhagen Metman [États-Unis] | Deep brain stimulation for Parkinson's disease: Prevalence of adverse events and need for standardized reporting |
000E31 |
Gisela Llebaria [Espagne] ; Javier Pagonabarraga [Espagne] ; Jaime Kulisevsky [Espagne] ; Carmen García-Sánchez [Espagne] ; Berta Pascual-Sedano [Espagne] ; Alexandre Gironell [Espagne] ; Mercè Martínez-Corral [Espagne] | Cut‐off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease |
000E32 |
Alice Nieuwboer [Belgique] | Cueing for freezing of gait in patients with Parkinson's disease: A rehabilitation perspective |
000E33 |
Angelo Antonini [Italie] ; Patrizia Berto [Italie] ; Stefania Lopatriello [Italie] ; Filippo Tamma [Italie] ; Lieven Annemans [Belgique] ; Mike Chambers [Royaume-Uni] | Cost‐effectiveness of 123I‐FP‐CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy |
000E34 |
Alison R. Oates [Canada] ; Jim S. Frank [Canada] ; Aftab E. Patla [Canada] ; Karen Vanooteghem [Canada] ; Fay B. Horak [États-Unis] | Control of dynamic stability during gait termination on a slippery surface in Parkinson's disease |
000E35 |
M. Steiger [Royaume-Uni] | Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease |
000E37 |
Coro Paisán-Ruíz [États-Unis] ; Priti Nath [États-Unis] ; Nicole Washecka [États-Unis] ; J. Raphael Gibbs [États-Unis, Royaume-Uni] ; Andrew B. Singleton [États-Unis] | Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls |
000E38 |
David Devos [France] ; Kathy Dujardin [France] ; Isabelle Poirot [France] ; Caroline Moreau [France] ; Olivier Cottencin [France] ; Pierre Thomas [France] ; Alain Destée [France] ; Regis Bordet [France] ; Luc Defebvre [France] | Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study |
000E39 |
Charlotte A. Haaxma [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] ; George F. Borm [Pays-Bas] ; Martin W. I. M. Horstink [Pays-Bas] | Comparison of a timed motor test battery to the Unified Parkinson's Disease Rating Scale‐III in Parkinson's disease |
000E40 |
Karen M. Powers [États-Unis] ; Denise M. Kay [États-Unis] ; Stewart A. Factor [Géorgie (pays), États-Unis] ; Cyrus P. Zabetian [États-Unis] ; Donald S. Higgins [États-Unis] ; Ali Samii [États-Unis] ; John G. Nutt [États-Unis] ; Alida Griffith [États-Unis] ; Berta Leis [États-Unis] ; John W. Roberts [États-Unis] ; Erica D. Martinez [États-Unis] ; Jennifer S. Montimurro [États-Unis] ; Harvey Checkoway [États-Unis] ; Haydeh Payami [États-Unis] | Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk |
000E41 |
Rufus O. Akinyemi [Nigeria] ; Njideka N. Okubadejo [Nigeria] ; Joshua O. Akinyemi [Nigeria] ; Mayowa O. Owolabi [Nigeria] ; Lukman F. Owolabi [Nigeria] ; Adesola Ogunniyi [Nigeria] | Cognitive dysfunction in Nigerians with Parkinson's disease |
000E43 |
Maurizio F. Facheris [États-Unis] ; Nicole K. Schneider [États-Unis] ; Timothy G. Lesnick [États-Unis] ; Mariza De Andrade [États-Unis] ; Julie M. Cunningham [États-Unis] ; Walter A. Rocca [États-Unis] ; Demetrius M. Maraganore [États-Unis] | Coffee, caffeine‐related genes, and Parkinson's disease: A case–control study |
000E44 |
Anke H. Snijders [Pays-Bas] ; Maarten J. Nijkrake [Pays-Bas] ; Maaike Bakker [Pays-Bas] ; Marten Munneke [Pays-Bas] ; Carina Wind [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] | Clinimetrics of freezing of gait |
000E46 |
Nathan Pankratz [États-Unis] ; Karen S. Marder [États-Unis] ; Cheryl A. Halter [États-Unis] ; Alice Rudolph [États-Unis] ; Cliff W. Shults [États-Unis] ; William C. Nichols [États-Unis] ; Tatiana Foroud [États-Unis] | Clinical correlates of depressive symptoms in familial Parkinson's disease |
000E47 |
Daisy L. Whitehead [Royaume-Uni] ; Ann D. M. Davies [Royaume-Uni] ; Jeremy R. Playfer [Royaume-Uni] ; Christopher J. Turnbull [Royaume-Uni] | Circadian rest‐activity rhythm is altered in Parkinson's disease patients with hallucinations |
000E50 |
R. Cilia [Italie] ; G. Marotta [Italie] ; A. Landi [Italie] ; I. U. Isaias [Italie] ; F. Vergani [Italie] ; R. Benti [Italie] ; E. Sganzerla [Italie] ; P. Gerundini [Italie] ; G. Pezzoli [Italie] ; A. Antonini [Italie] | Cerebral activity modulation by extradural motor cortex stimulation in Parkinson's disease: a perfusion SPECT study |
000E53 |
Pablo Martinez-Martin [Espagne] ; Susana Arroyo [Espagne] ; Jose Manuel Rojo-Abuin [Espagne] ; Carmen Rodriguez-Blazquez [Espagne] ; Belen Frades [Espagne] ; Jesus De Pedro Cuesta [Espagne] | Burden, perceived health status, and mood among caregivers of Parkinson's disease patients |
000E54 |
Blanca Ramírez-Ruiz [Espagne] ; María-José Martí [Espagne] ; Eduardo Tolosa [Espagne] ; Carlos Falc N [Espagne] ; Nuria Bargall [Espagne] ; Francesc Valldeoriola [Espagne] ; Carme Junqué [Espagne] | Brain response to complex visual stimuli in Parkinson's patients with hallucinations: A functional magnetic resonance imaging study |
000E64 |
Carl E. Clarke [Royaume-Uni] | Are delayed‐start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? |
000E65 |
Giuseppe Nicoletti [Italie] ; Caterina Tonon [Italie] ; Raffaele Lodi [Italie] ; Francesca Condino [Italie] ; David Manners [Italie] ; Emil Malucelli [Italie] ; Maurizio Morelli [Italie] ; Fabiana Novellino [Italie] ; Sandra Paglionico [Italie] ; Pierluigi Lanza [Italie] ; Demetrio Messina [Italie] ; Paolo Barone [Italie] ; Letterio Morgante [Italie] ; Mario Zappia [Italie] ; Bruno Barbiroli [Italie] ; Aldo Quattrone [Italie] | Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease |
000E67 |
Albert F. G. Leentjens [Pays-Bas] ; Kathy Dujardin [France] ; Laura Marsh [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Irene H. Richard [États-Unis] ; Sergio E. Starkstein [Australie] ; Daniel Weintraub [États-Unis] ; Cristina Sampaio [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] | Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations |
000E68 |
Albert F. G. Leentjens [Pays-Bas] ; Kathy Dujardin [France] ; Laura Marsh [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Irene H. Richard [États-Unis] ; Sergio E. Starkstein [Australie] ; Daniel Weintraub [États-Unis] ; Christina Sampaio [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] | Anxiety rating scales in Parkinson's disease: Critique and recommendations |
000E69 |
Bart P. C. Van De Warrenburg [Royaume-Uni, Pays-Bas] ; Andrew J. Church [Royaume-Uni] ; Davide Martino [Royaume-Uni, Italie] ; Paul M. Candler [Royaume-Uni] ; Kailash P. Bhatia [Royaume-Uni] ; Gavin Giovannoni [Royaume-Uni] ; Niall P. Quinn [Royaume-Uni] | Antineuronal antibodies in Parkinson's disease |
000E75 |
Jennifer S. A. M. Reijnders [Pays-Bas] ; Uwe Ehrt [Norvège] ; Wim E. J. Weber [Pays-Bas] ; Dag Aarsland [Norvège] ; Albert F. G. Leentjens [Pays-Bas] | A systematic review of prevalence studies of depression in Parkinson's disease |
000E78 |
C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France] | A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics |
000E79 |
Javier Pagonabarraga [Espagne] ; Gisela Llebaria [Espagne] ; Carmen García-Sánchez [Espagne] ; Berta Pascual-Sedano [Espagne] ; Alexandre Gironell [Espagne] ; Jaime Kulisevsky [Espagne] | A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia |
000E83 |
Haruko Tanji [États-Unis] ; Ann L. Gruber-Baldini [États-Unis] ; Karen E. Anderson [États-Unis] ; Ingrid Pretzer-Aboff [États-Unis] ; Stephen G. Reich [États-Unis] ; Paul S. Fishman [États-Unis] ; William J. Weiner [États-Unis] ; Lisa M. Shulman [États-Unis] | A comparative study of physical performance measures in Parkinson's disease |
000E84 |
Sanne Boesveldt [Pays-Bas] ; Dagmar Verbaan [Pays-Bas] ; Dirk L. Knol [Pays-Bas] ; Martine Visser [Pays-Bas] ; Stephanie M. Van Rooden [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas] ; Henk W. Berendse [Pays-Bas] | A comparative study of odor identification and odor discrimination deficits in Parkinson's disease |
000E85 |
Elza Khusnutdinova [Russie] ; Irina Gilyazova [Russie] ; Eduardo Ruiz-Pesini [Espagne, États-Unis] ; Olga Derbeneva [États-Unis] ; Rita Khusainova [Russie] ; Irina Khidiyatova [Russie] ; Rim Magzhanov [Russie] ; Douglas C. Wallace [États-Unis] | A Mitochondrial Etiology of Neurodegenerative Diseases: Evidence from Parkinson's Disease |
000F15 |
Yael Manor [Israël] ; Nir Giladi [Israël] ; Alma Cohen [Israël] ; Dan M. Fliss [Israël] ; Jacob T. Cohen [Israël] | Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson's disease |
000F16 |
Santiago Perez Lloret [Argentine] ; Gabriel Pirán Arce [Argentine] ; Malco Rossi [Argentine] ; María Laura Caivano Nemet [Argentine] ; Paz Salsamendi [Argentine] ; Marcelo Merello [Argentine] | Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease |
000F18 |
Andrew Lees (neurologue) [Royaume-Uni] | Unresolved issues relating to the Shaking Palsy on the celebration of James Parkinson's 250th birthday |
000F19 |
Anne-Marie Willems [Belgique] ; Alice Nieuwboer [Belgique] ; Fabienne Chavret [Belgique] ; Kaat Desloovere [Belgique] ; René Dom [Belgique] ; Lynn Rochester [Royaume-Uni] ; Gert Kwakkel [Pays-Bas] ; Erwin Van Wegen [Pays-Bas] ; Diana Jones [Royaume-Uni] | Turning in Parkinson's disease patients and controls: The effect of auditory cues |
000F20 |
J Rgen H. Olsen [Danemark] ; Karina Tangerud [Danemark] ; Lene Wermuth [Danemark] ; Kirsten Frederiksen [Danemark] ; S Ren Friis [Danemark] | Treatment with levodopa and risk for malignant melanoma |
000F23 |
Yu-Wen Huang [Taïwan] ; Jiann-Shing Jeng [Taïwan] ; Chung-Fen Tsai [Taïwan] ; Li-Ling Chen [Taïwan] ; Ruey-Meei Wu [Taïwan] | Transcranial imaging of substantia nigra hyperechogenicity in a Taiwanese cohort of Parkinson's disease |
000F24 |
Ebru Mihci [Turquie] ; Babür Dora [Turquie] ; Sevin Balkan [Turquie] | Transcranial doppler ultrasonographic evaluation of cerebral circulation during passive tilting in patients with Parkinson's disease |
000F26 |
Risa Sakai [Japon] ; Yoshifumi Irie [Japon] ; Takeshi Murata [Japon] ; Atsushi Ishige [Japon] ; Naoko Anjiki [Japon] ; Kenji Watanabe [Japon] | Toki‐to protects dopaminergic neurons in the substantia nigra from neurotoxicity of MPTP in mice |
000F27 |
Fabio Blandini [Italie] ; Giovanna Levandis [Italie] ; Eleonora Bazzini [Italie] ; Giuseppe Nappi [Italie] ; Marie-Therese Armentero [Italie] | Time‐course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6‐hydroxydopamine in the rat: new clues from an old model |
000F28 |
Brenda L. Den Oudsten [Pays-Bas] ; Guus L. Van Heck [Pays-Bas] ; Jolanda De Vries [Pays-Bas] | The suitability of patient‐based measures in the field of Parkinson's disease: A systematic review |
000F31 |
Mauro Fasano [Italie] ; Bruno Bergamasco [Italie] ; Leonardo Lopiano [Italie] | The proteomic approach in Parkinson's disease |
000F32 |
Li Cao [République populaire de Chine] ; Ting Zhang [République populaire de Chine] ; Qin Xiao [République populaire de Chine] ; Ying Wang [République populaire de Chine] ; Li Bai [République populaire de Chine] ; Guo Qiang Lu [République populaire de Chine] ; Jian Fang Ma [République populaire de Chine] ; Jing Zhang [République populaire de Chine] ; Jian Qing Ding [République populaire de Chine] ; Sheng Di Chen [République populaire de Chine] | The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease |
000F34 |
C. Warren Olanow [États-Unis] | The pathogenesis of cell death in Parkinson's disease – 2007 |
000F39 |
Tanya Gurevich [Israël] ; Chava Peretz [Israël] ; Orna Moore [Israël] ; Nina Weizmann [Israël] ; Nir Giladi [Israël] | The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: A double blind placebo‐controlled pilot study |
000F40 |
Koichi Wakabayashi ; Kunikazu Tanji ; Fumiaki Mori ; Hitoshi Takahashi [Japon] | The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of α‐synuclein aggregates |
000F43 |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa |
000F46 |
Takeshi Iwatsubo [Japon] | THIS ARTICLE HAS BEEN RETRACTED: Pathological biochemistry of α‐synucleinopathy |
000F48 |
Uwe Ehrt [Norvège] ; Kolbj Rn Br Nnick [Norvège] ; Peter Paul De Deyn [Belgique] ; Murat Emre [Turquie] ; Sibel Tekin [États-Unis] ; Roger Lane [États-Unis] ; Dag Aarsland [Norvège] | Subthreshold depression in patients with Parkinson's disease and dementia––clinical and demographic correlates |
000F50 |
M. J. Hurley [Royaume-Uni] ; P. H. Patel [Royaume-Uni] ; M. J. Jackson [Royaume-Uni] ; L. A. Smith [Royaume-Uni] ; S. Rose [Royaume-Uni] ; P. Jenner [Royaume-Uni] | Striatal leucine‐rich repeat kinase 2 mRNA is increased in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned common marmosets (Callithrix jacchus) with l‐3, 4‐dihydroxyphenylalanine methyl ester‐induced dyskinesia |
000F53 |
Marc G. Weisskopf [États-Unis] ; Francine Grodstein [États-Unis] ; Alberto Ascherio [États-Unis] | Smoking and cognitive function in Parkinson's disease |
000F54 |
Cynthia L. Comella [États-Unis] | Sleep disorders in Parkinson's disease: An overview |
000F55 |
Jordan J. Elm [États-Unis] ; Cornelia Kamp [États-Unis] ; Barbara C. Tilley [États-Unis] ; Paulo Guimaraes [États-Unis] ; Debbie Fraser [États-Unis] ; Patricia Deppen [États-Unis] ; Alicia Brocht [États-Unis] ; Chris Weaver [États-Unis] ; Susan Bennett [États-Unis] | Self‐reported adherence versus pill count in Parkinson's disease: The NET‐PD experience |
000F56 |
V. Pursiainen [Finlande] ; T. J. Korpelainen [Finlande] ; H. T. Haapaniemi [Finlande] ; A. K. Sotaniemi [Finlande] ; V. V. Myllyl [Finlande] | Selegiline and blood pressure in patients with Parkinson's disease |
000F57 |
Margaret A. Piggott [Royaume-Uni] ; Clive G. Ballard [Royaume-Uni] ; Elise Rowan [Royaume-Uni] ; Clive Holmes [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni] ; Evelyn Jaros [Royaume-Uni] ; Robert H. Perry [Royaume-Uni] ; Elaine K. Perry [Royaume-Uni] | Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline |
000F58 |
G. Xiromerisiou [Grèce, États-Unis] ; G. M. Hadjigeorgiou [Grèce] ; V. Gourbali [Grèce] ; J. Johnson [États-Unis] ; I. Papakonstantinou [Grèce] ; A. Papadimitriou [Grèce] ; A. B. Singleton [États-Unis] | Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants |
000F60 |
Nir Giladi [Israël] ; Babak Boroojerdi [Allemagne] ; Amos D. Korczyn [Israël] ; David J. Burn [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Anthony H. V. Schapira [Royaume-Uni] | Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropinirole |
000F61 |
Christoph Scherfler [Autriche] ; Johannes Schwarz [Allemagne] ; Angelo Antonini [Italie] ; Donald Grosset [Royaume-Uni] ; Francesc Valldeoriola [Espagne] ; Kenneth Marek [États-Unis] ; Wolfgang Oertel [Allemagne] ; Eduardo Tolosa [Espagne] ; Andrew Lees (neurologue) [Royaume-Uni] ; Werner Poewe [Autriche] | Role of DAT‐SPECT in the diagnostic work up of Parkinsonism |
000F62 |
Andrew Siderowf [États-Unis] ; Danna Jennings [États-Unis] ; James Connolly [États-Unis] ; Richard L. Doty [États-Unis] ; Kenneth Marek [États-Unis] ; Matthew B. Stern [États-Unis] | Risk factors for Parkinson's disease and impaired olfaction in relatives of patients with Parkinson's disease |
000F63 |
Jeffrey M. Hausdorff [Israël, États-Unis] ; Justine Lowenthal [Israël] ; Talia Herman [Israël] ; Leor Gruendlinger [Israël] ; Chava Peretz [Israël] ; Nir Giladi [Israël] | Rhythmic auditory stimulation modulates gait variability in Parkinson's disease |
000F65 |
Juan C. G Mez-Esteban [Espagne] ; Juan J. Zarranz [Espagne] ; Beatriz Tijero [Espagne] ; Fernando Velasco [Espagne] ; Joseba Barcena [Espagne] ; Idoia Rouco [Espagne] ; Elena Lezcano [Espagne] ; María C. Lachen [Espagne] ; Amaia Jauregui [Espagne] ; Amaia Ugarte | Restless legs syndrome in Parkinson's disease |
000F66 |
Alex Iranzo [Espagne] ; Cynthia L. Comella [États-Unis] ; Joan Santamaria [Espagne] ; Wolfgang Oertel [Allemagne] | Restless legs syndrome in Parkinson's disease and other neurodegenerative diseases of the central nervous system |
000F67 |
Thomas Eckert [États-Unis, Allemagne] ; Andrew Feigin [États-Unis] ; Daniel E. Lewis [États-Unis] ; Vijay Dhawan [États-Unis] ; Steven Frucht [États-Unis] ; David Eidelberg [États-Unis] | Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging |
000F69 |
Anette Schrag [Royaume-Uni] ; Richard Dodel [Allemagne] ; Annika Spottke [Allemagne] ; Bernhard Bornschein [Autriche] ; Uwe Siebert [Autriche, États-Unis] ; Niall P. Quinn [Royaume-Uni] | Rate of clinical progression in Parkinson's disease. A prospective study |
000F70 |
Vincent Paillé [France] ; Vincent Henry [France] ; Laurent Lescaudron [France] ; Philippe Brachet [France] ; Philippe Damier [France] | Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias |
000F71 |
Ana Djarmati [Allemagne] ; Miodrag Gužvi [Allemagne, Serbie] ; Anne Grünewald [Allemagne] ; Anthony E. Lang [Canada] ; Peter P. Pramstaller [Italie] ; David K. Simon [États-Unis] ; Angela M. Kaindl [Allemagne] ; Peter Vieregge [Allemagne] ; Anders O. H. Nygren [Pays-Bas] ; Christian Beetz [Allemagne] ; Katja Hedrich [Allemagne] ; Christine Klein [Allemagne] | Rapid and reliable detection of exon rearrangements in various movement disorders genes by multiplex ligation‐dependent probe amplification |
000F72 |
Timothy M. Fountaine [Royaume-Uni] ; Richard Wade-Martins [Royaume-Uni] | RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport |
000F73 |
William C. Nichols [États-Unis] ; Diane K. Marek [États-Unis] ; Michael W. Pauciulo [États-Unis] ; Nathan Pankratz [États-Unis] ; Cheryl A. Halter [États-Unis] ; Alice Rudolph [États-Unis] ; Clifford W. Shults [États-Unis] ; Joanne Wojcieszek [États-Unis] ; Tatiana Foroud [États-Unis] | R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation |
000F74 |
Brenda L. Den Oudsten [Pays-Bas] ; Guus L. Van Heck [Pays-Bas] ; Jolanda De Vries [Pays-Bas] | Quality of life and related concepts in Parkinson's disease: A systematic review |
000F75 |
I. Rite [Espagne] ; S. Argüelles [Espagne] ; J. L. Venero [Espagne] ; S. García-Rodriguez [Espagne] ; A. Ayala [Espagne] ; J. Cano [Espagne] ; A. Machado [Espagne] | Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration |
000F79 |
Bart Post [Pays-Bas] ; Maruschka P. Merkus [Pays-Bas] ; Rob J. De Haan [Pays-Bas] ; Johannes D. Speelman [Pays-Bas] | Prognostic factors for the progression of Parkinson's disease: A systematic review |
000F81 |
Elan D. Louis [États-Unis] ; Steven J. Frucht [États-Unis] | Prevalence of essential tremor in patients with Parkinson's disease vs. Parkinson‐plus syndromes |
000F83 |
Yue Huang [Australie] ; Glenda M. Halliday [Australie] ; Himesha Vandebona [Australie] ; George D. Mellick [Australie] ; Frank Mastaglia [Australie] ; Julia Stevens [Australie] ; John Kwok [Australie] ; Michael Garlepp [Australie] ; Peter A. Silburn [Australie] ; Malcolm K. Horne [Australie] ; Katya Kotschet [Australie] ; Alison Venn [Australie] ; Dominic B. Rowe [Australie] ; Justin P. Rubio [Australie] ; Carolyn M. Sue [Australie] | Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's Disease |
000F86 |
Maarit Matinolli [Finlande] ; Juha T. Korpelainen [Finlande] ; Raija Korpelainen [Finlande] ; Kyösti A. Sotaniemi [Finlande] ; Minna Virranniemi [Finlande] ; Vilho V. Myllyl [Finlande] | Postural sway and falls in Parkinson's disease: A regression approach |
000F89 |
Chen [États-Unis] ; Swope [États-Unis] | Pharmacotherapy for Parkinson's Disease |
000F90 |
David A. Gallagher [Royaume-Uni] ; Sean S. O'Sullivan [Royaume-Uni] ; Andrew H. Evans [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Anette Schrag [Royaume-Uni] | Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series |
000F94 |
C. H. Hawkes ; K. Del Tredici [Allemagne] ; H. Braak [Allemagne] | Parkinson's disease: a dual‐hit hypothesis |
000F96 |
Mark Lew [États-Unis] | Overview of Parkinson's Disease |
000F97 |
Spiridon Papapetropoulos [États-Unis] ; Lina Shehadeh [États-Unis] ; Donald Mccorquodale [États-Unis] | Optimizing human post‐mortem brain tissue gene expression profiling in Parkinson's disease and other neurodegenerative disorders: From target “fishing” to translational breakthroughs |
000F98 |
Roberta Frigerio [États-Unis] ; Monique M. B. Breteler [Pays-Bas] ; Lonneke M. L. De Lau [Pays-Bas] ; Kevin R. Sanft [États-Unis] ; James H. Bower [États-Unis] ; J. Eric Ahlskog [États-Unis] ; Brandon R. Grossardt [États-Unis] ; Mariza de Andrade [États-Unis] ; Demetrius M. Maraganore [États-Unis] ; Walter A. Rocca [États-Unis] | Number of children and risk of Parkinson's disease |
000F99 |
Chiung-Mei Chen [Taïwan] ; I-Cheng Chen [Taïwan] ; Kuo-Hsuan Chang [Taïwan] ; Yi-Chun Chen [Taïwan] ; Rong-Kuo Lyu [Taïwan] ; Yen-Tzu Liu [Taïwan] ; Fen-Ju Hu [Taïwan] ; Chih-Ying Chao [Taïwan] ; Guey-Jen Lee-Chen [Taïwan] ; Yih-Ru Wu [Taïwan] | Nuclear receptor NR4A2 IVS6 +18insG and brain derived neurotrophic factor (BDNF) V66M polymorphisms and risk of Taiwanese parkinson's disease |
001004 |
Hyun Jung Park [Corée du Sud] ; Phil Hyu Lee [Corée du Sud] ; Young Whan Ahn [Corée du Sud] ; Yun Jung Choi [Corée du Sud] ; Gwang Lee [Corée du Sud] ; Da-Yong Lee [Corée du Sud] ; Eun S. Chung [Corée du Sud] ; Byung Kwan Jin [Corée du Sud] | Neuroprotective effect of nicotine on dopaminergic neurons by anti‐inflammatory action |
001005 |
Maria Teresa Giordana [Italie] ; Carla D'Agostino [Italie] ; Giovanni Albani [Italie] ; Alessandro Mauro [Italie] ; Alessio Di Fonzo [Pays-Bas, Italie] ; Angelo Antonini [Italie] ; Vincenzo Bonifati [Pays-Bas] | Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation |
001006 |
Smaranda Leu-Semenescu [France] ; Emmanuel Roze [France] ; Marie Vidailhet [France] ; André-Pierre Legrand [France] ; Jean-Marc Trocello [France] ; Valérie Cochen [France] ; Sophie Sangla [France] ; Emmanuelle Apartis [France] | Myoclonus or tremor in orthostatism: An under‐recognized cause of unsteadiness in Parkinson's disease |
001007 |
Michael W. M. Schüpbach [France] ; Marie Laure Welter [France] ; Anne Marie Bonnet [France] ; Alexis Elbaz [France] ; Brandon R. Grossardt [États-Unis] ; Valerie Mesnage [France] ; Jean Luc Houeto [France] ; David Maltête [France] ; Luc Mallet [France] ; Walter A. Rocca [États-Unis] ; Alain Mallet [France] ; Yves Agid [France] | Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus |
001008 |
Fernandez [États-Unis] ; Chen [États-Unis] | Monoamine Oxidase‐B Inhibition in the Treatment of Parkinson's Disease |
001009 |
M. C. Shih [Brésil] ; A. C. Felicio [Brésil] ; C. De Oliveira Godeiro-Junior [Brésil] ; P. De Carvalho Aguiar [Brésil] ; L. A. F. De Andrade [Brésil] ; H. B. Ferraz ; R. A. Bressan [Brésil] | Molecular imaging in hereditary forms of parkinsonism |
001011 |
Wei Zhang [États-Unis, République populaire de Chine] ; Shannon Dallas [États-Unis] ; Dan Zhang [États-Unis] ; Jian-Ping Guo [Canada] ; Hao Pang [États-Unis] ; Belinda Wilson [États-Unis] ; David S. Miller [États-Unis] ; Biao Chen [République populaire de Chine] ; Wanqin Zhang [République populaire de Chine] ; Patrick L. Mcgeer [Canada] ; Jau-Shyong Hong [États-Unis] ; Jing Zhang [États-Unis] | Microglial PHOX and Mac‐1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha‐synuclein |
001014 |
Gregor Simonis [Allemagne] ; Joerg T. Fuhrmann [Allemagne] ; Ruth H. Strasser [Allemagne] | Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists |
001016 |
Richard M. Camicioli [Canada] ; Christopher C. Hanstock [Canada] ; Thomas P. Bouchard [Canada] ; Myrlene Gee [Canada] ; Nancy J. Fisher [Canada] ; W. R. Wayne Martin [Canada] | Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease |
001018 |
Roberta Zangaglia [Italie] ; Emilia Martignoni [Italie] ; Margaret Glorioso [Italie] ; Maria Ossola [Italie] ; Giulio Riboldazzi [Italie] ; Daniela Calandrella [Italie] ; Gabriele Brunetti [Italie] ; Claudio Pacchetti [Italie] | Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo‐controlled study |
001020 |
Xuemei Huang [États-Unis] ; Honglei Chen [États-Unis] ; William C. Miller [États-Unis] ; Richard B. Mailman [États-Unis] ; Jennifer L. Woodard [États-Unis] ; Peter C. Chen [États-Unis] ; Dong Xiang [États-Unis] ; Richard W. Murrow [États-Unis] ; Yi-Zhe Wang [États-Unis] ; Charles Poole [États-Unis] | Lower low‐density lipoprotein cholesterol levels are associated with Parkinson's disease |
001021 |
Tua Annanmaki [Finlande] ; Antti Muuronen [Finlande] ; Kari Murros [Finlande] | Low plasma uric acid level in Parkinson's disease |
001023 |
F. Grandas [Espagne] ; B. Hernández [Espagne] | Long‐term effectiveness and quality of life improvement in entacapone‐treated Parkinson's disease patients: the effects of an early therapeutic intervention |
001024 |
Selma Aybek [Suisse] ; Aline Gronchi-Perrin [Suisse] ; Alexandre Berney [Suisse] ; Sabina Catalano Chiuvé [Suisse] ; Jean-Guy Villemure [Suisse] ; Pierre R. Burkhard [Suisse] ; François J. G. Vingerhoets [Suisse] | Long‐term cognitive profile and incidence of dementia after STN‐DBS in Parkinson's disease |
001029 |
Radu Constantinescu [États-Unis] ; Irene Richard [États-Unis] ; Roger Kurlan [États-Unis] | Levodopa responsiveness in disorders with parkinsonism: A review of the literature |
001030 |
Panida Piboolnurak [Canada, Thaïlande] ; Anthony E. Lang [Canada] ; Andres M. Lozano [Canada] ; Janis M. Miyasaki [Canada] ; Jean A. Saint-Cyr [Canada] ; Yu-Yan W. Poon [Canada] ; William D. Hutchison [Canada] ; Jonathan O. Dostrovsky [Canada] ; Elena Moro [Canada] | Levodopa response in long‐term bilateral subthalamic stimulation for Parkinson's disease |
001031 |
Lindsy N. Williams [États-Unis] ; Paul Seignourel [États-Unis] ; Gregory P. Crucian [États-Unis] ; Michael S. Okun [États-Unis] ; Ramon L. Rodriguez [États-Unis] ; Frank M. Skidmore [États-Unis] ; Paul S. Foster [États-Unis] ; Charles E. Jacobson Iv [États-Unis] ; Janet Romrell [États-Unis] ; Dawn Bowers [États-Unis] ; Hubert H. Fernandez [États-Unis] | Laterality, region, and type of motor dysfunction correlate with cognitive impairment in Parkinson's disease |
001035 |
Claudio Lucetti [Italie] ; Paulo Del Dotto [Italie] ; Gianna Gambaccini [Italie] ; Roberto Ceravolo [Italie] ; Chiara Logi [Italie] ; Caterina Berti [Italie] ; Giuseppe Rossi [Italie] ; Maria Cristina Bianchi [Italie] ; Michela Tosetti [Italie] ; Luigi Murri [Italie] ; Ubaldo Bonuccelli [Italie] | Influences of dopaminergic treatment on motor cortex in Parkinson disease: A MRI/MRS study |
001036 |
Orly Weinreb [Israël] ; Tamar Amit [Israël] ; Orit Bar-Am [Israël] ; Moussa B. H. Youdim [Israël] | Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil |
001037 |
Francisco Javier Carod-Artal [Brésil] ; Pablo Martinez-Martin [Espagne] ; Antonio Pedro Vargas [Brésil] | Independent validation of SCOPA–psychosocial and metric properties of the PDQ‐39 Brazilian version |
001038 |
Hisayoshi Oka [Japon] ; Masayuki Yoshioka [Japon] ; Kenji Onouchi [Japon] ; Masayo Morita [Japon] ; Soichiro Mochio [Japon] ; Masahiko Suzuki [Japon] ; Toshiaki Hirai [Japon] ; Mitsuyoshi Urashima [Japon] ; Kiyoharu Inoue [Japon] | Impaired cardiovascular autonomic function in Parkinson's disease with visual hallucinations |
001039 |
Donna White [États-Unis] ; Suzanne Moore [États-Unis] ; Stephen Waring [États-Unis] ; Karon Cook [États-Unis] ; Eugene Lai [États-Unis] | Identifying incident cases of parkinsonism among veterans using a tertiary medical center |
001040 |
Emilie Lacombe ; Carole Carcenac ; Sabrina Boulet ; Claude Feuerstein [France] ; Anne Bertrand ; Annie Poupard ; Marc Savasta [France] | High‐frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l‐3,4‐dihydroxyphenylalanine in dopaminergic denervated rats |
001042 |
Joaquim J. Ferreira [Portugal, Pays-Bas] ; Leonor Correia Guedes [Portugal] ; Mário Miguel Rosa [Portugal] ; Miguel Coelho [Portugal] ; Marina Van Doeselaar [Pays-Bas] ; Dorothea Schweiger [Pays-Bas] ; Alessio Di Fonzo [Pays-Bas] ; Ben A. Oostra [Pays-Bas] ; Cristina Sampaio [Portugal] ; Vincenzo Bonifati [Pays-Bas] | High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal |
001044 |
Paolo Ragonese [Italie] ; Marco D'Amelio [Italie] ; Graziella Callari [Italie] ; Fabio Aiello [Italie] ; Letterio Morgante [Italie] ; Giovanni Savettieri [Italie] | Height as a potential indicator of early life events predicting Parkinson's disease: A case‐control study |
001047 |
Julian P. Rodrigues [Australie] ; Susan E. Walters [Australie] ; Peter Watson [Australie] ; Rick Stell [Australie] ; Frank L. Mastaglia [Australie] | Globus pallidus stimulation improves both motor and nonmotor aspects of quality of life in advanced Parkinson's disease |
001050 |
Anthony H. V. Schapira [Royaume-Uni] | Future directions in the treatment of Parkinson's disease |
001052 |
Orna Moore [Israël] ; Chava Peretz [Israël] ; Nir Giladi [Israël] | Freezing of gait affects quality of life of peoples with Parkinson's disease beyond its relationships with mobility and gait |
001054 |
Roberto Cilia [Italie] ; Andrea Landi [Italie] ; Francesco Vergani [Italie] ; Erik Sganzerla [Italie] ; Gianni Pezzoli [Italie] ; Angelo Antonini [Italie] | Extradural motor cortex stimulation in Parkinson's disease |
001058 |
| Entacapone to tolcapone switch: Multicenter double‐blind, randomized, active‐controlled trial in advanced Parkinson's disease |
001059 |
Günther Deuschl [Allemagne] ; Antanas Vaitkus [Lituanie] ; Gabriele-Cornelia Fox ; Torsten Roscher ; Dieter Schremmer [Allemagne] ; Ariel Gordin | Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing‐off |
001060 |
Ken Nakamura [États-Unis] ; Chadwick W. Christine [États-Unis] ; Philip A. Starr [États-Unis] ; William J. Marks Jr. [États-Unis] | Effects of unilateral subthalamic and pallidal deep brain stimulation on fine motor functions in Parkinson's disease |
001061 |
Neeraja Sadagopan [États-Unis] ; Jessica E. Huber [États-Unis] | Effects of loudness cues on respiration in individuals with Parkinson's disease |
001062 |
Tatiana Witjas [France] ; Elsa Kaphan [France] ; Jean Régis [France] ; Elisabeth Jouve [France] ; André Ali Chérif [France] ; Jean-Claude Péragut [France] ; Jean Philippe Azulay [France] | Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's disease |
001065 |
Pablo Martinez-Martin [Espagne] ; Günther Deuschl [Allemagne] | Effect of medical and surgical interventions on health‐related quality of life in Parkinson's disease |
001066 |
Angelo Antonini [Italie] ; Ioannis U. Isaias [Italie] ; Margherita Canesi [Italie] ; Maurizio Zibetti [Italie] ; Francesca Mancini [Italie] ; Luigi Manfredi [Italie] ; Marco Dal Fante [Italie] ; Leonardo Lopiano [Italie] ; Gianni Pezzoli [Italie] | Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome |
001067 |
Sabrina Schröder [Allemagne] ; York Francis Zöllner [Allemagne] ; Marion Schaefer [Allemagne] | Drug related problems with Antiparkinsonian agents: consumer Internet reports versus published data |
001068 |
Quincy J. Almeida [Canada] ; James S. Frank [Canada] ; Eric A. Roy [Canada] ; Aftab E. Patla [Canada] ; Mandar S. Jog [Canada] | Dopaminergic modulation of timing control and variability in the gait of Parkinson's disease |
001071 |
Soon S. Park [États-Unis] ; Emily M. Schulz [États-Unis] ; Daewoo Lee [États-Unis] | Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by α‐synuclein |
001073 |
Martin Köllensperger [Autriche] ; Klaus Seppi [Autriche] ; Claudia Liener [Autriche] ; Sylvia Boesch [Autriche] ; Dirk Heute [Autriche] ; Katherina J. Mair [Autriche] ; Joerg Mueller [Autriche] ; Martin Sawires [Autriche] ; Christoph Scherfler [Autriche] ; Michael F. Schocke [Autriche] ; Eveline Donnemilier [Autriche] ; Irene Virgolini [Autriche] ; Gregor K. Wenning [Autriche] ; Werner Poewe [Autriche] | Diffusion weighted imaging best discriminates PD from MSA‐P: A comparison with tilt table testing and heart MIBG scintigraphy |
001074 |
Chul Hyoung Lyoo [Corée du Sud] ; Sargo Aalto [Finlande] ; Juha O. Rinne [Finlande] ; Ki Ook Lee [Corée du Sud] ; Seung Hun Oh [Corée du Sud] ; Jin Woo Chang [Corée du Sud] ; Myung Sik Lee [Corée du Sud] | Different cerebral cortical areas influence the effect of subthalamic nucleus stimulation on parkinsonian motor deficits and freezing of gait |
001075 |
Bruno Dubois [France] ; David Burn [Royaume-Uni] ; Christopher Goetz [États-Unis] ; Dag Aarsland [Norvège] ; Richard G. Brown [Royaume-Uni] ; Gerald A. Broe [Australie] ; Dennis Dickson [États-Unis] ; Charles Duyckaerts [France] ; Jefferey Cummings [États-Unis] ; Serge Gauthier [Canada] ; Amos Korczyn [Israël] ; Andrew Lees (neurologue) [Royaume-Uni] ; Richard Levy [France] ; Irene Litvan [États-Unis] ; Yoshikuni Mizuno [Japon] ; Ian G. Mckeith [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Eduardo Tolosa [Espagne] ; Murat Emre [Turquie] | Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force |
001078 |
Francisco Javier Carod-Artal [Brésil] ; Antonio Pedro Vargas [Brésil] ; Pablo Martinez-Martin [Espagne] | Determinants of quality of life in Brazilian patients with Parkinson's disease |
001079 |
M. Brandt-Christensen ; A. G. Lopez [Danemark] ; F. M. Nilsson [Danemark] ; P. K. Andersen [Danemark] ; L. V. Kessing | Depressive disorders and anti‐parkinson drug treatment: a case register study |
001080 |
Anette Schrag [Royaume-Uni] ; Paolo Barone [Italie] ; Richard G. Brown [Royaume-Uni] ; Albert F. G. Leentjens [Pays-Bas] ; William M. Mcdonald [États-Unis] ; Sergio Starkstein [Australie] ; Daniel Weintraub [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] | Depression rating scales in Parkinson's disease: Critique and recommendations |
001081 |
Peijun Chen [États-Unis] ; Helen C. Kales [États-Unis] ; Daniel Weintraub [États-Unis] ; Frederic C. Blow [États-Unis] ; Lan Jiang [États-Unis] ; Rosalinda V. Ignacio [États-Unis] ; Alan M. Mellow [États-Unis] | Depression in veterans with Parkinson's disease: frequency, co‐morbidity, and healthcare utilization |
001086 |
Karla Eggert [Allemagne] ; Ullrich Wüllner [Allemagne] ; Gisela Antony [Allemagne] ; Thomas Gasser [Allemagne] ; Bernd Janetzky [Allemagne] ; Christine Klein [Allemagne] ; Ludger Schöls [Allemagne] ; Wolfgang Oertel [Allemagne] | Data protection in biomaterial banks for Parkinson's disease research: The model of GEPARD (Gene bank Parkinson's Disease Germany) |
001087 |
Javier Pagonabarraga [Espagne] ; Carmen García-Sánchez [Espagne] ; Gisela Llebaria [Espagne] ; Berta Pascual-Sedano [Espagne] ; Alexandre Gironell [Espagne] ; Jaime Kulisevsky [Espagne] | Controlled study of decision‐making and cognitive impairment in Parkinson's disease |
001091 |
Kyum-Yil Kwon [Corée du Sud] ; Choong G. Choi [Corée du Sud] ; Jae S. Kim [Corée du Sud] ; Myoung C. Lee [Corée du Sud] ; Sun J. Chung [Corée du Sud] | Comparison of brain MRI and 18F‐FDG PET in the differential diagnosis of multiple system atrophy from Parkinson's disease |
001093 |
Nuria Caballol [Espagne] ; Maria J. Martí [Espagne] ; Eduardo Tolosa [Espagne] | Cognitive dysfunction and dementia in Parkinson disease |
001095 |
Gang Hu [Finlande] ; Siamak Bidel [Finlande] ; Pekka Jousilahti [Finlande] ; Riitta Antikainen [Finlande] ; Jaakko Tuomilehto [Finlande] | Coffee and tea consumption and the risk of Parkinson's disease |
001098 |
Murat Emre [Turquie] ; Dag Aarsland [Norvège] ; Richard Brown [Royaume-Uni] ; David J. Burn [Royaume-Uni] ; Charles Duyckaerts [France] ; Yoshikino Mizuno [Japon] ; Gerald Anthony Broe [Australie] ; Jeffrey Cummings [États-Unis] ; Dennis W. Dickson [États-Unis] ; Serge Gauthier [Canada] ; Jennifer Goldman [États-Unis] ; Christopher Goetz [États-Unis] ; Amos Korczyn [Israël] ; Andrew Lees (neurologue) [Royaume-Uni] ; Richard Levy [France] ; Irene Litvan [États-Unis] ; Ian Mckeith [Royaume-Uni] ; Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; Christina Sampaio [Portugal] ; Eduardo Tolosa [Espagne] ; Bruno Dubois [France] | Clinical diagnostic criteria for dementia associated with Parkinson's disease |
001102 |
B. Ramírez-Ruiz [Espagne] ; M. Martí [Espagne] ; E. Tolosa [Espagne] ; M. Giménez [Espagne] ; N. Bargall [Espagne] ; F. Valldeoriola [Espagne] ; C. Junqué [Espagne] | Cerebral atrophy in Parkinson's disease patients with visual hallucinations |
001107 |
V. Pursiainen [Finlande] ; J. T. Korpelainen ; T. H. Haapaniemi ; K. A. Sotaniemi ; V. V. Myllyl | Blood pressure and heart rate in parkinsonian patients with and without wearing‐off |
001110 |
Eric M. Cheng [États-Unis] ; Kari Swarztrauber [États-Unis] ; Andrew D. Siderowf [États-Unis] ; Mahmood S. Eisa [États-Unis] ; Martin Lee [États-Unis] ; Stefanie Vassar [États-Unis] ; Erin Jacob [États-Unis] ; Barbara G. Vickrey [États-Unis] | Association of specialist involvement and quality of care for Parkinson's disease |
001112 |
Martine Visser [Pays-Bas] ; Dagmar Verbaan [Pays-Bas] ; Stephanie M. Van Rooden [Pays-Bas] ; Anne M. Stiggelbout [Pays-Bas] ; Johan Marinus [Pays-Bas] ; Jacobus J. Van Hilten [Pays-Bas] | Assessment of psychiatric complications in Parkinson's disease: The SCOPA‐PC |
001116 |
Connie Marras [Canada] ; Alexander Kopp [Canada] ; Feng Qiu [Canada] ; Anthony E. Lang [Canada] ; Kathy Sykora [Canada] ; Kenneth I. Shulman [Canada] ; Paula A. Rochon [Canada] | Antipsychotic use in older adults with Parkinson's disease |
001117 |
Ji Youn Kim [Corée du Sud] ; Won Yong Lee [Corée du Sud] ; Eun Joo Chung [Corée du Sud] ; Hun-Jong Dhong [Corée du Sud] | Analysis of olfactory function and the depth of olfactory sulcus in patients with Parkinson's disease |
001119 |
Eng-King Tan [Singapour] ; Yi Zhao [Singapour] ; Louis Tan [Singapour] ; Hui-Qin Lim [Singapour] ; Jasinda Lee [Singapour] ; Yih Yuen [Singapour] ; Ratnagopal Pavanni [Singapour] ; Meng-Cheong Wong [Singapour] ; Stephanie Fook-Chong [Singapour] ; Jian-Jun Liu [Singapour] | Analysis of LRRK2 Gly2385Arg genetic variant in non‐Chinese Asians |
001125 |
Marie-Laure Mille [États-Unis] ; Marjorie Johnson Hilliard [États-Unis] ; Katherine M. Martinez [États-Unis] ; Tanya Simuni [États-Unis] ; Mark W. Rogers [États-Unis] | Acute effects of a lateral postural assist on voluntary step initiation in patients with Parkinson's disease |
001126 |
Katia Noyes [États-Unis] ; Hangsheng Liu [États-Unis] ; Robert Holloway [États-Unis] ; Andrew W. Dick [États-Unis] | Accuracy of medicare claims data in identifying Parkinsonism cases: Comparison with the medicare current beneficiary survey |
001134 |
Gabriella Santangelo [Italie] ; Luigi Trojano [Italie] ; Carmine Vitale [Italie] ; Marta Ianniciello [Italie] ; Marianna Amboni [Italie] ; Dario Grossi [Italie] ; Paolo Barone [Italie] | A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations |
001135 |
Imad Ghorayeb [France] ; Anderson Loundou [France] ; Pascal Auquier [France] ; Yves Dauvilliers [France] ; Bernard Bioulac [France] ; François Tison [France] | A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France |
001137 |
Ruth M. Pickering [Royaume-Uni] ; Yvette A. M. Grimbergen [Pays-Bas] ; Una Rigney [Royaume-Uni] ; Ann Ashburn [Royaume-Uni] ; Gordon Mazibrada [Royaume-Uni] ; Brian Wood [Royaume-Uni] ; Peggy Gray [Canada] ; Graham Kerr [Australie] ; Bastiaan R. Bloem [Pays-Bas] | A meta‐analysis of six prospective studies of falling in Parkinson's disease |
001140 |
Carlos Singer [États-Unis] ; Janice Lamb [Royaume-Uni] ; Amanda Ellis [Royaume-Uni] ; Gary Layton [Royaume-Uni] | A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease |
001141 |
S. N. Illarioshkin ; M. I. Shadrina [Russie] ; P. A. Slominsky [Russie] ; E. V. Bespalova [Russie] ; T. B. Zagorovskaya ; G. Kh. Bagyeva ; E. D. Markova ; S. A. Limborska [Russie] ; I. A. Ivanova-Smolenskaya | A common leucine‐rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia |
001158 |
A. Bloch [Suisse] ; A. Probst [Suisse] ; H. Bissig [Suisse] ; H. Adams [Suisse] ; M. Tolnay [Suisse] | α‐Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects |
001159 |
Brad A. Racette [États-Unis] ; Laura Good [États-Unis] ; Jo Ann Antenor [États-Unis] ; Lori Mcgee-Minnich [États-Unis] ; Stephen M. Moerlein [États-Unis] ; Tom O. Videen [États-Unis] ; Joel S. Perlmutter [États-Unis] | [18F]FDOPA PET as an endophenotype for Parkinson's Disease linkage studies |
001163 |
Christoph Scherfler ; Michael F. Schocke [Autriche] ; Klaus Seppi ; Regina Esterhammer [Autriche] ; Christian Brenneis ; Werner Jaschke [Autriche] ; Gregor K. Wenning ; Werner Poewe [Autriche] | Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease |
001165 |
Mona K. Beyer [Norvège] ; Dag Aarsland [Norvège] ; Ole Jacob Greve [Norvège] ; Jan P. Larsen [Norvège] | Visual rating of white matter hyperintensities in Parkinson's disease |
001167 |
Ji-Youn Kim [Corée du Sud] ; Eun Joo Chung [Corée du Sud] ; Seung Woo Park [Corée du Sud] ; Won Yong Lee [Corée du Sud] | Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists |
001168 |
William M. Mcdonald [États-Unis] ; Paul E. Holtzheimer [États-Unis] ; Michael Haber [États-Unis] ; Jerrold L. Vitek [États-Unis] ; Kimberly Mcwhorter [États-Unis] ; Mahlon Delong [États-Unis] | Validity of the 30‐item geriatric depression scale in patients with Parkinson's disease |
001169 |
Obering [États-Unis] ; Chen ; Swope [États-Unis] | Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's Disease |
001170 |
C. Warren Olanow [États-Unis] ; Kevin St. P. Mcnaught [États-Unis] | Ubiquitin–proteasome system and Parkinson's disease |
001173 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa‐induced dyskinesia from MPTP‐lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure |
001174 |
David A. Grimes [Canada] ; Fabin Han [Canada] ; Michel Panisset [Canada] ; Lemuel Racacho [Canada] ; Fengxia Xiao [Canada] ; Ruobing Zou [Canada] ; Kelly Westaff [Canada] ; Dennis E. Bulman [Canada] | Translated mutation in the Nurr1 gene as a cause for Parkinson's disease |
001182 |
Ann L. Hunt [États-Unis] ; Kapil D. Sethi [États-Unis] | The pull test: A history |
001185 |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease |
001190 |
Honglei Chen [États-Unis] ; Shumin M. Zhang [États-Unis] ; Michael A. Schwarzschild [États-Unis] ; Miguel A. Hernán [États-Unis] ; Alberto Ascherio [États-Unis] | Survival of Parkinson's disease patients in a large prospective cohort of male health professionals |
001192 |
Carmen Cristea Janvin [Norvège] ; Jan Petter Larsen [Norvège] ; Dag Aarsland [Norvège] ; Kenneth Hugdahl [Norvège] | Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia |
001194 |
Galit Kleiner-Fisman [États-Unis] ; Jan Herzog [Allemagne] ; David N. Fisman [États-Unis] ; Filippo Tamma [Italie] ; Kelly E. Lyons [États-Unis] ; Rajesh Pahwa [États-Unis] ; Anthony E. Lang [Canada] ; Günther Deuschl [Allemagne] | Subthalamic nucleus deep brain stimulation: Summary and meta‐analysis of outcomes |
001197 |
Anna L. Bartels [Pays-Bas] ; Bauke M. De Jong [Pays-Bas] ; Nir Giladi [Israël] ; Joanna D. Schaafsma [Pays-Bas] ; R. Paul Maguire [Pays-Bas] ; Lammy Veenma [Pays-Bas] ; Jan Pruim [Pays-Bas] ; Yacov Balash [Israël] ; Moussa B. H. Youdim [Israël] ; Klaus L. Leenders [Pays-Bas] | Striatal dopa and glucose metabolism in PD patients with freezing of gait |
001199 |
Michela Barichella [Italie] ; Agnieszka Marczewska [Italie] ; Roberta De Notaris [Italie] ; Antonella Vairo [Italie] ; Cinzia Baldo [Italie] ; Andrea Mauri [Italie] ; Chiara Savardi [Italie] ; Gianni Pezzoli [Italie] | Special low‐protein foods ameliorate postprandial off in patients with advanced Parkinson's disease |
001202 |
D. Guehl [France] ; E. Cuny [France] ; A. Benazzouz [France] ; A. Rougier [France] ; F. Tison [France] ; S. Machado [France] ; D. Grabot [France] ; C. Gross [France] ; B. Bioulac [France] ; P. Burbaud [France] | Side‐effects of subthalamic stimulation in Parkinson's disease: clinical evolution and predictive factors |
001203 |
Heather L. Katzen [États-Unis] ; Bonnie E. Levin [États-Unis] ; William Weiner [États-Unis] | Side and type of motor symptom influence cognition in Parkinson's disease |
001206 |
M. Horstink [Pays-Bas] ; E. Tolosa [Espagne] ; U. Bonuccelli [Italie] ; G. Deuschl [Allemagne] ; A. Friedman [Pologne] ; P. Kanovsky [République tchèque] ; J. P. Larsen [Norvège] ; A. Lees [Royaume-Uni] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; C. Sampaio [Portugal] | Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease |
001207 |
M. Horstink [Pays-Bas] ; E. Tolosa [Espagne] ; U. Bonuccelli [Italie] ; G. Deuschl [Allemagne] ; A. Friedman [Pologne] ; P. Kanovsky [République tchèque] ; J. P. Larsen [Norvège] ; A. Lees [Royaume-Uni] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; C. Sampaio [Portugal] | Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease |
001211 |
F. Stocchi [Italie] | Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease |
001212 |
Kevin M. Biglan [États-Unis] ; Steven Schwid [États-Unis] ; Shirley Eberly [États-Unis] ; Karen Blindauer [États-Unis] ; Stanley Fahn [États-Unis] ; Tamar Goren [Israël] ; Karl Kieburtz [États-Unis] ; David Oakes [États-Unis] ; Sandra Plumb [États-Unis] ; Andrew Siderowf [États-Unis] ; Matthew Stern [États-Unis] ; Ira Shoulson [États-Unis] | Rasagiline improves quality of life in patients with early Parkinson's disease |
001213 |
Angelo Antonini [Italie] ; Silvana Tesei [Italie] ; Anna Zecchinelli [Italie] ; Paolo Barone [Italie] ; Danilo De Gaspari [Italie] ; Margherita Canesi [Italie] ; Giorgio Sacilotto [Italie] ; Nicoletta Meucci [Italie] ; Claudio Mariani [Italie] ; Gianni Pezzoli [Italie] | Randomized study of sertraline and low‐dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life |
001215 |
Omar R. Tumilasci [Argentine] ; M. G. Cers Simo [Argentine] ; Juan E. Belforte [Argentine] ; Federico E. Micheli [Argentine] ; Eduardo E. Benarroch [États-Unis] ; Jorge H. Pazo [Argentine] | Quantitative study of salivary secretion in Parkinson's disease |
001216 |
Tanya Schmitz-Hübsch [Allemagne] ; Derek Pyfer [Allemagne] ; Karin Kielwein [Allemagne] ; Rolf Fimmers [Allemagne] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne] | Qigong exercise for the symptoms of Parkinson's disease: A randomized, controlled pilot study |
001217 |
Kazumichi Yamada [Japon] ; Satoshi Goto [Japon] ; Kazuhito Matsuzaki ; Shinji Nagahiro ; Nagako Murase [Japon] ; Hideki Shimazu [Japon] ; Ryuji Kaji [Japon] ; Jun-Ichi Kuratsu [Japon] ; Yukitaka Ushio [Japon] | Psychiatric Symptoms and Subthalamic Nucleus Stimulation in Parkinson's Disease. A Retrospective Study in Our Japanese Patients |
001218 |
Laura Marsh [États-Unis] ; William M. Mcdonald [États-Unis] ; Jeffrey Cummings [États-Unis] ; Bernard Ravina [États-Unis] | Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group |
001222 |
Kenichi Sato [Japon] ; Taku Hatano [Japon] ; Kazuo Yamashiro [Japon] ; Maki Kagohashi [Japon] ; Kenya Nishioka [Japon] ; Nana Izawa [Japon] ; Hideki Mochizuki [Japon] ; Nobutaka Hattori [Japon] ; Hideo Mori [Japon] ; Yoshikuni Mizuno [Japon] | Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations |
001223 |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa‐induced dyskinesias by a selective NR1A/2B N‐methyl‐D‐aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin |
001225 |
Nathan Pankratz [États-Unis] ; Lisa Byder [États-Unis] ; Cheryl Halter [États-Unis] ; Alice Rudolph [États-Unis] ; Clifford W. Shults [États-Unis] ; P. Michael Conneally [États-Unis] ; Tatiana Foroud [États-Unis] ; William C. Nichols [États-Unis] | Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia |
001226 |
Ergun Y. Uc [États-Unis] ; Lynn K. Struck [États-Unis] ; Robert L. Rodnitzky [États-Unis] ; Bridget Zimmerman [États-Unis] ; Judith Dobson [États-Unis] ; William J. Evans [États-Unis] | Predictors of weight loss in Parkinson's disease |
001227 |
Peter Valkovi [Allemagne, Slovaquie] ; Siegbert Krafczyk [Allemagne] ; Marian Šaling [Slovaquie] ; Ján Benetin [Slovaquie] ; Kai Bötzel [Allemagne] | Postural reactions to neck vibration in Parkinson's disease |
001230 |
Kate S. M. Taylor [Royaume-Uni] ; Carl E. Counsell [Royaume-Uni] ; Clare E. Harris [Royaume-Uni] ; Joanna C. Gordon [Royaume-Uni] ; W. Cairns S. Smith [Royaume-Uni] | Pilot study of the incidence and prognosis of degenerative Parkinsonian disorders in Aberdeen, United Kingdom: Methods and preliminary results |
001231 |
Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada, États-Unis] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
001235 |
Wolfgang H. Oertel [Allemagne] ; Erik Wolters [Pays-Bas] ; Cristina Sampaio [Portugal] ; Santiago Gimenez-Roldan [Espagne] ; Bruno Bergamasco [Italie] ; Max Dujardin [France] ; Donald G. Grosset [Royaume-Uni] ; Guy Arnold [Allemagne] ; Klaus L. Leenders [Pays-Bas] ; Hans-Peter Hundemer [États-Unis] ; Alberto Lled [États-Unis] ; Andrew Wood [États-Unis] ; Paul Frewer [États-Unis] ; Johannes Schwarz [Allemagne] | Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study |
001236 |
Claire Ardouin [France] ; Valerie Voon [Canada] ; Yulia Worbe [France] ; Nehman Abouazar [France] ; Virginie Czernecki [France] ; Hassan Hosseini [France] ; Antoine Pelissolo [France] ; Elena Moro [Canada] ; Eugénie Lhommée [France] ; Anthony E. Lang [Canada] ; Yves Agid [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] ; Luc Mallet [France] ; Paul Krack [France] | Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation |
001237 |
Maira Tonidandel Barbosa [Brésil] ; Paulo Caramelli [Brésil] ; Débora Palma Maia [Brésil] ; Mauro César Quintão Cunningham [Brésil] ; Henrique Leonardo Guerra [Brésil] ; Maria Fernanda Lima-Costa [Brésil] ; Francisco Cardoso [Brésil] | Parkinsonism and Parkinson's disease in the elderly: A community‐based survey in Brazil (the Bambuí study) |
001238 |
D. Gosal [Irlande (pays)] ; O. A. Ross [États-Unis] ; M. Toft [États-Unis, Norvège] | Parkinson's disease: the genetics of a heterogeneous disorder |
001239 |
François Sellal [France] | Parkinson's disease with dementia and dementia with Lewy body disease: two syndromes, the same disease? |
001240 |
Javier Sim N-Sánchez [Espagne] ; José-Félix Martí-Mass [Espagne] ; José Vicente Sánchez-Mut [Espagne] ; Coro Paisán-Ruiz [États-Unis] ; Angel Martínez-Gil [Espagne] ; Javier Ruiz-Martínez [Espagne] ; Amets Sáenz [Espagne] ; Andrew B. Singleton [États-Unis] ; Adolfo L Pez De Munain [Espagne] ; Jordi Pérez-Tur [Espagne] | Parkinson's disease due to the R1441G mutation in Dardarin: A founder effect in the basques |
001241 |
Kirsti K. Martikainen [Finlande] ; Tiina H. Luukkaala [Finlande] ; Reijo J. Marttila [Finlande] | Parkinson's disease and working capacity |
001244 |
Eng-King Tan [Singapour] ; Kenneth Yew [Singapour] ; Eva Chua [Singapour] ; K. Puvan [Singapour] ; Hui Shen [Singapour] ; Esther Lee [Singapour] ; Kim-Yoong Puong [Singapour] ; Yi Zhao [Singapour] ; Ratnagopal Pavanni [Singapour] ; Meng-Cheong Wong [Singapour] ; Dominic Jamora [Singapour] ; Deidre De Silva [Singapour] ; Kyaw-Thu Moe [Singapour] ; Fung-Peng Woon [Singapour] ; Yih Yuen [Singapour] ; Louis Tan [Singapour] | PINK1 mutations in sporadic early‐onset Parkinson's disease |
001245 |
Plamen Gatev [États-Unis] ; Olivier Darbin [États-Unis] ; Thomas Wichmann [États-Unis] | Oscillations in the basal ganglia under normal conditions and in movement disorders |
001246 |
Liesl M. Allcock [Royaume-Uni] ; Rose Anne Kenny [Royaume-Uni] ; Urs Peter Mosimann [Royaume-Uni] ; Sherley Tordoff [Royaume-Uni] ; Keith A. Wesnes [Royaume-Uni] ; Anthony J. Hildreth [Royaume-Uni] ; David J. Burn [Royaume-Uni] | Orthostatic hypotension in Parkinson's disease: association with cognitive decline? |
001249 |
Joseph H. Friedman [États-Unis] ; Robert M. Berman [États-Unis] ; Christopher G. Goetz [États-Unis] ; Stewart A. Factor [États-Unis] ; William G. Ondo [États-Unis] ; Joanne Wojcieszek [États-Unis] ; William H. Carson [États-Unis] ; Ronald N. Marcus [États-Unis] | Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease |
001251 |
Felipe Fregni [États-Unis] ; Paulo S. Boggio [Brésil] ; Marcelo C. Santos [Brésil] ; Moises Lima [Brésil] ; Adriana L. Vieira [Brésil] ; Sergio P. Rigonatti [Brésil] ; M. Teresa A. Silva [Brésil] ; Egberto R. Barbosa [Brésil] ; Michael A. Nitsche [Allemagne] ; Alvaro Pascual-Leone [États-Unis] | Noninvasive cortical stimulation with transcranial direct current stimulation in Parkinson's disease |
001252 |
Paola Piccini [Royaume-Uni] ; David J. Brooks [Royaume-Uni] | New developments of brain imaging for Parkinson's disease and related disorders |
001256 |
Nathan Pankratz [États-Unis] ; Michael W. Pauciulo [États-Unis] ; Veronika E. Elsaesser [États-Unis] ; Diane K. Marek [États-Unis] ; Cheryl A. Halter [États-Unis] ; Alice Rudolph [États-Unis] ; Clifford W. Shults [États-Unis] ; Tatiana Foroud [États-Unis] ; William C. Nichols [États-Unis] | Mutations in LRRK2 other than G2019S are rare in a north american–based sample of familial Parkinson's disease |
001260 |
Anette Schrag [Royaume-Uni] ; Cristina Sampaio [Portugal] ; Nicholas Counsell [Royaume-Uni] ; Werner Poewe [Autriche] | Minimal clinically important change on the unified Parkinson's disease rating scale |
001265 |
J. M. Hertz [Danemark] ; K. Stergaard [Danemark] ; I. Juncker [Danemark] ; S. Pedersen [Danemark] ; A. Romstad [Danemark] ; L. B. M Ller [Danemark] ; F. Güttler [Danemark] ; E. Dupont [Danemark] | Low frequency of Parkin, Tyrosine Hydroxylase, and GTP Cyclohydrolase I gene mutations in a Danish population of early‐onset Parkinson's Disease |
001267 |
Andrew Siderowf [États-Unis] ; Jurg L. Jaggi [États-Unis] ; Sharon X. Xie [États-Unis] ; Catherine Loveland-Jones [États-Unis] ; Lewis Leng [États-Unis] ; Howard Hurtig [États-Unis] ; Amy Colcher [États-Unis] ; Matthew Stern [États-Unis] ; Kelvin L. Chou [États-Unis] ; Grace Liang [États-Unis] ; Heather Maccarone [États-Unis] ; Tanya Simuni [États-Unis] ; Gordon Baltuch [États-Unis] | Long‐term effects of bilateral subthalamic nucleus stimulation on health‐related quality of life in advanced Parkinson's disease |
001272 |
Andrea Carmine Belin [Suède] ; Marie Westerlund [Suède] ; Olof Sydow [Suède] ; Karin Lundströmer [Suède] ; Anna H Kansson [Suède] ; Hans Nissbrandt [Suède] ; Lars Olson [Suède] ; Dagmar Galter [Suède] | Leucine‐rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian |
001275 |
Antti J. V N Nen [Finlande] ; Pekka Rauhala [Finlande] ; Raimo K. Tuominen [Finlande] ; P Ivi Liesi [Finlande, États-Unis] | KDI tripeptide of γ1 laminin protects rat dopaminergic neurons from 6‐OHDA induced toxicity |
001277 |
Kallol Ray Chaudhuri [Royaume-Uni] ; Pablo Martinez-Martin [Espagne] ; Anthony H. V. Schapira [Royaume-Uni] ; Fabrizio Stocchi [Italie] ; Kapil Sethi [États-Unis] ; Per Odin [Allemagne] ; Richard G. Brown [Royaume-Uni] ; William Koller [États-Unis] ; Paolo Barone [Italie] ; Graeme Macphee [Royaume-Uni] ; Linda Kelly [Royaume-Uni] ; Martin Rabey [Israël] ; Doug Macmahon [Royaume-Uni] ; Sue Thomas [Royaume-Uni] ; William Ondo [États-Unis] ; David Rye [États-Unis] ; Alison Forbes [Royaume-Uni] ; Susanne Tluk [Royaume-Uni] ; Vandana Dhawan [Royaume-Uni] ; Annette Bowron [Royaume-Uni] ; Adrian J. Williams [Royaume-Uni] ; Charles W. Olanow [États-Unis] | International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study |
001282 |
Paolo Ragonese [Italie] ; Marco D'Amelio [Italie] ; Giovanni Savettieri [Italie] | Implications for Estrogens in Parkinson's Disease |
001284 |
Hideaki Kobayashi [Japon] ; Hiroshi Ujike [Japon] ; Junko Hasegawa [Japon] ; Mitsutoshi Yamamoto [Japon] ; Akihiro Kanzaki [Japon] ; Ichiro Sora [Japon] | Identification of a risk haplotype of the α‐synuclein gene in Japanese with sporadic Parkinson's disease |
001285 |
Pedro Schestatsky [Brésil] ; Josep Valls-Solé ; João Arthur Ehlers [Brésil] ; Carlos R. M. Rieder [Brésil] ; Irênio Gomes [Brésil] | Hyperhidrosis in Parkinson's disease |
001286 |
Leland E. Dibble [États-Unis] ; Tessa F. Hale [États-Unis] ; Robin L. Marcus [États-Unis] ; John Droge [États-Unis] ; J. Parry Gerber [États-Unis] ; Paul C. Lastayo [États-Unis] | High‐intensity resistance training amplifies muscle hypertrophy and functional gains in persons with Parkinson's disease |
001290 |
Pablo Martínez-Martín [Espagne] ; M. João Forjaz [Espagne] ; Esther Cubo [Espagne] ; Belén Frades [Espagne] ; Jesús De Pedro Cuesta [Espagne] | Global versus factor‐related impression of severity in Parkinson's disease: A new clinimetric index (CISI‐PD) |
001296 |
L. Joseph Melton Iii [États-Unis] ; Cynthia L. Leibson [États-Unis] ; Sara J. Achenbach [États-Unis] ; James H. Bower [États-Unis] ; Demetrius M. Maraganore [États-Unis] ; Ann L. Oberg [États-Unis] ; Walter A. Rocca [États-Unis] | Fracture risk after the diagnosis of Parkinson's disease: Influence of concomitant dementia |
001301 |
Rodrigo Mercado [Canada] ; Constantine Constantoyannis [Canada] ; Tomasz Mandat [Canada] ; Ajit Kumar [Canada] ; Michael Schulzer [Canada] ; A. Jon Stoessl [Canada] ; Christopher R. Honey [Canada] | Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation |
001303 |
Isaac Shpirer [Israël] ; Ala Miniovitz [Israël] ; Colin Klein [Israël] ; Richard Goldstein [Israël] ; Tatiana Prokhorov [Israël] ; Jack Theitler [Israël] ; Lea Pollak [Israël] ; Jose Martin Rabey [Israël] | Excessive daytime sleepiness in patients with Parkinson's disease: A polysomnography study |
001309 |
P. Odin [Allemagne] ; C. Oehlwein [Allemagne] ; A. Storch [Allemagne] ; U. Polzer [Allemagne] ; G. Werner [Allemagne] ; R. Renner [Allemagne] ; M. Shing [Allemagne] ; A. Ludolph [Allemagne] ; P. Schüler [Allemagne] | Efficacy and safety of high‐dose cabergoline in Parkinson's disease |
001310 |
Vincent Chung [Hong Kong] ; Liang Liu [Hong Kong] ; Zhaoxiang Bian [Hong Kong] ; Zhongzhen Zhao [Hong Kong] ; Wai Leuk Fong [Hong Kong] ; Wan Fung Kum [Hong Kong] ; Jing Gao [Hong Kong] ; Min Li [Hong Kong] | Efficacy and safety of herbal medicines for idiopathic Parkinson's disease: A systematic review |
001311 |
J. Antonelle Demarcaida [États-Unis] ; Steven R. Schwid [États-Unis] ; William B. White [États-Unis] ; Karen Blindauer [États-Unis] ; Stanley Fahn [États-Unis] ; Karl Kieburtz [États-Unis] ; Matthew Stern [États-Unis] ; Ira Shoulson [États-Unis] | Effects of tyramine administration in Parkinson's disease patients treated with selective MAO‐B inhibitor rasagiline |
001312 |
A. E. Dias [Brésil] ; E. R. Barbosa [Brésil] ; K. Coracini [Brésil] ; F. Maia [Brésil] ; M. A. Marcolin [Brésil] ; F. Fregni [États-Unis] | Effects of repetitive transcranial magnetic stimulation on voice and speech in Parkinson's disease |
001313 |
Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Roshan Cools [Royaume-Uni] ; Paul Krack [France] ; Valérie Fraix [France] ; Alina Batir [France] ; Stephan Chabardès [France] ; Alim-Louis Benabid [France] ; Trevor W. Robbins [Royaume-Uni] ; Pierre Pollak [France] | Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease |
001314 |
S. Badarny [Israël] ; A. Stern [Israël] ; Z. Susel [Israël] ; S. Honigman [Israël] ; S. Hocherman [Israël] | Effect of ropinirole on visuo‐motor test in newly diagnosed Parkinson's disease patients |
001316 |
Eman M. Khedr [Égypte] ; John C. Rothwell [Royaume-Uni] ; Ola A. Shawky [Égypte] ; Mohamed A. Ahmed [Égypte] ; Ahmed Hamdy [Égypte] | Effect of daily repetitive transcranial magnetic stimulation on motor performance in Parkinson's disease |
001317 |
Olivier Rascol [France] ; Bruno Dubois [France] ; Alexandre Castro Caldas [Portugal] ; Stephen Senn [Royaume-Uni] ; Susanna Del Signore [France] ; Andrew Lees (neurologue) [Royaume-Uni] | Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study |
001318 |
C. Vossius [Norvège] ; M. Gjerstad [Norvège] ; H. Baas [Allemagne] ; J. P. Larsen [Norvège] | Drug costs for patients with Parkinson's disease in two different European countries |
001319 |
Cynthia L. Leibson [États-Unis] ; Kirsten Hall Long [États-Unis] ; Demetrius M. Maraganore [États-Unis] ; James H. Bower [États-Unis] ; Jeanine E. Ransom [États-Unis] ; Peter C. O'Brien [États-Unis] ; Walter A. Rocca [États-Unis] | Direct medical costs associated with Parkinson's disease: A population‐based study |
001322 |
Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni] | Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa |
001324 |
Uwe Ehrt [Norvège] ; Kolbj Rn Br Nnick [Norvège] ; Albert F. G. Leentjens [Pays-Bas] ; Jan Petter Larsen [Norvège] ; Dag Aarsland [Norvège] | Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease |
001325 |
A. Lieberman [États-Unis] | Depression in Parkinson's disease – a review |
001327 |
Anthony E. Lang [Canada] ; Jean-Luc Houeto [France] ; Paul Krack [France] ; Cynthia Kubu [États-Unis] ; Kelly E. Lyons [États-Unis] ; Elena Moro [Canada] ; William Ondo [États-Unis] ; Rajesh Pahwa [États-Unis] ; Werner Poewe [Autriche] ; Alexander I. Tröster [États-Unis] ; Ryan Uitti [États-Unis] ; Valerie Voon [Canada, États-Unis] | Deep brain stimulation: Preoperative issues |
001328 |
Günther Deuschl [Allemagne] ; Jan Herzog [Allemagne] ; Galit Kleiner-Fisman [États-Unis] ; Cynthia Kubu [États-Unis] ; Andres M. Lozano [Canada] ; Kelly E. Lyons [États-Unis] ; Maria C. Rodriguez-Oroz [Espagne] ; Filippo Tamma [Italie] ; Alexander I. Tröster [États-Unis] ; Jerrold L. Vitek [États-Unis] ; Jens Volkmann [Allemagne] ; Valerie Voon [États-Unis] | Deep brain stimulation: Postoperative issues |
001329 |
Valerie Voon [Canada, États-Unis] ; Cynthia Kubu [États-Unis] ; Paul Krack [France] ; Jean-Luc Houeto [France] ; Alexander I. Tröster [États-Unis] | Deep brain stimulation: Neuropsychological and neuropsychiatric issues |
001330 |
Ali R. Rezai [États-Unis] ; Brian H. Kopell [États-Unis] ; Robert E. Gross [États-Unis] ; Jerrold L. Vitek [États-Unis] ; Ashwini D. Sharan [États-Unis] ; Patricia Limousin [Royaume-Uni] ; Alim-Louis Benabid [France] | Deep brain stimulation for Parkinson's disease: Surgical issues |
001335 |
Cynthia L. Leibson [États-Unis] ; Demetrius M. Maraganore [États-Unis] ; James H. Bower [États-Unis] ; Jeanine E. Ransom [États-Unis] ; Peter C. O'Brien [États-Unis] ; Walter A. Rocca [États-Unis] | Comorbid conditions associated with Parkinson's disease: A population‐based study |
001336 |
Carmen Cristea Janvin [Norvège] ; Jan Petter Larsen [Norvège] ; David P. Salmon [États-Unis] ; Douglas Galasko [États-Unis] ; Kenneth Hugdahl [Norvège] ; Dag Aarsland [Norvège] | Cognitive profiles of individual patients with Parkinson's disease and dementia: Comparison with dementia with lewy bodies and Alzheimer's disease |
001337 |
Liesl M. Allcock [Royaume-Uni] ; Rose Anne Kenny [Royaume-Uni] ; David J. Burn [Royaume-Uni] | Clinical phenotype of subjects with Parkinson's disease and orthostatic hypotension: Autonomic symptom and demographic comparison |
001342 |
Guido Alves [Norvège] ; Jan Petter Larsen [Norvège] ; Murat Emre [Turquie] ; Tore Wentzel-Larsen [Norvège] ; Dag Aarsland [Norvège] | Changes in motor subtype and risk for incident dementia in Parkinson's disease |
001343 |
George I. Turnbull | Changes in gait and symptoms after bilateral pallidotomy: a client with Parkinson's disease |
001344 |
Eng-King Tan [Singapour] ; Kim-Yoong Puong [Singapour] ; Stephanie Fook-Chong [Singapour] ; Eva Chua [Singapour] ; Hui Shen [Singapour] ; Yih Yuen [Singapour] ; Ratnagopal Pavanni [Singapour] ; Meng-Cheong Wong [Singapour] ; Kathiravelu Puvan [Singapour] ; Yi Zhao [Singapour] | Case–control study of UCHL1 S18Y variant in Parkinson's disease |
001345 |
H. Oka [Japon] ; S. Mochio [Japon] ; M. Yoshioka [Japon] ; M. Morita [Japon] ; K. Onouchi [Japon] ; K. Inoue [Japon] | Cardiovascular dysautonomia in Parkinson's disease and multiple system atrophy[This article has been retracted] |
001347 |
Cornelius G. Bachmann [Allemagne] ; Claudia Trenkwalder [Allemagne] | Body weight in patients with Parkinson's disease |
001351 |
Carl-Albrecht Haensch [Allemagne] ; Johannes Jörg [Allemagne] | Beat‐to‐beat blood pressure analysis after premature ventricular contraction indicates sensitive baroreceptor dysfunction in Parkinson's disease |
001353 |
Martin Wilhelm Kurz [Allemagne, Norvège] ; Jan Petter Larsen [Norvège] ; Jan Terje Kvaloy [Norvège] ; Dag Aarsland [Norvège] | Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: A community‐based, longitudinal study |
001354 |
G. Webster Ross [États-Unis] ; Robert D. Abbott [États-Unis] ; Helen Petrovitch [États-Unis] ; Caroline M. Tanner [États-Unis] ; Daron G. Davis [États-Unis] ; James Nelson [États-Unis] ; William R. Markesbery [États-Unis] ; John Hardman [États-Unis] ; Kamal Masaki [États-Unis] ; Lenore Launer [États-Unis] ; Lon R. White [États-Unis] | Association of olfactory dysfunction with incidental Lewy bodies |
001356 |
Chava Peretz [Israël] ; Talia Herman [Israël] ; Jeffrey M. Hausdorff [Israël, États-Unis] ; Nir Giladi [Israël] | Assessing fear of falling: Can a short version of the Activities‐specific Balance Confidence scale be useful? |
001357 |
B. Feldman [Israël] ; J. Chapman [Israël] ; A. D. Korczyn [Israël] | Apolipoprotein ɛ4 advances appearance of psychosis in patients with Parkinson's disease |
001358 |
Marc J. Mentis [États-Unis] ; Dominique Delalot [États-Unis] ; Hassan Naqvi [États-Unis] ; Mark F. Gordon [États-Unis] ; Mark Gudesblatt [États-Unis] ; Christine Edwards [États-Unis] ; Luke Donatelli [États-Unis] ; Vijay Dhawan [États-Unis] ; David Eidelberg [États-Unis] | Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease |
001359 |
E. K. Tan [Singapour] ; Lisa Skipper [Singapour] ; Eva Chua [Singapour] ; Meng-Cheong Wong [Singapour] ; Ratnagopal Pavanni [Singapour] ; Carine Bonnard [Singapour] ; Prasanna Kolatkar [Singapour] ; Jian-Jun Liu [Singapour] | Analysis of 14 LRRK2 mutations in Parkinson's plus syndromes and late‐onset Parkinson's disease |
001360 |
Noël L. W. Keijsers [Pays-Bas] ; Martin W. I. M. Horstink [Pays-Bas] ; Stan C. A. M. Gielen [Pays-Bas] | Ambulatory motor assessment in Parkinson's disease |
001361 |
Christopher G. Goetz [États-Unis] ; Joanne Wuu [États-Unis] ; Linda Curgian [États-Unis] ; Sue Leurgans [États-Unis] | Age‐related influences on the clinical characteristics of new‐onset hallucinations in Parkinson's disease patients |
001366 |
L. Ishihara [Royaume-Uni] ; C. Brayne [Royaume-Uni] | A systematic review of depression and mental illness preceding Parkinson's disease |
001387 |
Brad A. Racette [États-Unis] ; Jo Ann Antenor [États-Unis] ; Lori Mcgee-Minnich [États-Unis] ; Stephen M. Moerlein [États-Unis] ; Tom O. Videen [États-Unis] ; Vikas Kotagal [États-Unis] ; Joel S. Perlmutter [États-Unis] | [18F]FDOPA PET and clinical features in parkinsonism due to manganism |
001393 |
Bart Post [Pays-Bas] ; Maruschka P. Merkus [Pays-Bas] ; Rob M. A. De Bie [Pays-Bas] ; Rob J. De Haan [Pays-Bas] ; Johannes D. Speelman [Pays-Bas] | Unified Parkinson's disease rating scale motor examination: Are ratings of nurses, residents in neurology, and movement disorders specialists interchangeable? |
001396 |
Katherine Grosset [Royaume-Uni] ; Donald Grosset [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Trial of subtherapeutic pergolide in de novo Parkinson's disease |
001399 |
Hasmet A. Hanagasi ; Murat Emre [Turquie] | Treatment of behavioural symptoms and dementia in Parkinson's disease |
001400 |
Silvi Frenkel-Toledo [Israël] ; Nir Giladi [Israël] ; Chava Peretz [Israël] ; Talia Herman [Israël] ; Leor Gruendlinger [Israël] ; Jeffrey M. Hausdorff [Israël, États-Unis] | Treadmill walking as an external pacemaker to improve gait rhythm and stability in Parkinson's disease |
001402 |
Meg Morris [Australie] ; Robert Iansek [Australie] ; Jennifer Mcginley [Australie] ; Thomas Matyas [Australie] ; Frances Huxham [Australie] | Three‐dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder |
001404 |
K. Haugarvoll [Norvège] ; D. Aarsland [Norvège] ; T. Wentzel-Larsen [Norvège] ; J. P. Larsen [Norvège] | The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease |
001406 |
Mahmoud M. Iravani [Royaume-Uni] ; Clement C. M. Leung [Royaume-Uni] ; Mona Sadeghian [Royaume-Uni] ; Claire O. Haddon [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | The acute and the long‐term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation |
001412 |
Mariese A. Hely [Australie] ; John G. L. Morris [Australie] ; Wayne G. J. Reid [Australie] ; Robert Trafficante [Australie] | Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years |
001413 |
Francisca Sueli Monte [Brésil] ; Francisco Pereira Da Silva-Júnior [Brésil] ; Pedro Braga-Neto [Brésil] ; Miguel Ngelo Nobre E Souza [Brésil] ; Veralice Meireles Sales De Bruin [Brésil] | Swallowing abnormalities and dyskinesia in Parkinson's disease |
001415 |
Katherine A. Grosset [Royaume-Uni] ; Ian Bone [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] | Suboptimal medication adherence in Parkinson's disease |
001416 |
Pedro Barroso-Chinea [Espagne] ; Ignacio Cruz-Muros [Espagne] ; María S. Aymerich [Espagne] ; Manuel Rodríguez-Díaz [Espagne] ; Domingo Afonso-Oramas [Espagne] ; José L. Lanciego [Espagne] ; Tomás González-Hernández [Espagne] | Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells |
001417 |
Colum D. Mackinnon [États-Unis] ; Ruth M. Webb [Royaume-Uni] ; Paul Silberstein [Royaume-Uni] ; Steven Tisch [Royaume-Uni] ; Peter Asselman [Royaume-Uni] ; Patricia Limousin [Royaume-Uni] ; John C. Rothwell [Royaume-Uni] | Stimulation through electrodes implanted near the subthalamic nucleus activates projections to motor areas of cerebral cortex in patients with Parkinson's disease |
001420 |
Angelo Insola [Italie] ; Paolo Mazzone [Italie] ; Massimiliano Valeriani [Italie] | Somatosensory evoked potential and clinical changes after electrode implant in basal ganglia of parkinsonian patients |
001421 |
Connie Marras [États-Unis] ; Samuel Goldman [États-Unis] ; Amanda Smith [États-Unis] ; Peter Barney [États-Unis] ; Diana Aston [États-Unis] ; Kathleen Comyns [États-Unis] ; Monica Korell [États-Unis] ; J. William Langston [États-Unis] ; G. Webster Ross [États-Unis] ; Caroline M. Tanner [États-Unis] | Smell identification ability in twin pairs discordant for Parkinson's disease |
001422 |
Nico J. Diederich ; Michel Vaillant [Luxembourg (pays)] ; Mike Leischen [Luxembourg (pays)] ; Giovanna Mancuso [Luxembourg (pays)] ; Serge Golinval ; Romain Nati ; Marc Schlesser | Sleep apnea syndrome in Parkinson's disease. A case–control study in 49 patients |
001423 |
D. Kaynak ; G. Kiziltan ; H. Kaynak ; G. Benbir ; O. Uysal [Turquie] | Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment |
001425 |
Melisa Proulx [Canada] ; François P. De Courval [Canada] ; Michael A. Wiseman [Canada] ; Michel Panisset [Canada] | Salivary production in Parkinson's disease |
001427 |
Leo Verhagen Metman [États-Unis] ; Shaun T. O'Leary [États-Unis] | Role of surgery in the treatment of motor complications |
001428 |
Katherine L. Widnell [États-Unis] ; Cynthia Comella [États-Unis] | Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations |
001430 |
Nico J. Diederich [Luxembourg (pays), États-Unis] ; Christopher G. Goetz [États-Unis] ; Glenn T. Stebbins [États-Unis] | Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: Focused review and a new integrative model |
001432 |
K. Winge [Danemark] ; L. Friberg [Danemark] ; L. Werdelin [Danemark] ; K. K. Nielsen [Danemark] ; H. Stimpel [Danemark] | Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease |
001433 |
Claudio Pacchetti [Italie] ; Raffaele Manni [Italie] ; Roberta Zangaglia [Italie] ; Francesca Mancini [Italie] ; Enrico Marchioni [Italie] ; Cristina Tassorelli [Italie] ; Michele Terzaghi [Italie] ; Maria Ossola [Italie] ; Emilia Martignoni [Italie] ; Arrigo Moglia [Italie] ; Giuseppe Nappi [Italie] | Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease |
001437 |
Katsumi Tsuchiya [Japon] ; Hisao Tajima [Japon] ; Toyoyasu Kuwae [Japon] ; Takao Takeshima [Japon] ; Toshiya Nakano [Japon] ; Masaharu Tanaka [Japon] ; Katsuyoshi Sunaga [Japon] ; Yoko Fukuhara [Japon] ; Kenji Nakashima [Japon] ; Eisaku Ohama [Japon] ; Hideki Mochizuki [Japon] ; Yoshikuni Mizuno [Japon] ; Nobuo Katsube [Japon] ; Ryoichi Ishitani [Japon] | Pro‐apoptotic protein glyceraldehyde‐3‐phosphate dehydrogenase promotes the formation of Lewy body‐like inclusions |
001440 |
R. Totaro [Italie] ; C. Marini [Italie] ; F. Pistoia [Italie] ; S. Sacco [Italie] ; T. Russo [Italie] ; A. Carolei [Italie] | Prevalence of Parkinson's disease in the L'Aquila district, central Italy |
001446 |
M. Macht [Allemagne] ; R. Schwarz [Allemagne] ; H. Ellgring [Allemagne] | Patterns of psychological problems in Parkinson's disease |
001450 |
Cheryl Waters [États-Unis] | Other pharmacological treatments for motor complications and dyskinesias |
001452 |
Aida M. Bertoli-Avella [Pays-Bas] ; José L. Giroud-Benitez [Cuba] ; Ali Akyol [Turquie] ; Egberto Barbosa [Brésil] ; Onno Schaap [Pays-Bas] ; Herma C. Van Der Linde [Pays-Bas] ; Emilia Martignoni [Italie] ; Leonardo Lopiano [Italie] ; Paolo Lamberti [Italie] ; Emiliana Fincati [Italie] ; Angelo Antonini [Italie] ; Fabrizio Stocchi [Italie] ; Pasquale Montagna [Italie] ; Ferdinando Squitieri [Italie] ; Paolo Marini [Italie] ; Giovanni Abbruzzese [Italie] ; Giovanni Fabbrini [Italie] ; Roberto Marconi [Italie] ; Alessio Dalla Libera [Italie] ; Giorgio Trianni [Italie] ; Marco Guidi [Italie] ; Antonio De Gaetano [Italie] ; Gustavo Boff Maegawa [Brésil] ; Antonino De Leo [Italie] ; Virgilio Gallai [Italie] ; Giulia De Rosa [Italie] ; Nicola Vanacore [Italie] ; Giuseppe Meco [Italie] ; Cornelia M. Van Duijn [Pays-Bas] ; Ben A. Oostra [Pays-Bas] ; Peter Heutink [Pays-Bas] ; Vincenzo Bonifati [Pays-Bas, Italie] | Novel parkin mutations detected in patients with early‐onset Parkinson's disease |
001454 |
Ryoko Yamamoto ; Eizo Iseki ; Wami Marui ; Takashi Togo ; Omi Katsuse ; Masanori Kato ; Daisuke Isojima [Japon] ; Hiroyasu Akatsu [Japon] ; Kenji Kosaka [Japon] ; Heii Arai | Non‐uniformity in the regional pattern of Lewy pathology in brains of dementia with Lewy bodies |
001455 |
Charles H. Adler [États-Unis] | Nonmotor complications in Parkinson's disease |
001458 |
C. Warren Olanow [États-Unis] ; Joseph Jankovic [États-Unis] | Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis‐targeted, disease‐modifying strategy |
001464 |
Joseph Jankovic [États-Unis] | Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations |
001468 |
Katherine A. Grosset [Royaume-Uni] ; John L. Reid [Royaume-Uni] ; Donald G. Grosset [Royaume-Uni] | Medicine‐taking behavior: Implications of suboptimal compliance in Parkinson's disease |
001472 |
Eilís Dowd [Royaume-Uni] ; Christelle Monville [Royaume-Uni] ; Eduardo M. Torres [Royaume-Uni] ; Liang-Fong Wong [Royaume-Uni] ; Mimoun Azzouz [Royaume-Uni] ; Nicholas D. Mazarakis [Royaume-Uni] ; Stephen B. Dunnett [Royaume-Uni] | Lentivector‐mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model |
001477 |
M. F. Silva ; P. Faria ; F. S. Regateiro ; V. Forjaz ; C. Janua Rio [Portugal] ; A. Freire [Portugal] ; M. Castelo-Branco | Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson's disease |
001478 |
Joanna Iczkiewicz [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Increased osteopontin expression following intranigral lipopolysaccharide injection in the rat |
001479 |
Masayuki Sugie [Japon] ; Jun Goto [Japon] ; Mitsuru Kawamura ; Hidekazu Ota [Japon] | Increased norepinephrine‐associated adrenomedullary inclusions in Parkinson's disease |
001480 |
Stéphane Chapuis [France] ; Lemlih Ouchchane [France] ; Olivier Metz [France] ; Laurent Gerbaud [France] ; Franck Durif [France] | Impact of the motor complications of Parkinson's disease on the quality of life |
001481 |
Mark Stacy [États-Unis] ; Annette Bowron [Royaume-Uni] ; Mark Guttman [Canada] ; Robert Hauser [États-Unis] ; Kim Hughes [Royaume-Uni] ; Jan Petter Larsen [Norvège] ; Peter Lewitt [États-Unis] ; Wolfgang Oertel [Allemagne] ; Niall Quinn [Royaume-Uni] ; Kapil Sethi [États-Unis] ; Fabrizio Stocchi [Italie] | Identification of motor and nonmotor wearing‐off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment |
001485 |
Anne Doé De Maindreville [France] ; Gilles Fénelon [France] ; Florence Mahieux [France] | Hallucinations in Parkinson's disease: A follow‐up study |
001486 |
Maher A. Noureddine [États-Unis] ; Yi-Ju Li [États-Unis] ; Joelle M. Van Der Walt [États-Unis] ; Robert Walters [États-Unis] ; Rita M. Jewett [États-Unis] ; Hong Xu [États-Unis] ; Tianyuan Wang [États-Unis] ; Jeffrey W. Walter [États-Unis] ; Burton L. Scott [États-Unis] ; Christine Hulette [États-Unis] ; Don Schmechel [États-Unis] ; Judith E. Stenger [États-Unis] ; Fred Dietrich [États-Unis] ; Jeffery M. Vance [États-Unis] ; Michael A. Hauser [États-Unis] | Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra |
001487 |
Aideen Mcinerney-Leo [États-Unis] ; Donald W. Hadley [États-Unis] ; Katrina Gwinn-Hardy [États-Unis] ; John Hardy [États-Unis] | Genetic testing in Parkinson's disease |
001492 |
M. Mishina [Japon] ; K. Ishiwata [Japon] ; K. Ishii [Japon] ; S. Kitamura [Japon] ; Y. Kimura [Japon] ; K. Kawamura [Japon] ; K. Oda [Japon] ; T. Sasaki [Japon] ; O. Sakayori [Japon] ; M. Hamamoto [Japon] ; S. Kobayashi [Japon] ; Y. Katayama [Japon] | Function of sigma1 receptors in Parkinson's disease |
001493 |
Dario Grossi [Italie] ; Luigi Trojano [Italie] ; Maria Teresa Pellecchia [Italie] ; Marianna Amboni [Italie] ; Nina Antonetta Fragassi [Italie] ; Paolo Barone [Italie] | Frontal dysfunction contributes to the genesis of hallucinations in non‐demented Parkinsonian patients |
001497 |
Jörg Spiegel [Allemagne] ; Marc-Oliver Möllers [Allemagne] ; Wolfgang H. Jost [Allemagne] ; Gerhard Fuss [Allemagne] ; Samuel Samnick [Allemagne] ; Ulrich Dillmann [Allemagne] ; Georg Becker [Allemagne] ; Carl-Martin Kirsch [Allemagne] | FP‐CIT and MIBG scintigraphy in early Parkinson's disease |
001498 |
Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] | Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 |
001499 |
M. Péchevis [France] ; C. E. Clarke [Royaume-Uni] ; P. Vieregge [Allemagne] ; B. Khoshnood [France] ; C. Deschaseaux-Voinet [France] ; G. Berdeaux [France] ; M. Ziegler [France] | Effects of dyskinesias in Parkinson's disease on quality of life and health‐related costs: a prospective European study |
001500 |
Anna Lena Törnqvist [Suède] ; Lucyna Schalén ; Stig Rehncrona [Suède] | Effects of different electrical parameter settings on the intelligibility of speech in patients with Parkinson's disease treated with subthalamic deep brain stimulation |
001501 |
Paulo S. Boggio [Brésil] ; Felipe Fregni [États-Unis] ; Felix Bermpohl [États-Unis] ; Carlos G. Mansur [Brésil] ; Moacyr Rosa [Brésil] ; Demetrio O. Rumi [Brésil] ; Egberto R. Barbosa [Brésil] ; Marina Odebrecht Rosa [Brésil] ; Alvaro Pascual-Leone [États-Unis] ; Sérgio Paulo Rigonatti [Brésil] ; Marco A. Marcolin [Brésil] ; Maria Teresa Araujo Silva [Brésil] | Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression |
001505 |
William G. Ondo [États-Unis] ; Ron Tintner [États-Unis] ; Kevin Dat Voung [États-Unis] ; Dejian Lai [États-Unis] ; George Ringholz [États-Unis] | Double‐blind, placebo‐controlled, unforced titration parallel trial of quetiapine for dopaminergic‐induced hallucinations in Parkinson's disease |
001507 |
N. L. W. Keijsers [Pays-Bas] ; M. A. Admiraal [Pays-Bas] ; A. R. Cools [Pays-Bas] ; B. R. Bloem [Pays-Bas] ; C. C. A. M. Gielen [Pays-Bas] | Differential progression of proprioceptive and visual information processing deficits in Parkinson's disease |
001509 |
Philippe Remy [France] ; Miroslava Doder [France] ; Andrew Lees (neurologue) [Royaume-Uni, France] ; Nora Turjanski [France] ; David Brooks [France] | Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system |
001511 |
S. Papapetropoulos [États-Unis] ; J. Gonzalez [États-Unis] ; A. Lieberman [États-Unis] ; J. M. Villar [États-Unis] ; D. C. Mash [États-Unis] | Dementia in Parkinson's disease: a post‐mortem study in a population of brain donors |
001516 |
Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Hughes [Australie] ; Andrew Evans [Royaume-Uni] ; Alice J. Manson [Royaume-Uni] ; Marion Hoffman [Australie] ; Lesley Swinn [Royaume-Uni] ; Hilary Watt [Royaume-Uni] ; Kailash Bhatia [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single‐dose challenges |
001518 |
K. Stiasny-Kolster ; Y. Doerr ; J. C. Mo Ller ; H. Ho Ffken ; T. M. Behr ; W. H. Oertel ; G. Mayer [Allemagne] | Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT |
001521 |
N. J. Cordato ; A. J. Duggins ; G. M. Halliday ; J. G. L. Morris ; C. Pantelis | Clinical deficits correlate with regional cerebral atrophy in progressive supranuclear palsy |
001524 |
Jean-Philippe Galanaud [France] ; Alexis Elbaz [France] ; Jacqueline Clavel [France] ; Jean-Sébastien Vidal [France] ; Jean-René Corrèze [France] ; Annick Alpérovitch [France] ; Christophe Tzourio [France] | Cigarette smoking and Parkinson's disease: A case–control study in a population characterized by a high prevalence of pesticide exposure |
001526 |
Serge Pinto [France, Royaume-Uni] ; Michèle Gentil [France] ; Paul Krack [France] ; Paul Sauleau [France] ; Valérie Fraix [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] | Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech |
001527 |
J. Eric Ahlskog [États-Unis] | Challenging conventional wisdom: The etiologic role of dopamine oxidative stress in Parkinson's disease |
001528 |
S. Papapetropoulos [États-Unis] ; A. Lieberman [États-Unis] ; J. Gonzalez [États-Unis] ; D. C. Mash [États-Unis] | Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease? |
001529 |
Esther Cubo [Espagne] ; Elena Alvarez [Espagne] ; Consuelo Morant [Espagne] ; Jesús De Pedro Cuesta [Espagne] ; Pablo Martínez Martín [Espagne] ; Ricard Génova [Espagne] ; José Manuel Freire [Espagne] | Burden of disease related to Parkinson's disease in Spain in the year 2000 |
001530 |
L. Alvarez ; R. Macias ; G. Lopez ; E. Alvarez ; N. Pavon ; M. C. Rodriguez-Oroz ; J. L. Juncos ; C. Maragoto ; J. Guridi ; I. Litvan ; E. S. Tolosa ; W. Koller [États-Unis] ; J. Vitek ; M. R. Delong ; J. A. Obeso | Bilateral subthalamotomy in Parkinson's disease: initial and long-term response |
001531 |
Björn Holmberg [Suède] ; Olle Corneliusson [Suède] ; Mikael Elam [Suède] | Bilateral stimulation of nucleus subthalamicus in advanced Parkinson's disease: No effects on, and of, autonomic dysfunction |
001533 |
Richard Camicioli [Canada] ; Ali Rajput [Canada] ; Michelle Rajput [Canada] ; Christian Reece [Canada] ; Haydeh Payami [États-Unis] ; Chunhai Hao [Canada] ; Alex Rajput [Canada] | Apolipoprotein E ϵ4 and catechol‐O‐methyltransferase alleles in autopsy‐proven Parkinson's disease: Relationship to dementia and hallucinations |
001534 |
Daniel Weintraub [États-Unis] ; Knashawn H. Morales [États-Unis] ; Paul J. Moberg [États-Unis] ; Warren B. Bilker [États-Unis] ; Catherine Balderston [États-Unis] ; John E. Duda [États-Unis] ; Ira R. Katz [États-Unis] ; Matthew B. Stern [États-Unis] | Antidepressant studies in Parkinson's disease: A review and meta‐analysis |
001535 |
Wilfred F. A. Den Dunnen [Pays-Bas] ; Michiel J. Staal [Pays-Bas] | Anatomical alterations of the subthalamic nucleus in relation to age: A postmortem study |
001536 |
Peter H. Kraus [Allemagne] ; Peter Klotz [Allemagne] ; Arndt Hoffmann [Allemagne] ; Johannes Lewe [Allemagne] ; Horst Przuntek [Allemagne] | Analysis of the course of Parkinson's disease under dopaminergic therapy: Performance of “fast tapping” is not a suitable parameter |
001537 |
Carme Junqué [Espagne] ; Blanca Ramírez-Ruiz [Espagne] ; Eduardo Tolosa [Espagne] ; Christopher Summerfield [Espagne] ; María-José Martí [Espagne] ; Pau Pastor [Espagne] ; Beatriz G Mez-Ans N [Espagne] ; José Ma. Mercader [Espagne] | Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia |
001538 |
Eng-King Tan [Singapour] ; Van R. Chandran [Singapour] ; Stephanie Fook-Chong [Singapour] ; Hui Shen [Singapour] ; Kenneth Yew [Singapour] ; Mei-Lin Teoh [Singapour] ; Yih Yuen [Singapour] ; Yi Zhao [Singapour] | Alpha‐synuclein mRNA expression in sporadic Parkinson's disease |
001540 |
Dag Aarsland [Norvège] ; Julia Zaccai [Royaume-Uni] ; Carol Brayne [Royaume-Uni] | A systematic review of prevalence studies of dementia in Parkinson's disease |
001542 |
Carolyn F. Orr ; Dominic B. Rowe ; Yoshikuni Mizuno [Japon] ; Hideo Mori [Japon] ; Glenda M. Halliday | A possible role for humoral immunity in the pathogenesis of Parkinson's disease |
001545 |
Mahmoud M. Iravani [Royaume-Uni] ; Emilie Syed [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Louisa C. Johnston [Royaume-Uni] ; Lance A. Smith [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets |
001548 |
J. Wang [République populaire de Chine] ; Y. Jiang [République populaire de Chine] ; X. Liu [République populaire de Chine] ; Z. Chen [République populaire de Chine] ; L. Yang [République populaire de Chine] ; C. Liu [République populaire de Chine] ; J. Xiang [République populaire de Chine] ; H. Su [République populaire de Chine] | 99mTc‐TRODAT‐1 SPECT study in early Parkinson's disease and essential tremor |
001556 |
P. Poorkaj [États-Unis] ; J. G. Nutt [États-Unis] ; D. James [États-Unis] ; S. Gancher [États-Unis] ; T. D. Bird [États-Unis] ; E. Steinbart [États-Unis] ; G. D. Schellenberg [États-Unis] ; Haydeh Payami [États-Unis] | parkin mutation analysis in clinic patients with early‐onset Parkinson's disease |
001557 |
Cheryl H. Waters [États-Unis] ; Kapil D. Sethi [États-Unis] ; Robert A. Hauser [États-Unis] ; Eric Molho [États-Unis] ; John M. Bertoni [États-Unis] | Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study |
001561 |
W. Heiss [Allemagne] ; R. Hilker [Allemagne] | The sensitivity of 18‐fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease |
001565 |
M. Białecka ; M. Dro Dzik ; G. Kłodowska-Duda ; K. Honczarenko ; B. Gawro Ska-Szklarz ; G. Opala ; J. Stankiewicz [Pologne] | The effect of monoamine oxidase B (MAOB) and catechol‐O‐methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease |
001569 |
U. Fiszer ; B. Tomik ; P. Grzesiowski ; A. Krygowska-Wajs [Pologne] ; J. Walory ; M. Michałowska ; W. Palasik | The antibodies against Bordetella pertussis in sera of patients with Parkinson's disease and other non‐neurological diseases |
001576 |
Mohamed Farouk Allam [Espagne] ; Michael J. Campbell ; Albert Hofman [Pays-Bas] ; Amparo Serrano Del Castillo [Espagne] ; Rafael Fernández-Crehuet Navajas [Espagne] | Smoking and Parkinson's disease: Systematic review of prospective studies |
001579 |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study |
001582 |
Gurutz Linazasoro [Espagne] | Recent failures of new potential symptomatic treatments for parkinson's disease: Causes and solutions |
001584 |
Connie Marras [Canada] ; Anthony Lang [Canada] ; Murray Krahn [Canada] ; George Tomlinson [Canada] ; Gary Naglie [Canada] | Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations |
001585 |
A. Nuti ; R. Ceravolo ; A. Piccinni [Italie] ; G. Dell'Agnello ; G. Bellini ; G. Gambaccini ; C. Rossi ; C. Logi ; L. Dell'Osso [Italie] ; U. Bonuccelli | Psychiatric comorbidity in a population of Parkinson's disease patients |
001586 |
E. I. Agorogiannis [Grèce] ; G. I. Agorogiannis [Grèce] ; A. Papadimitriou [Grèce] ; G. M. Hadjigeorgiou [Grèce] | Protein misfolding in neurodegenerative diseases |
001587 |
Adolfo Brusa [Italie] ; Rolf Stoehr [Italie] ; Peter P. Pramstaller [Italie] | Progressive supranuclear palsy: New disease or variant of postencephalitic parkinsonism? |
001592 |
Joseph Wiley [Irlande (pays)] ; Timothy Lynch [Irlande (pays)] ; Sarah Lincoln [États-Unis] ; Lisa Skipper [États-Unis] ; Mary Hulihan [États-Unis] ; David Gosal [Irlande (pays)] ; Gina Bisceglio [États-Unis] ; Jennifer Kachergus [États-Unis] ; John Hardy [États-Unis] ; Matthew J. Farrer [États-Unis] | Parkinson's disease in Ireland: Clinical presentation and genetic heterogeneity in patients with parkin mutations |
001596 |
M. Desmurget ; V. Gaveau ; P. Vindras ; R. S. Turner ; E. Broussolle [États-Unis] ; S. Thobois [États-Unis] | On-line motor control in patients with Parkinson's disease |
001599 |
Bala V. Manyam [États-Unis] ; Muralikrishnan Dhanasekaran [États-Unis] ; Theodore A. Hare [États-Unis] | Neuroprotective effects of the antiparkinson drug Mucuna pruriens |
001605 |
Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Royaume-Uni] ; Glenn T. Stebbins [États-Unis] ; Carl Counsell [Portugal] ; Nir Giladi [Israël] ; Robert G. Holloway [États-Unis] ; Charity G. Moore [États-Unis] ; Gregor K. Wenning [Autriche] ; Melvin D. Yahr [États-Unis] ; Lisa Seidl [États-Unis] | Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease |
001607 |
Padraig E. O'Suilleabhain [États-Unis] ; Teodoro Bottiglieri [États-Unis] ; Richard B. Dewey Jr. [États-Unis] ; Shailja Sharma [États-Unis] ; Ramon Diaz-Arrastia [États-Unis] | Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease |
001612 |
Rau L De La Fuente-Ferna Ndez [Canada] ; Vesna Sossi [Canada] ; Zhigao Huang [Canada] ; Sarah Furtado [Canada] ; Jian-Qiang Lu [Canada] ; Donald B. Calne [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] | Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias |
001613 |
C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio [Portugal] ; Fabrizio Stocchi [Italie] | Levodopa in the treatment of Parkinson's disease: Current controversies |
001614 |
Michael S. Okun [États-Unis] ; Jerrold L. Vitek [États-Unis] | Lesion therapy for Parkinson's disease and other movement disorders: Update and controversies |
001615 |
Paul J. Lockhart [États-Unis] ; Rebecca Bounds [États-Unis] ; Mary Hulihan [États-Unis] ; Jennifer Kachergus [États-Unis] ; Sarah Lincoln [États-Unis] ; Chin-Hsien Lin ; Ruey-Meei Wu ; Matthew J. Farrer [États-Unis] | Lack of mutations in DJ‐1 in a cohort of Taiwanese ethnic Chinese with early‐onset parkinsonism |
001616 |
Moussa B. H. Youdim [Israël] ; Galia Stephenson [Israël] ; Dorit Ben Shachar [Israël] | Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28 |
001619 |
Patrick L. Mcgeer [Canada] ; Edith G. Mcgeer [Canada] | Inflammation and the Degenerative Diseases of Aging |
001623 |
Antony J. Harding [Australie] ; Anurina Das [Australie] ; Jillian J. Kril [Australie] ; William S. Brooks [Australie] ; David Duffy [Australie] ; Glenda M. Halliday [Australie] | Identification of families with cortical Lewy body disease |
001628 |
Stuart J. Fellows ; Johannes Noth | Grip force abnormalities in de novo Parkinson's disease |
001634 |
Bastiaan R. Bloem [Pays-Bas] ; Jeffrey M. Hausdorff [Israël, États-Unis] ; Jasper E. Visser [Pays-Bas] ; Nir Giladi [Israël] | Falls and freezing of gait in Parkinson's disease: A review of two interconnected, episodic phenomena |
001637 |
Catherine Lozza [France] ; Jean-Claude Baron [France, Royaume-Uni] ; David Eidelberg [États-Unis] ; Marc J. Mentis [États-Unis] ; Maren Carbon [États-Unis] ; Rose-Marie Marié [France] | Executive processes in Parkinson's disease: FDG‐PET and network analysis |
001638 |
H. Furumoto [Japon] | Excessive daytime somnolence in Japanese patients with Parkinson's disease |
001645 |
Maaike Bakker [Pays-Bas] ; Rianne A. J. Esselink [Pays-Bas] ; Marten Munneke [Pays-Bas] ; Patricia Limousin-Dowsey [Royaume-Uni] ; Hans D. Speelman [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] | Effects of stereotactic neurosurgery on postural instability and gait in Parkinson's disease |
001646 |
Kristian Winge [Danemark] ; Lene M. Werdelin [Danemark] ; Kurt K. Nielsen [Danemark] ; Hans Stimpel [Danemark] | Effects of dopaminergic treatment on bladder function in Parkinson's disease |
001648 |
Matthew B. Stern [États-Unis] ; Kenneth L. Marek [États-Unis] ; Joseph Friedman [États-Unis] ; Robert A. Hauser [États-Unis] ; Peter A. Lewitt [États-Unis] ; Daniel Tarsy [États-Unis] ; C. Warren Olanow [États-Unis] | Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients |
001653 |
Mathias Pessiglione [France] ; Dominique Guehl [France] ; Caroline Jan [France] ; Chantal François [France] ; Etienne C. Hirsch [France] ; Jean Féger [France] ; Léon Tremblay [France] | Disruption of self‐organized actions in monkeys with progressive MPTP‐induced parkinsonism: II. Effects of reward preference |
001654 |
Alexei Korchounov [Allemagne] ; Hayo I. Schipper [Allemagne] ; Irina S. Preobrazhenskaya [Russie] ; Kirn R. Kessler [Allemagne] ; Nikolay N. Yakhno [Russie] | Differences in age at onset and familial aggregation between clinical types of idiopathic Parkinson's disease |
001656 |
Federico Micheli [Argentine] ; María Clara Scorticati [Argentine] ; Silvia Folgar [Argentine] ; Emilia Gatto [Argentine] | Development of Parkinson's disease in patients with blepharospasm |
001659 |
Eilís Dowd [Royaume-Uni] ; Stephen B. Dunnett [Royaume-Uni] | Deficits in a lateralized associative learning task in dopamine‐depleted rats with functional recovery by dopamine‐rich transplants |
001660 |
Paola Costa-Mallen [États-Unis] ; Zahra Afsharinejad [États-Unis] ; Samir N. Kelada [États-Unis] ; Lucio G. Costa [États-Unis, Italie] ; Gary M. Franklin [États-Unis] ; Phillip D. Swanson [États-Unis] ; W. T. Longstreth Jr. [États-Unis] ; Hannah-Malia A. Viernes [États-Unis] ; Federico M. Farin [États-Unis] ; Terri Smith-Weller [États-Unis] ; Harvey Checkoway [États-Unis] | DNA sequence analysis of monoamine oxidase B gene coding and promoter regions in Parkinson's disease cases and unrelated controls |
001662 |
Enrique Noe [États-Unis, Espagne] ; Karen Marder [États-Unis] ; Karen L. Bell [États-Unis] ; Diane M. Jacobs [États-Unis] ; Jennifer J. Manly [États-Unis] ; Yaakov Stern [États-Unis] | Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia |
001668 |
A. W. Michell [Royaume-Uni] ; S. J. G. Lewis [Royaume-Uni] ; T. Foltynie [Royaume-Uni] ; R. A. Barker [Royaume-Uni] | Biomarkers and Parkinson's disease |
001673 |
Carl E. Clarke [Royaume-Uni] | A “cure” for Parkinson's disease: Can neuroprotection be proven with current trial designs? |
001681 |
Murat Emre [Turquie] | What causes mental dysfunction in Parkinson's disease? |
001691 |
M. Joebges [Allemagne] ; M. Mrowka [Allemagne] ; N. Schimke [Allemagne] ; M. Shing [Allemagne] ; R. Dengler [Allemagne] ; P. Odin [Allemagne] | Three‐dimensional computerized analysis of diadochokinetic movements of Parkinsonian patients |
001694 |
Kati Kühn ; Jennifer Wellen [Allemagne] ; Nina Link ; Lyutha Maskri ; Hermann Lübbert [Allemagne] ; Christine C. Stichel [Allemagne] | The mouse MPTP model: gene expression changes in dopaminergic neurons |
001695 |
K. Herlofson [Norvège] ; J. P. Larsen [Norvège] | The influence of fatigue on health‐related quality of life in patients with Parkinson's disease |
001699 |
| The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations |
001701 |
Kah Leong Lim ; Valina L. Dawson [États-Unis] ; Ted M. Dawson [États-Unis] | The Cast of Molecular Characters in Parkinson's Disease |
001703 |
Dominique Twelves [Royaume-Uni] ; Kate S. M. Perkins [Royaume-Uni] ; Carl Counsell [Royaume-Uni] | Systematic review of incidence studies of Parkinson's disease |
001704 |
Per-Arne Fall [Suède] ; Avin Saleh [Suède] ; Mats Fredrickson [Suède] ; Jan-Edvin Olsson [Suède] ; Ann-Kathrine Granérus [Suède] | Survival time, mortality, and cause of death in elderly patients with Parkinson's disease. A 9‐year follow‐up |
001705 |
Aida M. Bertoli-Avella [Pays-Bas, Cuba] ; Jose L. Giroud-Benitez [Cuba] ; Vincenzo Bonifati [Italie, Pays-Bas] ; Eduardo Alvarez-Gonzalez [Cuba] ; Luis Heredero-Baute [Cuba] ; Cornelia M. Van Duijn [Pays-Bas] ; Peter Heutink [Pays-Bas] | Suggestive linkage to chromosome 19 in a large Cuban family with late‐onset Parkinson's disease |
001706 |
Roland Wenzelburger [Allemagne] ; Florian Kopper [Allemagne] ; Bao-Rong Zhang [Allemagne] ; Karsten Witt [Allemagne] ; Wolfgang Hamel [Allemagne] ; Dieter Weinert [Allemagne] ; Johann Kuhtz-Buschbeck [Allemagne] ; Mukaddes Gölge [Allemagne] ; Michael Illert [Allemagne] ; Günther Deuschl [Allemagne] ; Paul Krack [Allemagne] | Subthalamic nucleus stimulation for Parkinson's disease preferentially improves akinesia of proximal arm movements compared to finger movements |
001709 |
Matthew A. Brodsky [États-Unis] ; James Godbold [États-Unis] ; Tom Roth [États-Unis] ; C. Warren Olanow [États-Unis] | Sleepiness in Parkinson's disease: A controlled study |
001710 |
Sebastian Paus [Allemagne] ; Hans Michael Brecht [Allemagne] ; Jürgen Köster [Allemagne] ; Gert Seeger [Allemagne] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne] | Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease |
001712 |
Alexis Elbaz [France] ; Clotilde Levecque [France] ; Jacqueline Clavel [France] ; Jean-Sébastien Vidal [France] ; Florence Richard [France] ; Jean-René Corrèze [France] ; Bernard Delemotte [France] ; Philippe Amouyel [France] ; Annick Alpérovitch [France] ; Marie-Christine Chartier-Harlin [France] ; Christophe Tzourio [France] | S18Y polymorphism in the UCH‐L1 gene and Parkinson's disease: Evidence for an age‐dependent relationship |
001713 |
Vicky Marshall [Royaume-Uni] ; Donald Grosset [Royaume-Uni] | Role of dopamine transporter imaging in routine clinical practice |
001716 |
Charles H. Adler [États-Unis] ; John N. Caviness [États-Unis] ; Joseph G. Hentz [États-Unis] ; Marlene Lind [États-Unis] ; Judy Tiede [États-Unis] | Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease |
001717 |
Noëlle G. A. Spliethoff-Kamminga [Pays-Bas] ; Aeilko H. Zwinderman [Pays-Bas] ; Machiel P. Springer [Pays-Bas] ; Raymund A. C. Roos [Pays-Bas] | Psychosocial problems in Parkinson's disease: Evaluation of a disease‐specific questionnaire |
001718 |
Werner Poewe [Autriche] | Psychosis in Parkinson's disease |
001720 |
Elina Nurmi [Finlande] ; Jörgen Bergman [Finlande] ; Olli Eskola [Finlande] ; Olof Solin [Finlande] ; Tero Vahlberg [Finlande] ; Pirkko Sonninen [Finlande] ; Juha O. Rinne [Finlande] | Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET |
001721 |
Frank L. Mastaglia [Australie] ; Russell D. Johnsen [Australie] ; Michelle L. Byrnes [Australie] ; Byron A. Kakulas [Australie] | Prevalence of amyloid‐β deposition in the cerebral cortex in Parkinson's disease |
001722 |
Zhen-Xin Zhang [République populaire de Chine] ; Dallas W. Anderson [États-Unis] ; Jue-Bin Huang [République populaire de Chine] ; Hui Li [République populaire de Chine] ; Xia Hong [République populaire de Chine] ; Jing Wei [République populaire de Chine] ; En-Li Yang [République populaire de Chine] ; Demetrius M. Maraganore [États-Unis] | Prevalence of Parkinson's disease and related disorders in the elderly population of greater Beijing, China |
001723 |
Julián Benito-Le N [Espagne] ; Félix Bermejo-Pareja [Espagne] ; Javier Rodríguez [Espagne] ; José-Antonio Molina [Espagne] ; Rafael Gabriel [Espagne] ; José-Manuel Morales [Espagne] | Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain |
001726 |
Peter Teismann [États-Unis] ; Kim Tieu [États-Unis] ; Oren Cohen [États-Unis] ; Dong-Kug Choi [États-Unis] ; Du Chu Wu [États-Unis] ; Daniel Marks [États-Unis] ; Miquel Vila [États-Unis] ; Vernice Jackson-Lewis [États-Unis] ; Serge Przedborski [États-Unis] | Pathogenic role of glial cells in Parkinson's disease |
001728 |
Richard Camicioli [États-Unis, Canada] ; M. Milar Moore [États-Unis] ; Anthony Kinney [États-Unis] ; Elizabeth Corbridge [États-Unis] ; Kathryn Glassberg [États-Unis] ; Jeffrey A. Kaye [États-Unis] | Parkinson's disease is associated with hippocampal atrophy |
001742 |
Michael Orth [Royaume-Uni] ; Sarah J. Tabrizi [Royaume-Uni] | Models of Parkinson's disease |
001745 |
Walter Pirker [Autriche] ; Iris Holler [Autriche] ; Willibald Gerschlager [Autriche] ; Susanne Asenbaum [Autriche] ; Georg Zettinig [Autriche] ; Thomas Brücke [Autriche] | Measuring the rate of progression of Parkinson's disease over a 5‐year period with β‐CIT SPECT |
001756 |
Paul K. Morrish [Royaume-Uni] | How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? |
001764 |
Jiang-Fan Chen [États-Unis] ; Michael A. Schwarzschild [États-Unis] | Gene knockout approach to adenosine A2A receptors in Parkinson's disease |
001765 |
Orly Weinreb [Israël] ; Silvia Mandel [Israël] ; Moussa B. H. Youdim [Israël] | Gene and Protein Expression Profiles of Anti‐ and Pro‐apoptotic Actions of Dopamine, R‐Apomorphine, Green Tea Polyphenol (−)‐Epigallocatechine‐3‐gallate, and Melatonin |
001767 |
Marwan I. Hariz [Suède, Royaume-Uni] | From functional neurosurgery to “interventional” neurology: Survey of publications on thalamotomy, pallidotomy, and deep brain stimulation for Parkinson's disease from 1966 to 2001 |
001768 |
Allan L. Adkin [Canada] ; James S. Frank [Canada] ; Mandar S. Jog [Canada] | Fear of falling and postural control in Parkinson's disease |
001769 |
M. Kurz ; G. Alves ; D. Aarsland [Norvège] ; J. P. Larsen | Familial Parkinson's disease: a community‐based study |
001771 |
Julie Hudry [France] ; Ste Phane Thobois ; Emmanuel Broussolle ; Patrice Adeleine ; Jean-Pierre Royet [France] | Evidence for Deficiencies in Perceptual and Semantic Olfactory Processesin Parkinson's Disease |
001776 |
Marc Ziegler ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France] | Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled study |
001777 |
Amy J. Bastian [États-Unis] ; Valerie E. Kelly [États-Unis] ; Joel S. Perlmutter [États-Unis] ; Jonathan W. Mink [États-Unis] | Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease |
001784 |
A. Albanese [Italie] ; C. Colosimo [Italie] | Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists |
001785 |
Amy J. Bastian [États-Unis] ; Valerie E. Kelly [États-Unis] ; Fredy J. Revilla [États-Unis] ; Joel S. Perlmutter [États-Unis] ; Jonathan W. Mink [États-Unis] | Different effects of unilateral versus bilateral subthalamic nucleus stimulation on walking and reaching in Parkinson's disease |
001787 |
Mickie Welsh [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Robert G. Holloway [États-Unis] ; Sandy Plumb [États-Unis] ; Ronald Pfeiffer ; Jean Hubble [États-Unis] | Development and testing of the Parkinson's disease quality of life scale |
001789 |
Stanley Fahn [États-Unis] | Description of Parkinson's Disease as a Clinical Syndrome |
001790 |
J. Uekermann [Allemagne] ; I. Daum [Allemagne] ; S. Peters [Allemagne] ; B. Wiebel [Allemagne] ; H. Przuntek [Allemagne] ; T. Müller [Allemagne] | Depressed mood and executive dysfunction in early Parkinson's disease |
001792 |
Taresa Stefurak [Canada] ; David Mikulis [Canada] ; Helen Mayberg [Canada] ; Anthony E. Lang [Canada] ; Stephanie Hevenor [Canada] ; Peter Pahapill [États-Unis] ; Jean Saint-Cyr [Canada] ; Andres Lozano [Canada] | Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: A functional MRI case study |
001793 |
David J. Burn [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni] | Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease |
001795 |
Walter Pirker [Autriche] | Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it? |
001796 |
Nico J. Diederich [Luxembourg (pays), États-Unis] ; Vannina Pieri [Luxembourg (pays)] ; Christopher G. Goetz [États-Unis] | Coping strategies for visual hallucinations in Parkinson's disease |
001797 |
Maria J. Martí [Espagne] ; Eduardo Tolosa [Espagne] ; Jaume Campdelacreu [Espagne] | Clinical overview of the synucleinopathies |
001800 |
Frédéric Courbon [France] ; Christine Brefel-Courbon [France] ; Claire Thalamas [France] ; Marie Jeanne Alibelli [France] ; Isabelle Berry [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France] | Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease |
001801 |
Antje M. Smala [Allemagne] ; E. Annika Spottke [Allemagne] ; Olaf Machat [Allemagne] ; Uwe Siebert [États-Unis] ; Dieter Meyer [Allemagne] ; Rudolf Köhne-Volland [Allemagne] ; Martin Reuther [Allemagne] ; Janeen Duchane [États-Unis] ; Wolfgang H. Oertel [Allemagne] ; Karin B. Berger [Allemagne] ; Richard C. Dodel [Allemagne] | Cabergoline versus levodopa monotherapy: A decision analysis |
001803 |
Michela Barichella [Italie] ; Agnieszka M. Marczewska [Italie] ; Claudio Mariani [Italie] ; Andrea Landi [Italie] ; Antonella Vairo [Italie] ; Gianni Pezzoli [Italie] | Body weight gain rate in patients with Parkinson's disease and deep brain stimulation |
001806 |
Masayo Shamoto-Nagai [Japon] ; Wakako Maruyama [Japon] ; Yoji Kato [Japon] ; Ken-Ichi Isobe [Japon] ; Masashi Tanaka [Japon] ; Makoto Naoi [Japon] ; Toshihiko Osawa [Japon] | An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH‐SY5Y cells |
001807 |
Georg Ebersbach [Allemagne] | An artist's view of drug‐induced hallucinosis |
001809 |
Stefano Tamburin [Italie] ; Antonio Fiaschi [Italie] ; Domenico Idone [Italie] ; Piergiorgio Lochner [Italie] ; Paolo Manganotti [Italie] ; Giampietro Zanette [Italie] | Abnormal sensorimotor integration is related to disease severity in Parkinson's disease: A TMS study |
001811 |
Shingo Okabe [Japon] ; Yoshikazu Ugawa [Japon] ; Ichiro Kanazawa [Japon] | 0.2‐Hz repetitive transcranial magnetic stimulation has no add‐on effects as compared to a realistic sham stimulation in Parkinson's disease |
001814 |
Willibald Gerschlager [Autriche, Royaume-Uni] ; Gerhard Bencsits [Autriche] ; Walter Pirker [Autriche] ; Bastiaan R. Bloem [Royaume-Uni, Pays-Bas] ; Susanne Asenbaum [Autriche] ; Daniella Prayer [Autriche] ; Jan C. M. Zijlmans [Royaume-Uni] ; Martha Hoffmann [Autriche] ; Thomas Brücke [Autriche] | [123I]β‐CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease |
001816 |
Simon G. Parkin [Royaume-Uni] ; Ralph P. Gregory [Royaume-Uni] ; Richard Scott [Royaume-Uni] ; Peter Bain [Royaume-Uni] ; Peter Silburn [Australie] ; Bruce Hall [Australie] ; Richard Boyle [Australie] ; Carole Joint [Royaume-Uni] ; Tipu Z. Aziz [Royaume-Uni] | Unilateral and bilateral pallidotomy for idiopathic Parkinson's disease: A case series of 115 patients |
001817 |
Pierre Pollak [France] ; Valérie Fraix [France] ; Paul Krack [France] ; Elena Moro [France] ; Alexandre Mendes [France] ; Stephan Chabardes [France] ; Adnan Koudsie [France] ; Alim-Louis Benabid [France] | Treatment results: Parkinson's disease |
001819 |
Bente Thommessen [Norvège] ; Dag Aarsland [Norvège] ; Anne Braekhus ; Anne Rita Oksengaard [Norvège] ; Knut Engedal ; Knut Laake [Norvège] | The psychosocial burden on spouses of the elderly with stroke, dementia and Parkinson's disease |
001820 |
Tamar C. Rubinstein [Israël] ; Nir Giladi [Israël] ; Jeffrey M. Hausdorff [Israël, États-Unis] | The power of cueing to circumvent dopamine deficits: A review of physical therapy treatment of gait disturbances in Parkinson's disease |
001821 |
T. Foltynie [Royaume-Uni] ; S. Sawcer [Royaume-Uni] ; C. Brayne [Royaume-Uni] ; R A Barker [Royaume-Uni] | The genetic basis of Parkinson's disease |
001826 |
Svenja Happe ; Klaus Berger | The association between caregiver burden and sleep disturbances in partners of patients with Parkinson's disease |
001828 |
P. H. Robert [France] ; S. Clairet [France] ; M. Benoit [France] ; J. Koutaich [France] ; C. Bertogliati [France] ; O. Tible [France] ; H. Caci [France] ; M. Borg [France] ; P. Brocker [France] ; P. Bedoucha [France] | The Apathy Inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment |
001829 |
Andrew Siderowf [États-Unis] ; Michael Mcdermott [États-Unis] ; Karl Kieburtz [États-Unis] ; Karen Blindauer [États-Unis] ; Sandra Plumb [États-Unis] ; Ira Shoulson [États-Unis] | Test–Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial |
001831 |
Katherine H. O. Deane [Royaume-Uni] ; Caroline Ellis-Hill [Royaume-Uni] ; Diana Jones [Royaume-Uni] ; Renata Whurr [Royaume-Uni] ; Yoav Ben-Shlomo [Royaume-Uni] ; E. Diane Playford [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] | Systematic review of paramedical therapies for Parkinson's disease |
001832 |
Claudia Ramaker [Pays-Bas] ; Johan Marinus [Pays-Bas] ; Anne Margarethe Stiggelbout [Pays-Bas] ; Bob Johannes Van Hilten [Pays-Bas] | Systematic evaluation of rating scales for impairment and disability in Parkinson's disease |
001843 |
Robert A. Hauser [États-Unis] ; Nicholas H. G. Holford [Nouvelle-Zélande] | Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease |
001844 |
Joseph O'Neill [États-Unis] ; Norbert Schuff [États-Unis] ; William J. Marks Jr. [États-Unis] ; Robert Feiwell [États-Unis] ; Michael J. Aminoff [États-Unis] ; Michael W. Weiner [États-Unis] | Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease |
001848 |
Walter Pirker [Autriche] ; Schiva Djamshidian [Autriche] ; Susanne Asenbaum [Autriche] ; Willibald Gerschlager [Autriche] ; Gotthard Tribl [Autriche] ; Martha Hoffmann [Autriche] ; Thomas Brücke [Autriche] | Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study |
001849 |
Eliezer Masliah [États-Unis] ; Lawrence A. Hansen [États-Unis] ; Edward Rockenstein [États-Unis] ; Makoto Hashimoto [États-Unis] | Progress in the development of new treatments for combined Alzheimer's and Parkinson's diseases |
001850 |
Marie Sarazin [France] ; Bernard Deweer [France] ; Angela Merkl [France] ; Natalia Von Poser [France] ; Bernard Pillon [France] ; Bruno Dubois [France] | Procedural learning and striatofrontal dysfunction in Parkinson's disease |
001851 |
Pille Taba [Estonie] ; Toomas Asser [Estonie] | Prevalence of Parkinson's disease in Estonia |
001852 |
Luis Erik Clavería [Espagne] ; Jacinto Duarte [Espagne] ; Maria Dolores Sevillano [Espagne] ; Angel Pérez-Sempere [Espagne] ; Carmen Cabezas [Espagne] ; Fernanda Rodríguez [Espagne] ; Jesús De Pedro-Cuesta [Espagne, Suède] | Prevalence of Parkinson's disease in Cantalejo, Spain: A door‐to‐door survey |
001855 |
Paul Krack [France] ; Valérie Fraix [France] ; Alexandre Mendes [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] | Postoperative management of subthalamic nucleus stimulation for Parkinson's disease |
001856 |
Christopher G. Goetz [États-Unis] ; Sue Leurgans [États-Unis] ; Rema Raman [États-Unis] | Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease |
001865 |
K. C. M. Leung ; E. H. N. Pow ; A. S. Mcmillan ; M. C. M. Wong ; L. S. W. Li ; S. Hi [Hong Kong] | Oral perception and oral motor ability in edentulous patients with stroke and Parkinson's disease |
001866 |
Marianne Caap-Ahlgren | Older Swedish women's experiences of living with symptoms related to Parkinson's disease |
001867 |
William G. Ondo [États-Unis] ; Joel K. Levy [États-Unis] ; Kevin Dat Vuong [États-Unis] ; Christine Hunter [États-Unis] ; Joseph Jankovic [États-Unis] | Olanzapine treatment for dopaminergic‐induced hallucinations |
001870 |
Bernard Pillon [France] | Neuropsychological assessment for management of patients with deep brain stimulation |
001875 |
Rajeev Kumar [États-Unis] | Methods for programming and patient management with deep brain stimulation of the globus pallidus for the treatment of advanced Parkinson's disease and dystonia |
001876 |
Gilberto Levy [États-Unis] ; Diane M. Jacobs [États-Unis] ; Ming-Xin Tang [États-Unis] ; Lucien J. Côté [États-Unis] ; Elan D. Louis [États-Unis] ; Brenda Alfaro [États-Unis] ; Helen Mejia [États-Unis] ; Yaakov Stern [États-Unis] ; Karen Marder [États-Unis] | Memory and executive function impairment predict dementia in Parkinson's disease |
001878 |
Flemming M. Nilsson ; Lars V. Kessing ; Tine M. S Rensen [Danemark] ; Per K. Andersen [Danemark] ; Tom G. Bolwig | Major depressive disorder in Parkinson's disease: a register‐based study |
001880 |
David A. Grimes [Canada] ; J. David Grimes [Canada] ; Lem Racacho [Canada] ; Kylie A. Scoggan [Canada] ; Fabin Han [Canada] ; Betty Anne Schwarz [Canada] ; John Woulfe [Canada] ; Dennise Bulman [Canada] | Large French‐Canadian family with Lewy body parkinsonism: Exclusion of known loci |
001882 |
Juan L. Sánchez ; Marina Rodríguez [Espagne] ; Juan Carro | Influence of cognitive reserve on neuropsychological functioning in Parkinson's disease |
001886 |
Helle Just [Danemark] ; Karen Ostergaard [Danemark] | Health‐Related quality of life in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nuclei |
001892 |
M. Zorzon [Italie] ; L. Capus [Italie] ; A. Pellegrino [Italie] ; G. Cazzato [Italie] ; R. Zivadinov [Italie] | Familial and environmental risk factors in Parkinson's disease: a case–control study in north‐east Italy |
001895 |
Giovanni Fabbrini [Italie] ; Piero Barbanti [Italie] ; Cinzia Aurilia [Italie] ; Nicola Vanacore [Italie] ; Caterina Pauletti [Italie] ; Giuseppe Meco [Italie] | Excessive daytime sleepiness in de novo and treated Parkinson's disease |
001898 |
Werner Poewe [Autriche] ; G. Deuschl ; A. Gordin [Finlande] ; E. Kultalahti [Finlande] ; M. Leinonen [Finlande] | Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study) |
001899 |
Karen Stergaard [Danemark] ; Niels Sunde [Danemark] ; Erik Dupont [Danemark] | Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations |
001906 |
A. H. V. Schapira | Dopamine agonists and neuroprotection in Parkinson's disease |
001907 |
Gilberto Levy [États-Unis] ; Ming-Xin Tang [États-Unis] ; Lucien J. Cote [États-Unis] ; Elan D. Louis [États-Unis] ; Brenda Alfaro [États-Unis] ; Helen Mejia [États-Unis] ; Yaakov Stern [États-Unis] ; Karen Marder [États-Unis] | Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study |
001910 |
Elan D. Louis [États-Unis] ; Gilberto Levy [États-Unis] ; Lucien J. Côte [États-Unis] ; Helen Mejia [États-Unis] ; Stanley Fahn [États-Unis] ; Karen Marder [États-Unis] | Diagnosing Parkinson's disease using videotaped neurological examinations: Validity and factors that contribute to incorrect diagnoses |
001911 |
D. J. Burn [Royaume-Uni] | Depression in Parkinson's disease |
001913 |
A. F. G. Leentjens [Pays-Bas] ; F. R. J. Verhey [Pays-Bas] | Depression and Parkinson's disease: a conceptual challenge |
001915 |
Anthony E. Lang [Canada] ; Hakan Widner [Suède] | Deep brain stimulation for Parkinson's disease: Patient selection and evaluation |
001916 |
Diego Garcia-Borreguero [Espagne] ; Ana B. Caminero [Espagne] ; Yolanda De La Llave [Espagne] ; Oscar Larrosa [Espagne] ; Soledad Barrio [Espagne] ; Juan J. Granizo [Espagne] ; Juan A. Pareja [Espagne] | Decreased phasic EMG activity during rapid eye movement sleep in treatment‐naïve Parkinson's disease: Effects of treatment with levodopa and progression of illness |
001920 |
Debbie Tolson [Royaume-Uni] ; Valerie Fleming [Royaume-Uni] ; Elgin Schartau [Royaume-Uni] | Coping with menstruation: understanding the needs of women with Parkinson's disease |
001923 |
Yun J. Kim [Canada] ; Masanori Ichise [Canada] ; James R. Ballinger [Canada] ; Douglas Vines [Canada] ; Sean S. Erami [Canada] ; Tatsuro Tatschida [Canada] ; Anthony E. Lang [Canada] | Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP |
001925 |
Lorna Schumann ; Jennifer Hagerty Lingler ; Daniel I. Kaufer | Cognitive and Motor Symptoms in Dementia: Focus on Dementia with Lewy Bodies |
001926 |
Azi H. Rajput [Canada] ; Mark E. Fenton [Canada] ; Sam Birdi [Canada] ; Rob Macaulay [Canada] ; David George [Canada] ; Bohdar Rozdilsky [Canada] ; Lee C. Ang [Canada] ; Ambikaipakan Senthilselvan [Canada] ; Oleh Hornykiewicz [Autriche] | Clinical–Pathological study of levodopa complications |
001931 |
Francesc Valldeoriola [Espagne] ; Manuela Pilleri [Espagne] ; Eduardo Tolosa [Espagne] ; José L. Molinuevo [Espagne] ; Jordi Rumià [Espagne] ; Enric Ferrer [Espagne] | Bilateral subthalamic stimulation monotherapy in advanced Parkinson's disease: Long‐term follow‐up of patients |
001932 |
Galit Pelled [Israël] ; Hagai Bergman [Israël] ; Gadi Goelman [Israël] | Bilateral overactivation of the sensorimotor cortex in the unilateral rodent model of Parkinson's disease – a functional magnetic resonance imaging study |
001933 |
David J. Burn [Royaume-Uni] | Beyond the iron mask: Towards better recognition and treatment of depression associated with Parkinson's disease |
001936 |
Alice J. Manson [Royaume-Uni] ; Kirsten Turner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long‐term follow‐up study of 64 patients |
001942 |
Kevin St P. Mcnaught [États-Unis] ; P. Shashidharan [États-Unis] ; Daniel P. Perl [États-Unis] ; Peter Jenner [Royaume-Uni] ; C. Warren Olanow [États-Unis] | Aggresome‐related biogenesis of Lewy bodies |
001981 |
M. J. Guerrero Crdenas ; M. Pea Salinasa | Papel del fisioterapeuta en una asociacin de Parkinson |
001990 |
Juha O. Rinne [Finlande] ; Elina Nurmi [Finlande] ; Hanna M. Ruottinen [Finlande] ; Jörgen Bergman [Finlande] ; Olli Eskola [Finlande] ; Olof Solin [Finlande] | [18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease |
001991 |
Tarja H. Haapaniemi [Finlande] ; Aapo Ahonen [Finlande] ; Pentti Torniainen [Finlande] ; Kyösti A. Sotaniemi [Finlande] ; Vilho V. Myllyl [Finlande] | [123I]β‐CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients |
001994 |
David E. Vaillancourt [États-Unis] ; Andrew B. Slifkin [États-Unis] ; Karl M. Newell [États-Unis] | Visual control of isometric force in Parkinson's disease |
001995 |
Marina E. Emborg [États-Unis] ; Nicole Deglon [Suisse] ; Liza Leventhal [États-Unis] ; Patrick Aebischer [Suisse] ; Jeffrey H. Kordower [États-Unis] | Viral vector-mediated gene therapy for Parkinson's disease |
001A03 |
W. J Weiner [États-Unis] ; S. A Factor [États-Unis] ; Joseph Jankovic [États-Unis] ; R. A Hauser [États-Unis] ; J. W Tetrud [États-Unis] ; C. H Waters [États-Unis] ; L. M Shulman [États-Unis] ; P. M Glassman [États-Unis] ; B. Beck [États-Unis] ; D. Paume [États-Unis] ; C. Doyle [États-Unis] | The long-term safety and efficacy of pramipexole in advanced Parkinson's disease |
001A08 |
Hitoshi Takahashi ; Koichi Wakabayashi [Japon] | The cellular pathology of Parkinson's disease |
001A15 |
D. B. Vodušek [Slovénie] | Sphincter EMG and differential diagnosis of multiple system atrophy |
001A16 |
S. Happe ; B. Schrödl ; M. Faltl [Autriche] ; C. Müller [Autriche] ; E. Auff [Autriche] ; J. Zeitlhofer | Sleep disorders and depression in patients with Parkinson's disease |
001A22 |
Elina Nurmi [Finlande] ; Hanna M. Ruottinen [Finlande] ; Jörgen Bergman [Finlande] ; Merja Haaparanta [Finlande] ; Olof Solin [Finlande] ; Pirkko Sonninen [Finlande] ; Juha O. Rinne [Finlande] | Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study |
001A31 |
Anna Brück [Finlande] ; Raija Portin [Finlande] ; Arja Lindell [Finlande] ; Arto Laihinen [Finlande] ; Jörgen Bergman [Finlande] ; Merja Haaparanta [Finlande] ; Olof Solin [Finlande] ; Juha O. Rinne [Finlande] | Positron emission tomography shows that impaired frontal lobe functioning in Parkinson’s disease is related to dopaminergic hypofunction in the caudate nucleus |
001A34 |
Anna R. Bentivoglio [Italie] ; Pietro Cortelli [Italie] ; Enza M. Valente [Italie] ; Tàmara Ialongo [Italie] ; Alessandro Ferraris [Italie] ; Antonio Elia [Italie] ; Pasquale Montagna [Italie] ; Alberto Albanese [Italie] | Phenotypic characterisation of autosomal recessive PARK6‐linked parkinsonism in three unrelated Italian families |
001A36 |
A. Berardelli ; J. C. Rothwell ; P. D. Thompson ; M. Hallett | Pathophysiology of bradykinesia in Parkinson's disease |
001A41 |
Takahiro Fukuda [Japon] | Neurotoxicity of MPTP |
001A42 |
M. Fukuda ; M. J. Mentis ; Y. Ma ; V. Dhawan ; A. Antonini ; A. E. Lang ; A. M. Lozano ; J. Hammerstad ; K. Lyons ; W. C. Koller ; J. R. Moeller ; D. Eidelberg | Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease |
001A46 |
Claudio Da Cunha [Brésil] ; Monique S. Gevaerd [Brésil] ; Maria Aparecida B. F Vital [Brésil] ; Edmar Miyoshi [Brésil] ; Roberto Andreatini [Brésil] ; Rodolfo Silveira [Brésil] ; Reinaldo N. Takahashi [Brésil] ; Newton S. Canteras [Brésil] | Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia |
001A50 |
T. Caraceni [Italie] ; M. Musicco [Italie] | Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study |
001A53 |
Marianne Caap-Ahlgren [Suède] ; Ove Dehlin [Suède] | Insomnia and depressive symptoms in patients with Parkinson's disease |
001A54 |
V. Kaasinen ; E. Nurmi ; A. Bru Ck ; O. Eskola ; J. Bergman ; O. Solin ; J. O. Rinne | Increased frontal [18F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex |
001A64 |
Ruth Hardoff [Israël] ; Michael Sula [Israël] ; Ada Tamir [Israël] ; Adrian Soil [Israël] ; Avi Front [Israël] ; Samich Badarna [Israël] ; Silvia Honigman [Israël] ; Nir Giladi [Israël] | Gastric emptying time and gastric motility in patients with Parkinson's disease |
001A65 |
N. Giladi [Israël] ; H. Shabtai [Israël] ; E. Rozenberg [Israël] ; E. Shabtai [Israël] | Gait festination in Parkinson's disease |
001A66 |
T. Nakamura [États-Unis] ; M. F. Ghilardi [États-Unis] ; M. Mentis [États-Unis] ; V. Dhawan [États-Unis] ; M. Fukuda [États-Unis] ; A. Hacking [États-Unis] ; J. R. Moeller [États-Unis] ; C. Ghez [États-Unis] ; D. Eidelberg [États-Unis] | Functional networks in motor sequence learning: Abnormal topographies in Parkinson's disease |
001A68 |
Masafumi Fukuda [États-Unis] ; Christine Edwards [États-Unis] ; David Eidelberg [États-Unis] | Functional brain networks in Parkinson's disease |
001A69 |
J. Eric Ahlskog [États-Unis] ; Manfred D. Muenter [États-Unis] | Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature |
001A71 |
B. Haslinger ; P. Erhard ; N. Ka Mpfe ; H. Boecker ; E. Rummeny ; M. Schwaiger ; B. Conrad ; A. O. Ceballos-Baumann | Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa |
001A73 |
D. A. M. C. Van De Vijver [Pays-Bas] ; R. A. C. Roos [Pays-Bas] ; P. A. F. Jansen [Pays-Bas] ; A. J. Porsius [Pays-Bas] ; A. De Boer [Pays-Bas] | Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records |
001A76 |
N. Allert [Allemagne] ; J. Volkmann [Allemagne] ; S. Dotse [Allemagne] ; H. Hefter [Allemagne] ; V. Sturm [Allemagne] ; H. Freund [Allemagne] | Effects of bilateral pallidal or subthalamic stimulation on gait in advanced Parkinson's disease |
001A77 |
M. Faist ; J. Xie [France] ; D. Kurz ; W. Berger ; C. Maurer ; Pierre Pollak [France] ; C. H. Lu Cking | Effect of bilateral subthalamic nucleus stimulation on gait in Parkinson's disease |
001A78 |
M. Pai ; S. Chan [Taïwan] | Education and cognitive decline in Parkinson's disease: a study of 102 patients |
001A83 |
Richard Camicioli [États-Unis] ; Sandra J. Grossmann [États-Unis] ; Peter S. Spencer [États-Unis] ; Ken Hudnell [États-Unis] ; W. Kent Anger [États-Unis] | Discriminating mild parkinsonism: Methods for epidemiological research |
001A86 |
Neelima B. Chauhan [États-Unis] ; George J. Siegel [États-Unis] ; John M. Lee [États-Unis] | Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain |
001A87 |
Patricia Dowsey-Limousin [Royaume-Uni] ; Pierre Pollak [France] | Deep brain stimulation in the treatment of Parkinson's disease: a review and update |
001A91 |
Alexandra Roedter [Allemagne] ; Christian Winkler [Allemagne] ; Madjid Samii [Allemagne] ; Gerhard F. Walter [Allemagne] ; Almuth Brandis [Allemagne] ; Guido Nikkhah [Allemagne] | Comparison of unilateral and bilateral intrastriatal 6‐hydroxydopamine‐induced axon terminal lesions: Evidence for interhemispheric functional coupling of the two nigrostriatal pathways |
001A93 |
Stewart A. Factor [États-Unis] ; Joseph H. Friedman [États-Unis] ; Margaret C. Lannon [États-Unis] ; David Oakes [États-Unis] ; Keith Bourgeois [États-Unis] | Clozapine for the treatment of drug‐induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial |
001A99 |
Lorraine O. Ramig [États-Unis] ; Shimon Sapir [États-Unis] ; Cynthia Fox [États-Unis] ; Stefanie Countryman [États-Unis] | Changes in vocal loudness following intensive voice treatment (LSVT®) in individuals with Parkinson's disease: A comparison with untreated patients and normal age‐matched controls |
001B03 |
Björn Holmberg [Suède] ; Mika Kallio [Finlande] ; Bo Johnels [Suède] ; Mikael Elam [Suède] | Cardiovascular reflex testing contributes to clinical evaluation and differential diagnosis of Parkinsonian syndromes |
001B07 |
Saša R. Filipovi [Serbie] ; Nadežda Šterni [Serbie] ; Marina Svetel [Serbie] ; Nataša Dragaševi [Serbie] ; Dušica Le Ic [Serbie] ; Vladimir S. Kosti [Serbie] | Bereitschaftspotential in depressed and non‐depressed patients with Parkinson's disease |
001B10 |
P. K. Pal [Canada] ; C. S. Lee [Canada] ; A. Samii [Canada] ; M. Schulzer [Canada] ; A. J. Stoessl [Canada] ; E. K. Mak [Canada] ; J. Wudel [Canada] ; T. Dobko [Canada] ; J. K. C. Tsui [Canada] | Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET [18F]-DOPA Ki |
001B11 |
Subramianian Rajagopalan [États-Unis] ; Julie K. Andersen [États-Unis] | Alpha synuclein aggregation: is it the toxic gain of function responsible for neurodegeneration in Parkinson's disease? |
001B12 |
Michael K. Lee [États-Unis] ; Donald L. Price [États-Unis] | Advances in genetic models of Parkinson's disease |
001B14 |
I. Milanov [Bulgarie] | A cross-over clinical and electromyographic assessment of treatment for parkinsonian tremor |
001B15 |
Arvid Carlsson [Suède] | A Half‐Century of Neurotransmitter Research: Impact on Neurology and Psychiatry (Nobel Lecture) |
001B49 |
Katie Kompoliti [États-Unis] ; Christopher G. Goetz [États-Unis] ; Sue Leurgans [États-Unis] ; Mary Morrissey [États-Unis] ; Irwin M. Siegel [États-Unis] | “On” freezing in Parkinson's disease: Resistance to visual cue walking devices |
001B52 |
Rhonda J. Holmes [Australie] ; Jennifer M. Oates [Australie] ; Debbie J. Phyland [Australie] ; Andrew J. Hughes [Australie] | Voice characteristics in the progression of Parkinson's disease |
001B56 |
Ichiro Miyai [Japon] ; Yasuyuki Fujimoto [Japon] ; Yoshishige Ueda [Japon] ; Hiroshi Yamamoto [Japon] ; Sonoko Nozaki [Japon] ; Toshio Saito [Japon] ; Jin Kang [Japon] | Treadmill training with body weight support: Its effect on Parkinson's disease |
001B61 |
Albert F. G. Leentjens [Pays-Bas] ; Frans R. J. Verhey [Pays-Bas] ; Richel Lousberg [Pays-Bas] ; Harro Spitsbergen [Pays-Bas] ; Frederik W. Wilmink [Pays-Bas] | The validity of the Hamilton and Montgomery‐Åsberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease |
001B64 |
Claudia Ramaker [Pays-Bas] ; Willem Johan T. Van De Beek [Pays-Bas] ; Martijn J. J. Finken [Pays-Bas] ; Bob J. J. Van Hilten [Pays-Bas] | The efficacy and safety of adjunct bromocriptine therapy for levodopa‐induced motor complications: A systematic review |
001B70 |
K. Adam Baker [Canada] ; Damaso Sadi [Canada] ; Murray Hong [Canada] ; Ivar Mendez [Canada] | Simultaneous intrastriatal and intranigral dopaminergic grafts in the parkinsonian rat model: Role of the intranigral graft |
001B76 |
Rolf Libelius [Suède] ; Folke Johansson [Suède] | Quantitative electromyography of the external anal sphincter in Parkinson's disease and multiple system atrophy |
001B77 |
Rodger J. Elble [États-Unis] ; Keith Leffler [États-Unis] | Pushing and pulling with the upper extremities while standing: The effects of mild Alzheimer dementia and Parkinson's disease |
001B85 |
Dag Aarsland ; Jan Petter Larsen ; Elise Tandberg ; Knut Laake [Norvège] | Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study |
001B90 |
Beate Ritz [États-Unis] ; Fei Yu [États-Unis] | Parkinson's disease mortality and pesticide exposure in California 1984–1994 |
001B92 |
Yi Zhang ; Valina L. Dawson ; Ted M. Dawson | Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease |
001B97 |
Jean A. Saint-Cyr [Canada] ; Lisa L. Trépanier [Canada] | Neuropsychologic assessment of patients for movement disorder surgery |
001B98 |
John E. Duda [États-Unis] ; Virginia M. Lee [États-Unis] ; John Q. Trojanowski [États-Unis] | Neuropathology of synuclein aggregates |
001C05 |
I. Lamensdorf [États-Unis] ; G. Eisenhofer [États-Unis] ; J. Harvey-White [États-Unis] ; Y. Hayakawa [États-Unis] ; K. Kirk [États-Unis] ; I. J. Kopin [États-Unis] | Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4‐dihydroxyphenylacetaldehyde |
001C10 |
J. M. Henderson [Australie] ; K. Carpenter [Australie] ; H. Cartwright [Australie] ; G. M. Halliday [Australie] | Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications |
001C15 |
Silvio Aime [Italie] ; Bruno Bergamasco [Italie] ; Mariano Casu [Italie] ; Giuseppe Digilio [Italie] ; Mauro Fasano [Italie] ; Sabrina Giraudo [Italie] ; Leonardo Lopiano [Italie] | Isolation and 13C‐NMR characterization of an insoluble proteinaceous fraction from substantia nigra of patients with parkinson's disease |
001C17 |
K. A. Baker ; M. Hong ; D. Sadi ; I. Mendez | Intrastriatal and Intranigral Grafting of hNT Neurons in the 6-OHDA Rat Model of Parkinson's Disease |
001C26 |
Gilles Fe Nelon ; Florence Mahieux ; Renaud Huon ; Marc Zie Gler | Hallucinations in Parkinson's disease |
001C29 |
R. Horowski [Allemagne] ; L. Horowski [Allemagne] ; S. M. Calne [Canada] ; D. B. Calne [Canada] | From Wilhelm von Humboldt to Hitler—are prominent people more prone to have Parkinson's disease? |
001C34 |
J. Lyytinen [Finlande] ; S. Kaakkola [Finlande] ; A. Gordin [Finlande] ; E.-R Kultalahti [Finlande] ; H. Ter V Inen [Finlande] | Entacapone and selegiline with l-dopa in patients with Parkinson's disease: an interaction study |
001C37 |
A. P Strafella [Italie] ; F. Valzania [Italie] ; S. A Nassetti [Italie] ; A. Tropeani [Italie] ; A. Bisulli [Italie] ; M. Santangelo [Italie] ; C. A Tassinari [Italie] | Effects of chronic levodopa and pergolide treatment on cortical excitability in patients with Parkinson's disease: a transcranial magnetic stimulation study |
001C38 |
Erwin B. Montgomery Jr. [États-Unis] ; William C. Koller [États-Unis] ; Theodora J. K. Lamantia [États-Unis] ; Mary C. Newman [États-Unis] ; Elizabeth Swanson-Hyland [États-Unis] ; Alfred W. Kaszniak [États-Unis] ; Kelly Lyons [États-Unis] | Early detection of probable idiopathic Parkinson's disease: I. development of a diagnostic test battery |
001C39 |
Anette Schrag [Royaume-Uni] ; Niall Quinn [Royaume-Uni] | Dyskinesias and motor fluctuations in Parkinson's disease |
001C42 |
Ram N Leiguarda [Argentine] ; Marcelo Merello [Argentine] ; Jorge Balej [Argentine] ; Sergio Starkstein [Argentine] ; Martín Nogues [Argentine] ; C. David Marsden [Royaume-Uni] | Disruption of spatial organization and interjoint coordination in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy |
001C46 |
Massimo Valoti [Italie] ; Fabio Fusi [Italie] ; Maria Frosini [Italie] ; Federica Pessina [Italie] ; Keith F. Tipton [Irlande (pays)] ; Gian P. Sgaragli [Italie] | Cytochrome P450-dependent n-dealkylation of l-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, β-naphthoflavone and l-deprenyl |
001C47 |
G. Münch [Allemagne] ; H. J. Lüth [Allemagne] ; A. Wong [Allemagne] ; Th. Arendt [Allemagne] ; E. Hirsch [France] ; R. Ravid [Pays-Bas] ; P. Riederer [Allemagne] | Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? |
001C50 |
S. Blanchet ; R. M. Marié [France] ; F. Dauvillier ; B. Landeau ; K. Benali ; F. Eustache [France] ; C. Chavoix | Cognitive processes involved in delayed non‐matching‐to‐sample performance in Parkinson's disease |
001C51 |
Julie A. Fields ; Alexander I. Tröster | Cognitive Outcomes after Deep Brain Stimulation for Parkinson's Disease: A Review of Initial Studies and Recommendations for Future Research |
001C53 |
Siegfried Martin Heckmann ; Josef Georg Heckmann ; Hans-Peter Weber [États-Unis] | Clinical outcomes of three Parkinson's disease patients treated with mandibular implant overdentures |
001C55 |
Geralyn M. Schulz [États-Unis] ; Melvin Greer [États-Unis] ; William Friedman [États-Unis] | Changes in vocal intensity in Parkinson's disease following pallidotomy surgery |
001C57 |
Cheryl Waters [États-Unis] | Catechol‐O‐Methyltransferase (COMT) Inhibitors in Parkinson's Disease |
001C60 |
Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche] | Apomorphine: An underutilized therapy for Parkinson's disease |
001C61 |
Oleg V. Anichtchik [Finlande] ; Juha O. Rinne [Finlande] ; Hannu Kalimo [Finlande] ; Pertti Panula [Finlande] | An Altered Histaminergic Innervation of the Substantia Nigra in Parkinson's Disease |
001C62 |
B. Bergamasco ; L. Frattola ; A. Muratorio ; F. Piccoli ; F. Mailland ; L. Parnetti | Alpha‐dihydroergocryptine in the treatment of de novo parkinsonian patients: results ofa multicentre, randomized, double‐blind, placebo‐controlled study |
001C63 |
Heiko Braak [Allemagne] ; Kelly Del Tredici [Allemagne] ; Wei Ping Gai [Australie] ; Eva Braak [Allemagne] | Alpha-synuclein is not a requisite component of synaptic boutons in the adult human central nervous system |
001C64 |
Hans Forssberg [Suède] ; Páll E. Ingvarsson [Suède] ; Nobuaki Iwasaki [Suède] ; Roland S. Johansson [Suède] ; Andrew M. Gordon [États-Unis] | Action tremor during object manipulation in Parkinson's disease |
001D09 |
D. Brassat [France] ; A. Durr [France] ; Yves Agid [France] ; A. Brice [France] | Génétique de la maladie de Parkinson |
001D10 |
L. Defebvre [France] ; P. Derambure [France] ; J. L. Bourriez [France] ; A. Destée [France] ; J. D. Guieu [France] | Désynchronisation liée à l'événement et maladie de Parkinson. Intérêt dans l'analyse de la phase de préparation au mouvement |
001D11 |
F. Seijo ; J. M. Moreno ; F. Fernndez Gonzlez ; C. Salvador ; L. Menndez-Guisasola | Valor del registro neurofisiolgico en la ciruga de la enfermedad de Parkinson. Estudio preliminar |
001D15 |
E. Kraft [Allemagne, États-Unis] ; J. Winkelmann [Allemagne] ; C. Trenkwalder [Allemagne] ; D. P. Auer [Allemagne] | Visual hallucinations, white matter lesions and disease severity in Parkinson's disease |
001D16 |
T. Langheinrich [Allemagne] ; L. Tebartz Van Elst [Allemagne] ; W. A Lagrèze [Allemagne] ; M. Bach [Allemagne] ; C. H Lücking [Allemagne] ; M. W Greenlee [Allemagne] | Visual contrast response functions in Parkinson's disease: evidence from electroretinograms, visually evoked potentials and psychophysics |
001D20 |
Jean Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France] | Treatment of Parkinson's disease should begin with a dopamine agonist |
001D22 |
U. Bonuccelli [Italie] ; C. D'Avino [Italie] ; N. Caraccio [Italie] ; P. Del Guerra [Italie] ; A. Casolaro [Italie] ; N. Pavese [Italie] ; P. Del Dotto [Italie] ; F. Monzani [Italie] | Thyroid function and autoimmunity in Parkinson's disease: a study of 101 patients |
001D24 |
Judit Mally [Hongrie] ; T. W. Stone [Royaume-Uni] | Therapeutic and “dose‐dependent” effect of repetitive microelectroshock induced by transcranial magnetic stimulation in Parkinson's disease |
001D25 |
P. Damier ; E. C. Hirsch ; Yves Agid [France] ; A. M. Graybiel | The substantia nigra of the human brain |
001D26 |
William J. Weiner [États-Unis] | The initial treatment of Parkinson's disease should begin with levodopa |
001D27 |
A. Mesec [Slovénie] ; S. Šega [Slovénie] ; M. Trošt [Slovénie] ; T. Poga Nik [Slovénie] | The deterioration of cardiovascular reflexes in Parkinson's disease |
001D30 |
David F. Clayton ; Julia M. George | Synucleins in synaptic plasticity and neurodegenerative disorders |
001D34 |
M. A. Piggott ; E. F. Marshall ; N. Thomas ; S. Lloyd ; J. A. Court ; E. Jaros ; D. Burn ; M. Johnson ; R. H. Perry ; I. G. Mckeith ; C. Ballard ; E. K. Perry | Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution |
001D37 |
H. Boecker ; A. Ceballos-Baumann ; P. Bartenstein ; A. Weindl ; H. R. Siebner ; T. Fassbender ; F. Munz ; M. Schwaiger ; B. Conrad | Sensory processing in Parkinson's and Huntington's disease |
001D43 |
Anette Schrag [Royaume-Uni] ; Ludwig Schelosky [Allemagne] ; Udo Scholz [Allemagne] ; Werner Poewe [Autriche] | Reduction of parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single‐dose challenges |
001D45 |
A. Samii [Canada] ; I. M. Turnbull [Canada] ; A. Kishore [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; S. Yardley [Canada] ; D. B. Calne [Canada] | Reassessment of unilateral pallidotomy in Parkinson's disease |
001D49 |
Jose M. Errea [Espagne] ; Jose R. Ara [Espagne] ; Carlos Aibar [Espagne] ; Jesus De Pedro-Cuesta [Espagne, Suède] | Prevalence of Parkinson's disease in lower Aragon, Spain |
001D51 |
Angela G. E. M. De Boer [Pays-Bas] ; Mirjam A. G. Sprangers [Pays-Bas] ; Hans D. Speelman [Pays-Bas] ; Hanneke C. J. M. De Haes [Pays-Bas] | Predictors of health care use in patients with Parkinson's disease: A longitudinal study |
001D54 |
Emily Lin [États-Unis] ; Jack Jiang [États-Unis] ; Stephen Hone [États-Unis] ; David G. Hanson [États-Unis] | Photoglottographic measures in parkinson's disease |
001D55 |
A. M. Bonnet [France] ; J. L. Houeto [France] | Pathophysiology of Parkinson's disease |
001D61 |
Martin Goulet ; Marc Morissette ; Richard Grondin ; Pierre Falardeau ; Paul J. Bédard ; William Rostène [France] ; Thérèse Di Paolo | Neurotensin receptors and dopamine transporters: Effects of MPTP lesioning and chronic dopaminergic treatments in monkeys |
001D62 |
Ross Cunnington [Australie] ; Robert Iansek [Australie] ; John L. Bradshaw [Australie] | Movement‐related potentials in Parkinson's disease: External cues and attentional strategies |
001D64 |
Russell H. Swerdlow [États-Unis] ; W. Davis Parker Jr. [États-Unis] | Mitochondrial pathology in Parkinson's disease and implications for therapeutic intervention |
001D66 |
D. Aarsland [Norvège] ; J. P. Larsen [Norvège] ; K. Karlsen [Norvège] ; N. G. Lim [Norvège] ; E. Tandberg [Norvège] | Mental symptoms in Parkinson's disease are important contributors to caregiver distress |
001D67 |
Takashi Hanakawa ; Yukinori Katsumi ; Hidenao Fukuyama ; Manabu Honda ; Takuya Hayashi ; Jun Kimura ; Hiroshi Shibasaki | Mechanisms underlying gait disturbance in Parkinson's disease |
001D75 |
Christian Winkler [Suède] ; Claas Bentlage [Allemagne] ; Guido Nikkhah [Allemagne] ; Madjid Samii [Allemagne] ; Anders Björklund [Suède] | Intranigral Transplants of GABA-Rich Striatal Tissue Induce Behavioral Recovery in the Rat Parkinson Model and Promote the Effects Obtained by Intrastriatal Dopaminergic Transplants |
001D78 |
Piero Barbanti ; Giovanni Fabbrini ; Alberto Ricci ; Rosanna Cerbo ; Elena Bronzetti ; Brunella Caronti ; Caterina Calderaro ; Laura Felici ; Fabrizio Stocchi [Italie] ; Giuseppe Meco ; Francesco Amenta [Italie] ; Gian Luigi Lenzi | Increased expression of dopamine receptors on lymphocytes in Parkinson's disease |
001D79 |
Bruno J. Weder [Suisse] ; Klaus L. Leenders [Suisse] ; Peter Vontobel [Suisse] ; Matthias Nienhusmeier [Suisse] ; Alex Keel [Suisse] ; Wolfgang Zaunbauer [Suisse] ; Thomas Vonesch [Suisse] ; Hans-Peter Ludin [Suisse] | Impaired somatosensory discrimination of shape in Parkinson's disease: Association with caudate nucleus dopaminergic function |
001D83 |
Jack Jiang [États-Unis] ; Emily Lin [États-Unis] ; Jian Wang [États-Unis] ; David G. Hanson [États-Unis] | Glottographic Measures Before and After Levodopa Treatment in Parkinson's Disease |
001D84 |
Y. Mizuno [Japon] ; N. Hattori [Japon] ; H. Mori [Japon] | Genetics of Parkinson's disease |
001D85 |
P. Jenner [Royaume-Uni] | Genetic susceptibility and the occurrence of Parkinson's disease |
001D86 |
J. S. Rakshi ; T. Uema ; K. Ito ; D. L. Bailey ; P. K. Morrish ; J. Ashburner ; A. Dagher ; I. H. Jenkins ; K. J. Friston ; D. J. Brooks | Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [18F]dopa-PET study |
001D87 |
Paul Krack ; Pierre Pollak [France] ; Patricia Limousin ; Abdelhamid Benazzouz ; Gu Nther Deuschl ; Alim-Louis Benabid [France] | From off-period dystonia to peak-dose chorea |
001D88 |
Glenn T. Stebbins [États-Unis] ; Christopher G. Goetz [États-Unis] ; Anthony E. Lang [Canada] ; Esther Cubo [États-Unis] | Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off‐state |
001D91 |
C. A. Taylor [États-Unis] ; M. H. Saint-Hilaire [États-Unis] ; L. A. Cupples [États-Unis] ; C. A. Thomas [États-Unis] ; A. E. Burchard [États-Unis] ; R. G. Feldman [États-Unis] ; R. H. Myers [États-Unis] | Environmental, medical, and family history risk factors for Parkinson's disease: A New England‐based case control study |
001D96 |
A. L. Brownell [États-Unis] ; B. G. Jenkins [États-Unis] ; O. Isacson [États-Unis] | Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease |
001D97 |
Jeffrey L. Cummings [États-Unis] ; Donna L. Masterman [États-Unis] | Depression in patients with Parkinson's disease |
001E01 |
Yasushi Ito [Japon] ; Masahiro Fujita [Japon] ; Shoichi Shimada ; Yoshiyuki Watanabe [Japon] ; Tomoya Okada [Japon] ; Hideo Kusuoka [Japon] ; Masaya Tohyama [Japon] ; Tsunehiko Nishimura [Japon] | Comparison between the decrease of dopamine transporter and that of L‐DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models |
001E02 |
G. Ebersbach [Autriche] ; M. Sojer [Autriche] ; F. Valldeoriola [Autriche] ; J. Wissel [Autriche] ; J. Mu Ller [Autriche] ; E. Tolosa [Autriche] ; Werner Poewe [Autriche] | Comparative analysis of gait in Parkinson's disease, cerebellar ataxia and subcortical arteriosclerotic encephalopathy |
001E07 |
W. Gerschlager ; F. Alesch ; R. Cunnington ; L. Deecke ; G. Dirnberger ; W. Endl ; G. Lindinger ; W. Lang | Bilateral subthalamic nucleus stimulation improves frontal cortex function in Parkinson's disease |
001E12 |
L. Battistin [Italie] ; P. G. Bardin [Italie] ; F. Ferro-Milone ; C. Ravenna ; V. Toso [Italie] ; G. Reboldi | Alpha‐dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study |
001E13 |
Jack Jiang [États-Unis] ; Timothy O'Mara [États-Unis] ; Hui-Jun Chen [République populaire de Chine] ; Jennifer I. Stern [États-Unis] ; Demetra Vlagos [États-Unis] ; David Hanson [États-Unis] | Aerodynamic measurements of patients with parkinson's disease |
001E16 |
Jorrit I. Hoff [Pays-Bas] ; Bob J. Van Hilten [Pays-Bas] ; Raymund A. C. Roos [Pays-Bas] | A review of the assessment of dyskinesias |
001E17 |
Jean-Louis Montastruc [France] ; Marc Ziegler [France] ; Olivier Rascol [France] ; Muriel Malbezin [France] | A randomized, double‐blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease |
001E44 |
Jp Azulay [France] | Manipulation visuelle sensorielle et contrôle postural chez le parkinsonien |
001E66 |
Speelman [Pays-Bas] ; D. A. Bosch [Pays-Bas] | Resurgence of functional neurosurgery for Parkinson's disease: A historical perspective |
001E69 |
Andrew G. Riedl [Royaume-Uni] ; Paul M. Watts [Royaume-Uni] ; Jenner [Royaume-Uni] ; C. David Marsden [Royaume-Uni] | P450 enzymes and Parkinson's disease: The story so far |
001E70 |
J. William Langston ; Savitha Sastry ; Piu Chan ; Lysia S. Forno ; Laurel M. Bolin ; Donato A. Di Monte | Novel α-Synuclein-Immunoreactive Proteins in Brain Samples from the Contursi Kindred, Parkinson's, and Alzheimer's Disease |
001E72 |
Manuel B. Graeber [Allemagne] ; Eva Grasbon-Frodl [Allemagne] ; Ulrich V. Eitzen [Allemagne] ; Siegfried Kösel [Allemagne] | Neurodegeneration and aging: Role of the second genome |
001E82 |
Julie H. Carter [États-Unis] ; Barbara J. Stewart [États-Unis] ; Patricia G. Archbold [États-Unis] ; Iku Inoue [États-Unis] ; Jeana Jaglin [États-Unis] ; Meg Lannon [États-Unis] ; Elke Rost-Ruffner [États-Unis] ; Marsha Tennis [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Donna Amyot ; Ruth Barter [États-Unis] ; Lisa Cornelius [États-Unis] ; Carol Demong ; Judith Dobson [États-Unis] ; Jan Duff ; Judi Erickson [États-Unis] ; Nita Gardiner [États-Unis] ; Lisa Gauger [États-Unis] ; Peggy Gray ; Bernice Kanigan ; Barbara Kiryluk [États-Unis] ; Paula Lewis [États-Unis] ; Kathie Mistura [États-Unis] ; Teri Malapira [États-Unis] ; Mary Pay [États-Unis] ; Carol Sheldon [États-Unis] ; Linda Winfield [États-Unis] ; Kathy Wolfington-Shallow [États-Unis] ; Kim Zoog [États-Unis] | Living with a person who has parkinson's disease: The Spouse's perspective by stage of disease |
001E83 |
L. Manfredi [Italie] ; P. Garavaglia [Italie] ; S. Beretta [Italie] ; G. Pellegrini [Italie] | Increased cortical inhibition induced by apomorphine in patients with Parkinson's disease |
001E87 |
Federico A. Dajas-Bailador [Uruguay, Royaume-Uni] ; Anibal Martinez-Borges [Uruguay] ; Gustavo Costa [Uruguay] ; J. Andrés Abin [Uruguay] ; Emilia Martignoni [Italie] ; Giuseppe Nappi [Italie] ; Federico Dajas [Uruguay] | Hydroxyl radical production in the substantia nigra after 6-hydroxydopamine and hypoxia-reoxygenation |
001E96 |
John D. O'Sullivan [Australie] ; Catherine M. Said [Australie] ; Louise C. Dillon [Australie] ; Marion Hoffman [Australie] ; Hughes [Australie] | Gait analysis in patients with Parkinson's disease and motor fluctuations: Influence of levodopa and comparison with other measures of motor function |
001F07 |
Angelo Antonini [États-Unis] ; Ken Kazumata [États-Unis] ; Andrew Feigin [États-Unis] ; Francine Mandel [États-Unis] ; Vijay Dhawan [États-Unis] ; Claude Margouleff [États-Unis] ; Eidelberg [États-Unis] | Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET |
001F13 |
Ronald K. B. Pearce [Royaume-Uni] ; Tara Banerji [Royaume-Uni] ; Jenner [Royaume-Uni] ; C. David Marsden [Royaume-Uni] | De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmoset |
001F15 |
Dodel [Allemagne] ; Karla M. Eggert [Allemagne] ; Marika S. Singer [Allemagne] ; Tobias E. Eichhorn [Allemagne] ; Oliver Pogarell [Allemagne] ; Wolfgang H. Oertel [Allemagne] | Costs of drug treatment in Parkinson's disease |
001F19 |
P. J. Blanchet [États-Unis] ; S. Konitsiotis [États-Unis] ; K. Hyland [États-Unis] ; L. A. Arnold [États-Unis] ; K. D. Pettigrew [États-Unis] ; T. N. Chase [États-Unis] | Chronic Exposure to MPTP as a Primate Model of Progressive Parkinsonism: A Pilot Study with a Free Radical Scavenger |
001F27 |
Elise Tandberg [Norvège] ; Larsen [Norvège] ; Karen Karlsen [Norvège] | A community‐based study of sleep disorders in patients with Parkinson's disease |
001F76 |
Bonnet [France] ; J. Pichon [France] ; M. Vidailhet [France] ; N. Gouider-Khouja [France] ; G. Robain [France] ; M. Perrigot [France] ; Yves Agid [France] | Urinary disturbances in striatonigral degeneration and parkinson's disease: Clinical and urodynamic aspects |
001F77 |
Koehler ; Antoine Keyser [Pays-Bas] | Tremor in latin texts of dutch physicians: 16th‐18th centuries |
001F80 |
Louis [États-Unis] | The shaking palsy, the first forty‐five years: A Journey through the british literature |
001F81 |
LeWitt [États-Unis] ; David Oakes [États-Unis] ; Lu Cui [États-Unis] | The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α‐tocopherol |
001F83 |
Stewart A. Factor ; Friedman [États-Unis] | The emergin role of clozapine in the treatment of movement disorders |
001F84 |
Larsen [Norvège] ; Jette Boas [Danemark] | The effects of early selegiline therapy on long‐term levodopa treatment and parkinsonian disability: An interim analysis of a norwegian–danish 5‐year study |
001F85 |
Satu-Mari Kokko [Finlande] ; Jaana Paltamaa [Finlande] ; Erja Ahola [Finlande] ; Esko M Lki [Finlande] | The assessment of functional ability in patients with Parkinson's disease: The PLM‐test and three clinical tests |
001F86 |
Ed G. Gonera [Pays-Bas] ; Martin Van'T Hof [Pays-Bas] ; Hans J. C. Berger [Pays-Bas] ; Chris Van Weel [Pays-Bas] ; Horstink [Pays-Bas] | Symptoms and duration of the prodromal phase in parkinson's disease |
001F88 |
S. Schwalen [Allemagne] ; J. Leclaire [Allemagne] ; M. Rechlin [Allemagne] ; J. Jörg [Allemagne] | Sleep related breathing disturbances and nocturnal akinesia in Parkinson's disease patients: a cross section study |
001F90 |
Viktor Müller [Allemagne] ; Mohr [Allemagne] ; Regina Rosin [Allemagne] ; Friedemann Pulvermüller [Allemagne] ; Friedemann Müller [Allemagne] ; Niels Birbaumer [Allemagne, Italie] | Short‐term effects of behavioral treatment on movement initiation and postural control in Parkinson's disease: A controlled clinical study |
001F92 |
V. V. Myllyl [Finlande] ; K. A. Sotaniemi [Finlande] ; P. Hakulinen [Finlande] ; O. M Ki-Lkola [Finlande] ; E. H. Heinonen [Finlande] | Selegiline as the primary treatment of Parkinson's disease — a long‐term double‐blind study |
001F94 |
P. Stanzione [Italie] ; R. Traversa [Italie] ; M. Pierantozzi [Italie] ; R. Semprini [Italie] ; M. Loberti [Italie] ; A. Peppe [Italie] ; A. M. Santilli [Italie] ; G. Bernardi [Italie] | SEPs N30 amplitude in Parkinson's disease and in pharmacologically induced rigidity: relationship with the clinical status |
001F95 |
Avissar [Israël] ; Liza Barki-Harrington [Israël] ; Yuval Herishanu [Israël] ; Gabriel Schreiber [Israël] | Reduced Gs protein function and Gαs levels in leukocytes of patients with Parkinson's disease |
001F96 |
Ivar Mendez [Canada] ; Murray Hong [Canada] | Reconstruction of the striato-nigro-striatal circuitry by simultaneous double dopaminergic grafts: a tracer study using fluorogold and horseradish peroxidase |
002000 |
Mario O. Melcon [Argentine] ; Anderson [États-Unis] ; Rodolfo H. Vergara [Argentine] ; Walter A. Rocca [États-Unis] | Prevalence of Parkinson's disease in junín, Buenos Aires province, argentina |
002003 |
C. I. Blake [États-Unis] ; E. Spitz [États-Unis] ; M. Leehey [États-Unis] ; Hoffer [États-Unis] ; S. J. Boyson [États-Unis] | Platelet mitochondrial respiratory chain function in Parkinson's disease |
002007 |
Bernhard A. Haug [Allemagne] ; Eva-Maria Hermsteiner [Allemagne] ; Borwin Bandelow [Allemagne] ; Walter Paulus [Allemagne] | Parallel increase of heterochromatic increment threshold and postadaptation thresholds in Parkinson's disease and in neuroleptic treatment |
002016 |
Ackermann [Allemagne] ; Ingo Hertrich [Allemagne] ; Irene Daum [Allemagne] ; Gabriele Scharf [Allemagne] ; Sybille Spieker [Allemagne] | Kinematic analysis of articulatory movements in central motor disorders |
002027 |
Regina Rosin [Allemagne] ; Topka [Allemagne] ; Johannes Dichgans [Allemagne] | Gait initiation in parkinson's disease |
002033 |
V. V. Myllyl [Finlande] ; M. Jackson [Royaume-Uni] ; J. P. Larsen [Norvège] ; H. Baas [Allemagne] | Efficacy and safety of tolcapone in levodopa‐treated Parkinson's disease patients with “wearing‐off” phenomenon: a multicentre, double‐blind, randomized, placebo‐controlled trial |
002036 |
G. Rozas [Espagne] ; J. L. Labandeira Garca [Espagne] | Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test |
002038 |
Scheider [États-Unis] ; L. A. Hershey [États-Unis] ; J. E. Vena [États-Unis] ; T. Holmlund [États-Unis] ; J. R. Marshall [États-Unis] ; J. L. Freudenheim [États-Unis] | Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease |
002041 |
Konczak [Allemagne] ; Hermann Ackermann [Allemagne] ; Ingo Hertrich [Allemagne] ; Sybille Spieker [Allemagne] ; Johannes Dichgans [Allemagne] | Control of repetitive lip and finger movements in parkinson's disease: Influence of external timing signals and simultaneous execution on motor performance |
002042 |
Margaret M. Tompkins [États-Unis] ; William D. Hill [États-Unis] | Contribution of somal Lewy bodies to neuronal death |
002044 |
Rajput [Canada] ; M. E. Fenton [Canada] ; D. George [Canada] ; Alex Rajput [États-Unis] ; W. Wilson [Canada] ; L. Mcculloch [Canada] | Concordance of common movement disorders among familial cases |
002046 |
Johnston [États-Unis] ; June A. Castell [États-Unis] ; Sharon Stumacher [États-Unis] ; Amy Colcher [États-Unis] ; R. Matthew Gideon [États-Unis] ; Qun Li [États-Unis] ; Donald O. Castell [États-Unis] | Comparison of swallowing function in Parkinson's disease and progressive supranuclear palsy |
002049 |
G. Gomez Arevalo [Argentine] ; R. Jorge [Argentine] ; S. Garcia [Argentine] ; O. Scipioni [Argentine] ; Gershanik [Argentine] | Clinical and pharmacological differences in early‐ versus late‐onset Parkinson's disease |
002056 |
R. Egensperger [Allemagne] ; S. Kösel [Allemagne] ; N. M. Schnopp [Allemagne] ; P. Mehraein [Allemagne] ; M. B. Graeber [Allemagne] | Association of the mitochondrial tRNAA4336G mutation with Alzheimer's and Parkinson's diseases |
002060 |
Javier Gamboa [Espagne] ; Félix Javier Jiménez-Jiménez [Espagne] ; Alberto Nieto [Espagne] ; Jose Montojo [Espagne] ; Miguel Ortí-Pareja [Espagne] ; José Antonio Molina ; Esteban García-Albea [Espagne] ; Ignacio Cobeta [Espagne] | Acoustic voice analysis in patients with Parkinson's disease treated with dopaminergic drugs |
002125 |
Gavan P. Duffy [États-Unis] ; Robert T. Trousdale [États-Unis] | Total knee arthroplasty in patients with Parkinson's disease |
002129 |
J. Boas [Danemark] ; J. Worm-Petersen [Danemark] ; E. Dupont [Danemark] ; B. Mikkelsen [Danemark] ; L. Wermuth [Danemark] | The levodopa dose‐sparing capacity of pergolide compared with that of bromocriptine in an open‐label, crossover study |
002131 |
Kathe S. Perez [États-Unis] ; Lorraine Olson Ramig [États-Unis] ; Marshall E. Smith [États-Unis] ; Christopher Dromey [États-Unis] | The Parkinson larynx: Tremor and videostroboscopic findings |
002133 |
Philippe Anglade [France] ; Annick Mouatt-Prigent [France] ; Yves Agid [France] ; Etienne C. Hirsch [France] | Synaptic Plasticity in the Caudate Nucleus of Patients with Parkinson's Disease |
002136 |
Brigitte Piallat [France] ; Abdelhamid Benazzouz [France] ; Alim-Louis Benabid [France] | Subthalamic Nucleus Lesion in Rats Prevents Dopaminergic Nigral Neuron Degeneration After Striatal 6‐OHDA Injection: Behavioural and Immunohistochemical Studies |
002161 |
Michael D. Brown [Géorgie (pays)] ; John M. Shoffner [Géorgie (pays)] ; Yoon L. Kim [Géorgie (pays)] ; Albert S. Jun [Géorgie (pays)] ; Brett H. Graham [Géorgie (pays)] ; Margaret F. Cabell [Géorgie (pays)] ; Daniel S. Gurley [Géorgie (pays)] ; Douglas C. Wallace [Géorgie (pays)] | Mitochondrial DNA sequence analysis of four Alzheimer's and Parkinson's disease patients |
002166 |
C. Rickards [Royaume-Uni] ; F. W. J. Cody [Royaume-Uni] | Increased use of target cues during visuo‐motor tracking in Parkinson's disease |
002173 |
R. Castellani [États-Unis] ; M. A. Smith [États-Unis] ; G. L. Richey [États-Unis] ; G. Perry [États-Unis] | Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease |
002179 |
G. De Michele ; A. Filla ; G. Volpe ; V. De Marco ; A. Gogliettino ; G. Ambrosio ; R. Marconi [Italie] ; A. E. Castellano [Italie] ; Campanella | Environmental and genetic risk factors in Parkinson's disease: A case–control study in southern italy |
002183 |
Dean E. Dluzen [États-Unis] | Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice |
002194 |
F. Durif [France] ; E. Albuisson [France] ; B. Debilly [France] ; J. F. Le Bas [France] ; Pierre Pollak [France] | Comparison of cerebral atrophy evaluated by MRI in Parkinson's disease and multiple system atrophy |
002198 |
Roos [Pays-Bas] ; J. C. F. Jongen [Pays-Bas] ; E. A. Van Der Velde [Pays-Bas] | Clinical course of patients with idiopathic Parkinson's disease |
002202 |
Geminiani [Italie] ; Vincenza Fetoni [Italie] ; Silvia Genitrini [Italie] ; Paolo Giovannini [Italie] ; Filippo Tamma [Italie] ; Tommaso Caraceni [Italie] | Cabergoline in Parkinson's disease complicated by motor fluctuations |
002204 |
W. Löscher [Allemagne] ; A. Richter [Allemagne] ; G. Nikkhah [Allemagne] ; C. Rosenthal [Allemagne] ; U. Ebert [Allemagne] ; H.-J. Hedrich [Allemagne] | Behavioural and neurochemical dysfunction in the circling (ci) rat: A novel genetic animal model of a movement disorder |
002206 |
Frank Q. Ye [Canada] ; Peter S. Allen [Canada] ; Martin [Canada] | Basal ganglia iron content in Parkinson's disease measured with magnetic resonance |
002207 |
J. J. Claus [Pays-Bas] ; E. Mohr [Canada] | Attentional deficits in Alzheimer's, Parkinson's, and Huntington's diseases |
002212 |
Manfred Gerlach [Allemagne] ; Wieland Gsell [Allemagne] ; Johannes Kornhuber [Allemagne] ; Kurt Jellinger [Autriche] ; Verena Krieger [Autriche] ; Felix Pantucek [Autriche] ; Reinhard Vock [Allemagne] ; Peter Riederer [Allemagne] | A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome |
002274 |
Elise Tandberg [Norvège] ; Larsen [Norvège] ; Ernst G. Nessler [Norvège] ; Trond Riise ; Johan A. Aarli [Norvège] | The epidemiology of Parkinson's disease in the county of Rogaland, Norway |
002277 |
Goetz [États-Unis] ; Glenn T. Stebbins [États-Unis] ; Teresa A. Chmura [États-Unis] ; Stanley Fahn [États-Unis] ; Harold L. Klawans [États-Unis] ; C. David Marsden [Royaume-Uni] | Teaching tape for the motor section of the unified Parkinson's disease rating scale |
002280 |
H. Ueda [Japon] ; K. Sato [Japon] ; F. Okumura [Japon] ; A. Inoue [Japon] ; Y. Nakata [Japon] ; N. Ozaki [Japon] ; J. L. Yue [Japon] ; Y. Misu [Japon] | Supersensitization of neurochemical responses by L-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson's disease model rats |
002283 |
F. Thibaut [France] ; B. A. Faucheux [France] ; J. Marquez [France] ; J. Villares [France] ; J. F. Menard [France] ; Yves Agid [France] ; E. C. Hirsch [France] | Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine |
002284 |
J. Knoll [Hongrie] | Rationale for (−)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes |
002289 |
Schägger | Quantification of oxidative phosphorylation enzymes after blue native electrophoresis and two‐dimensional resolution: Normal complex I protein amounts in Parkinson's disease conflict with reduced catalytic activities |
002291 |
Lawrence H. Price [États-Unis] ; Dennis D. Spencer [États-Unis] ; Kenneth L. Marek [États-Unis] ; Richard J. Robbins [États-Unis] ; Csaba Leranth [États-Unis] ; Anita Farhi [États-Unis] ; Frederick Naftolin [États-Unis] ; Robert H. Roth [États-Unis] ; Benjamin S. Bunney [États-Unis] ; Paul B. Hoffer [États-Unis] ; Robert Makuch [États-Unis] ; D. Eugene Redmond Jr. [États-Unis] | Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease |
002292 |
Guido Nikkhah [Suède] ; J. Eberhard [Suède] ; M. Olsson [Suède] ; A. Björklund [Suède] | Preservation of fetal ventral mesencephalic cells by cool storage: in-vitro viability and TH-positive neuron survival after microtransplantation to the striatum |
002293 |
C. Trenkwalder [Royaume-Uni] ; W. Paulus [Royaume-Uni] ; S. Krafczyk [Royaume-Uni] ; M. Hawken [Royaume-Uni] ; W. H. Oertel [Royaume-Uni] ; Th. Brandt [Royaume-Uni] | Postural stability differentiates “lower body” from idiopathic parkinsonism |
002294 |
Palmer [États-Unis] ; J. Thomas Hutton [États-Unis] | Postural finger tremor exhibited by Parkinson patients and age‐matched subjects |
002300 |
Juha O. Rinne [Finlande] ; Arto Laihinen [Finlande] ; Kjell N Gren [Finlande] ; Hanna Ruottinen [Finlande] ; Ulla Ruotsawnen [Finlande] ; Urpo K. Rinne [Finlande] | PET examination of the monoamine transporter with [11c]β‐CIT and [11c]β‐CFT in early parkinson's disease |
002302 |
Richard L. Doty [États-Unis] ; Steven M. Bromley [États-Unis] ; Matthew B. Stern [États-Unis] | Olfactory Testing as an Aid in the Diagnosis of Parkinson's Disease: Development of Optimal Discrimination Criteria |
002303 |
Ahlskog [États-Unis] ; Ryan J. Uitti [États-Unis] ; Phillip A. Low [États-Unis] ; Gertrude M. Tyce [États-Unis] ; Kim K. Nickander [États-Unis] ; Ronald C. Petersen [États-Unis] ; Emre Kokmen [États-Unis] | No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease |
002308 |
M. Matousek [Suède] ; C. Wikkelso [Suède] ; E. Blomsterwall [Suède] ; B. Johnels [Suède] ; G. Steg [Suède] | Motor performance in normal pressure hydrocephalus assessed with an optoelectronic measurement technique |
002309 |
L. Wermuth [Danemark] ; E. N. Stenager [Danemark] ; E. Stenager [Danemark] ; J. Boldsen [Danemark] | Mortality in patients with Parkinson's disease |
002313 |
Josef Vymazal [États-Unis] ; Rodney A. Brooks [États-Unis] ; Nicholas Patronas [États-Unis] ; Milan Hajek [États-Unis] ; Jeff W. M. Bulte [États-Unis] ; Giovanni Di Chiro [États-Unis] | Magnetic resonance imaging of brain iron in health and disease |
002315 |
E. R. P. Brunt [Pays-Bas] ; M. J. Boeree [Pays-Bas] | Low dose bromocriptine‐induced pleural effusion and pleuropulmonary fibrosis |
002316 |
O. Sydow [Suède] ; P. Hansson [Suède] ; D. Young [États-Unis] ; B. Meyerson [Suède] ; E-O. Backlund [Suède] ; T. Ebendal [Suède] ; L. O. Farnebo [Suède] ; R. Freedman ; B. Hamberger [Suède] ; B. Hoffer ; Seiger [Suède] ; I. Strömberq ; L. Olson | Long‐term beneficial effects of adrenal medullary autografts supported by nerve growth factor in Parkinson's disease |
002318 |
Pj Blanchet [Canada] ; B. Gomez-Mancilla [Canada] ; T. Di Paolo [Canada] ; Pj Bédard [Canada] | Is striatal dopaminergic receptor imbalance responsible for levodopa‐induced dyskinesia? |
002326 |
J. De Pedro-Cuesta [Suède, Espagne] ; I. J. Petersen ; L. Stawiarz [Suède] ; G. Gudmundsson ; G. Gudmundsson ; J. Almazán [Espagne] ; H. Tulinius [Islande] ; H. Johansson [Suède] | High levodopa use in periodically time‐clustered, Icelandic birth cohorts. A vestige of parkinsonism etiology? |
002331 |
H. Allain [France] ; A. Lieury [France] ; V. Thomas [France] ; J. M. Reymann [France] ; J. M. Gandon [France] ; S. Belliard [France] | Explicit and procedural memory in Parkinson's disease |
002335 |
Clarke [Royaume-Uni] | Does levodopa therapy delay death in Parkinson's disease? A review of the evidence |
002346 |
A. Espino [Espagne] ; J. Llorens [Espagne] ; M. Calopa [Espagne] ; R. Bartrons [Espagne] ; E. Rodriguez-Farre [Espagne] ; S. Ambrosio [Espagne] | Cerebrospinal dopamine metabolites in rats after intrastriatal administration of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion |
002352 |
G. Mathé [France] | Can an adjuvant treatment or a pharmacologic prevention be common to several diseases? The case of those associated to neuromediator defects |
002357 |
D. Muguet [France] ; E. Broussolle [France] ; G. Chazot [France] | Apomorphine in patients with Parkinson's disease |
002358 |
John Hardy [États-Unis] | Apolipoprotein E in the genetics and epidemiology of Alzheimer's disease |
002359 |
Przedborski [États-Unis] ; Vernice Jackson-Lewis [États-Unis] ; Stanley Fahn [États-Unis] | Antiparkinsonian therapies and brain mitochondrial complex I activity |
002362 |
M. A. Hely ; J. G. L. Morris ; W. G. J. Reid ; D. J. O'Sullivan ; P. M. Williamson ; G. A. Broe [Australie] ; M. A. Adena [Australie] | Age at onset: the major determinant of outcome in Parkinson's disease |
002363 |
Hufschmidt [Allemagne] ; Carl-Herrmann Lücking [Allemagne] | Abnormalities of tracking behavior in Parkinson's disease |
002365 |
P. Davous [France] ; P. Auquier [France] ; S. Grignon [France] ; H. C. Neukirch [France] | A prospective study of depression in French patients with Parkinson's disease. The Depar study |
002367 |
Glosser [États-Unis] ; Christopher Clark [États-Unis] ; Bruce Freundlich [États-Unis] ; Lori Kliner-Krenzel [États-Unis] ; Phyllis Flaherty [États-Unis] ; Matthew Stern [États-Unis] | A controlled investigation of current and premorbid personality: Characteristics of Parkinson's disease patients |
002395 |
Haug [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Geoffrey B. Arden [Royaume-Uni] ; Wolfgang H. Oertel [Allemagne] ; Walter Paulus [Allemagne] | Visual thresholds to low‐contrast pattern displacement, color contrast, and luminance contrast stimuli in Parkinson's disease |
002402 |
A. Röhl [Allemagne] ; H. Friedrich [Allemagne] ; G. Ulm [Allemagne] ; P. Vieregge [Allemagne] | The relevance of clinical subtypes for disease course, family history and epidemiological variables in Parkinson's disease |
002406 |
A. Morano [Espagne] ; F. J. Jiménez-Jiménez [Espagne] ; J. A. Molina [Espagne] ; M. A. Antolín [Espagne] | Risk‐factors for Parkinson's disease: case‐control study in the province of Cáceres, Spain |
002414 |
Scarpa [Italie] ; Umberto Castiello [Italie] | Perturbation of a prehension movement in Parkinson's disease |
002416 |
Ross L. Levine [États-Unis] ; John C. Jones [États-Unis] ; Nancy Bee [États-Unis] | Parkinson's disease, ischemic stroke, dementia, and cranial computed tomography: Preliminary study |
002417 |
Shigeki Takeda ; Kazunori Yamazaki ; Teruo Miyakawa ; Hiroyuki Arai | Parkinson's Disease: Distribution of Lewy Bodies in the Peripheral Autonomic Nervous System |
002419 |
K. Shannak ; A. Rajput [Canada] ; B. Rozdilsky [Canada] ; S. Kish ; J. Gilbert [Canada] ; O. Hornykiewicz | Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects |
002423 |
L. Verhagen Metman [États-Unis] ; V. H. Sethy [États-Unis] ; J. R. Roberts [États-Unis] ; D. Bravi [États-Unis] ; J. I. Hoff [États-Unis] ; M. M. Mouradian [États-Unis] ; Chase [États-Unis] | Motor effects of the partial dopamine agonist (−)‐3‐(3‐hydroxyphenyl)‐N‐n‐propylpiperidine (preclamol) in Parkinson's disease |
002428 |
Roberto Marconi [France, Italie] ; Dominique Lefebvre-Caparros [France] ; Anne-Marie Bonnet [France] ; Marie Vidailhet [France] ; Bruno Dubois [France] ; Agid [France] | Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology |
002436 |
Gokhan S. Hotamisligil [États-Unis] ; A. Sule Girmen [États-Unis] ; J. Stephen Fink [États-Unis] ; Elizabeth Tivol [États-Unis] ; Christo Shalish [États-Unis] ; James Trofatter [États-Unis] ; John Baenziger [États-Unis] ; Shirley Diamond [États-Unis] ; Charles Markham [États-Unis] ; Jack Sullivan [États-Unis] ; John Growdon [États-Unis] ; Xandra O. Breakefield [États-Unis] | Hereditary variations in monoamine oxidase as a risk factor for Parkinson's disease |
002439 |
E. Farina ; S. F. Cappa [Italie] ; M. Polimeni ; E. Magni [Italie] ; M. Canesi ; A. Zecchinelli ; G. Scarlato ; C. Mariani | Frontal dysfunction in early Parkinson's diseases |
002442 |
H. Ikeda [Royaume-Uni] ; G. M. Head [Royaume-Uni] ; C. J K. Ellis [Royaume-Uni] | Electrophysiological signs of retinal dopamine deficiency in recently diagnosed Parkinson's disease and a follow up study |
002445 |
Annick Mouatt-Prigent [France] ; Yves Agid [France] ; Etienne C. Hirsch [France] | Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease? |
002448 |
J. P. Larsen [Norvège] ; E. Dupont [Danemark] ; E. Tandberg [Norvège] | Clinical diagnosis of Parkinson's disease. Proposal of diagnostic subgroups classified at different levels of confidence |
002462 |
Olanow [États-Unis] ; S. Fahn [États-Unis] ; M. Muenter [États-Unis] ; H. Klawans [États-Unis] ; H. Hurtig [États-Unis] ; M. Stern [États-Unis] ; I. Shoulson [États-Unis] ; R. Kurlan [États-Unis] ; J. D. Grimes [Canada] ; Joseph Jankovic [États-Unis] ; M. Hoehn [États-Unis] ; C. H. Markham [États-Unis] ; R. Duvisin [États-Unis] ; O. Reinmuth [États-Unis] ; H. A. Leonard [États-Unis] ; E. Ahlskog [États-Unis] ; R. Feldman [États-Unis] ; L. Hershey [États-Unis] ; M. D. Yahr [États-Unis] | A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease |
002464 |
P. D. Griffiths [Royaume-Uni] ; R. H. Perry [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] | A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease |
002504 |
Youdim [Israël] ; D. Ben-Shachar [Israël] ; P. Riederer [Allemagne] | The possible role of iron in the etiopathology of parkinson's disease |
002518 |
G. Nikkhah [Suède] ; W.-M. Duan [Suède] ; U. Knappe [Allemagne] ; A. Jo Dicke [Allemagne] ; A. Bjo Rklund [Suède] | Restoration of complex sensorimotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat parkinson model |
002523 |
E. Nicolle [France] ; Pierre Pollak [France] ; F. Serre-Debeauvais [France] ; P. Richard [France] ; Cl Gervason [France] ; E. Broussolle [France] ; M. Gavend [France] | Pharmacokinetics of apomorphine in parkinsonian patients |
002527 |
G. Kennedy [Royaume-Uni] ; Pring [Royaume-Uni] ; R. Fawcus [Royaume-Uni] | No place for motor speech acts in the assessment of dysphagia? Intelligibility and swallowing difficulties in stroke and Parkinson's disease patients |
002528 |
Rinne [Finlande] | Nigral degeneration in parkinson's disease |
002535 |
Philip Seeman [Canada] ; Hong-Chang Guan [Canada] ; Hubert H. M. Van Tol [Canada] ; Hyman B. Niznik [Canada] | Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata |
002542 |
Takahiro Fukuda [Japon] ; Junichi Tanaka [Japon] ; Kazuhiko Watabe [Japon] ; Robert Tomohiko Numoto [Japon] ; Motoyuki Minamitani [Japon] | Immunohistochemistry of neuronal inclusions in the cerebral cortex and brain‐stem in Lewy body disease |
002550 |
Factor [États-Unis] ; William J. Weiner [États-Unis] | Early combination therapy with bromocriptine and levodopa in parkinson's disease |
002551 |
G. Masson [France] ; D. Mestre [France] ; O. Blin [France] | Dopaminergic modulation of visual sensitivity in man |
002563 |
Ruey-Meei Wu [Taïwan, États-Unis] ; Chuang C. Chiueh [États-Unis] ; Agu Pert [États-Unis] ; Dennis L. Murphy [États-Unis] | Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo |
002603 |
J. C. Pin [France] ; J. P. Neau [France] ; J. Paquereau [France] ; C. Rostykus [France] ; D. Guehl [France] ; I. Aubert [France] ; A. Marillaud [France] ; R. Gil [France] | Étude comparative de la démence de type Alzheimer et de celle de la maladie de Parkinson en EEG quantifiée |
002605 |
L. Lorigados [Suède, Cuba] ; S. Söderström [Suède] ; T. Ebendal [Suède] | Two‐site enzyme immunoassay for βNGF applied to human patient sera |
002609 |
Guylaine Le Dorze [Canada] ; Louise Dionne [Canada] ; John Ryalls [Canada] ; Marie Julien [Canada] ; Lisa Ouellet [Canada] | The effects of speech and language therapy for a case of dysarthria associated with Parkinson's disease |
002618 |
Jiméanez‐Jiméanez [Espagne] ; Dolores Mateo [Espagne] ; Santigo Giméanez-Roldan [Espagne] | Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: A case‐control study |
002635 |
K. Kuroda [Japon] ; K. Tatara [Japon] ; T. Takatorige [Japon] ; F. Shinsho [Japon] | Effect of physical exercise on mortality in patients with Parkinson's disease |
002643 |
Scott G. Adams [Canada] ; Anthony E. Lang [Canada] | Can the Lombard effect be used to improve low voice intensity in Parkinson's disease? |
002682 |
H. Allain [France] ; J. Cougnard [France] ; H-C. Neukirch [France] | Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT) |
002685 |
A. Friedman [Pologne] ; J. Sienkiewicz [Pologne] | Psychotic complications of long‐term levodopa treatment of Parkinson's disease |
002686 |
R. J. Marttila [Finlande] ; U. K. Rinne [Finlande] ; R. J. Marttila [Finlande] | Progression and survival in Parkinson's disease |
002687 |
Factor [États-Unis] ; William J. Weiner [États-Unis] | Prior history of head trauma in Parkinson's disease |
002689 |
J. De Pedro-Cuesta [Espagne] ; J. De Pedro-Cuesta [Espagne] | Parkinson's disease occurrence in Europe |
002690 |
J. De Pedro-Cuesta [Suède, Espagne] ; L. Stawiarz [Suède] | Parkinson's disease incidence: magnitude, comparability, time trends |
002692 |
J. O. Rinne [Finlande] | Nigral degeneration in Parkinson's disease in relation to clinical features |
002693 |
U. K. Rinne [Finlande] | New strategies in the treatment of early Parkinson's disease |
002701 |
G. Cusimano [Italie] ; C. Capriani [Italie] ; V. Bonifati [Italie] ; G. Meco [Italie] | Hypothalamo‐pituitary function and dopamine dependence in untreated parkinsonian patients |
002703 |
A. Lieberman [États-Unis] ; E. Fazzini [États-Unis] | Experience with selegiline and levodopa in advanced Parkinson's disease |
002705 |
J. De Pedro-Cuesta [Suède] ; L. Stawiarz [Espagne] | Evaluation of how age modifies the risk for Parkinson's disease, based on stratified comparisons of descriptive data |
002706 |
S. W. Pederson [Suède] ; T. Eriksson [Suède] ; B. Öberg [Suède] | Effects of withdrawal of antiparkinson medication on gait and clinical score in the Parkinson patient |
002708 |
P. A. Lewitt | Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study |
002715 |
S. W. Pedersen [Suède] ; E. B Ckman [Suède] ; B. Öberg [Suède] | Characteristics of tetanic muscle contraction in Parkinson patients |
002749 |
Johnson [États-Unis] ; Susan E. Hodge [États-Unis] ; Roger Duvoisin [États-Unis] | Twin studies and the genetics of Parkinson's disease—a reappraisal |
002750 |
Eidelberg [États-Unis] ; Moeller [États-Unis] ; V. Dhawan [États-Unis] ; Sidtis [États-Unis] ; J. Z. Ginos [États-Unis] ; Strother [États-Unis] ; J. Cedarbaum [États-Unis] ; P. Greene [États-Unis] ; S. Fahn [États-Unis] ; Rottenberg [États-Unis] | The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies |
002751 |
Cedarbaum [États-Unis] ; Mary Clark [États-Unis] ; Linda H. Toy [États-Unis] ; Alison Green-Parsons [États-Unis] | Sustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation |
002752 |
J. A. Johnson [Royaume-Uni] ; T. R. Pring [Royaume-Uni] | Speech therapy and Parkinson's disease: A review and further data |
002759 |
Clyde Hertzman [Canada] ; Michele Wiens ; David Bowering ; Barry Snow ; Donald Calne | Parkinson's disease: A case‐control study of occupational and environmental risk factors |
002769 |
B. Bergamasco [Italie] ; P. Benna [Italie] ; L. Scarzella [Italie] | Long‐term bromocriptine treatment of de novo patients with Parkinson's disease. A seven‐year follow‐up |
002773 |
Thomas K. Pitcairn [Royaume-Uni] ; Susan Clemie [Royaume-Uni] ; John M. Gray [Royaume-Uni] ; Brian Pentland [Royaume-Uni] | Impressions of parkinsonian patients from their recorded voices |
002779 |
R. F. Peppard ; W. R. W. Martin ; C. M. Clark ; G. D. Carr ; P. L. Mcgeer ; D. B. Calne | Cortical glucose metabolism in parkinson's and alzheimer's disease |
002786 |
M. Camerlingo [Italie] ; B. Ferraro [Italie] ; G. C. Gazzaniga [Italie] ; L. Casto [Italie] ; B. M. Cesana [Italie] ; A. Mamoli [Italie] | Cardiovascular reflexes in Parkinson's disease: long‐term effects of levodopa treatment on de novo patients |
002816 |
O. Lindvall [Suède] ; A. Björklund [Suède] | Transplantation strategies in the treatment of Parkinson's disease: experimental basis and clinical trials |
002817 |
I. C. Dissing [Danemark] ; F. Güttler [Danemark] ; H. Pakkenberg [Danemark] ; H. Lou [Danemark] ; A. Gerdes [Danemark] ; C. Lykkelund [Danemark] ; V. Rasmussen [Danemark] | Tetrahydrobiopterin and Parkinson's disease |
002822 |
G. J. D. Birkmayer [Autriche] ; W. Birkmayer [Autriche] | Stimulation of endogenous L‐dopa biosynthesis — a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH) |
002823 |
Heinonen E. H [Finlande] ; Rinne U. K [Finlande] | Selegiline in the treatment of Parkinson's disease |
002833 |
M. B. H. Youdim ; D. Ben-Shachar ; P. Riederer [Allemagne] | Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? |
002836 |
R. J. Marttila [Finlande] ; U. K. Rinne [Finlande] | Epidemiological approaches to the etiology of Parkinson's disease |
002839 |
Roser Cortés [Suisse, Suède] ; Montserrat Camps [Suisse, Espagne] ; Bianca Gueye [Suisse] ; Alphonse Probst [Suisse] ; Josém. Palacios [Suisse] | Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology |
002840 |
I. Shoulson [États-Unis] | Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP) |
002847 |
A. Lieberman [États-Unis] ; J. Ransohoff [États-Unis] ; P. Berczeller [États-Unis] ; P. Brous [États-Unis] ; K. Eng [États-Unis] ; M. Goldstein [États-Unis] ; B. Kaufman [États-Unis] ; M. Koslow [États-Unis] ; L. Chin [États-Unis] | Adrenal medullary transplants as a treatment for advanced Parkinson's disease |
002866 |
Stewart A. Factor [États-Unis] ; Juan Sanchez-Ramos [États-Unis] ; Weiner [États-Unis] | Trauma as an etiology of parkinsonism: A historical review of the concept |
002872 |
J. P. Kesslak [États-Unis] ; C. W. Cotman [États-Unis] ; H. C. Chui [États-Unis] ; S. Van Den Noort [États-Unis] ; H. Fang [États-Unis] ; R. Pfeffer [États-Unis] ; G. Lynch [États-Unis] | Olfactory tests as possible probes for detecting and monitoring Alzheimer's disease |
002884 |
L. Cipparrone [Italie] ; A. Ginanneschi [Italie] ; F. Degl'Innocenti [Italie] ; P. Porzio [Italie] ; P. Pagnini [Italie] ; P. Marini M. D [Italie] | Electro‐oculographic routine examination in Parkinson's disease |
002886 |
M. Hietanen [Finlande] ; Teräväinen [Finlande] | Dementia and treatment with L‐dopa in Parkinson's disease |
002887 |
Maloteaux [Belgique] ; E. C. Laterre [Belgique] ; P. M. Laduron [France] ; F. Javoy-Agid [France] ; Yves Agid [France] | Decrease of serotonin‐S2 receptors in temporal cortex of patients with Parkinson's disease and progressive supranuclear palsy |
002910 |
Niall Quinn [Royaume-Uni] ; Peter Critchley [Royaume-Uni] ; Marsden [Royaume-Uni] | Young onset Parkinson's disease |
002919 |
A. Laihinen [Finlande] ; J. Alihanka [Finlande] ; S. Raitasuo [Finlande] ; U. K. Rinne [Finlande] | Sleep movements and associated autonomic nervous activities in patients with Parkinson's disease |
002980 |
M. Hietanen [Finlande] ; H. Ter V Inen [Finlande] | Cognitive performance in early Parkinson's disease |
002999 |
Etienne Hirsch [France] ; Merle Ruberg [France] ; Mireille Dardenne [France] ; Marie-Madeleine Portier ; France Javoy-Agid [France] ; Jean-Francois Bach [France] ; Yves Agid [France] | monoclonal antibodies raised against Lewy bodies in brains from subjects with Parkinson's disease |
002A15 |
Yasuo Toyokura ; Yoshikuni Mizuno ; Masao Kase ; Itsuro Sobue ; Yoshigoro Kuroiwa ; Hirotaro Narabayashi ; Masanori Uono ; Takao Nakanishi ; Masakuni Kameyama ; Hitoshi Ito ; Yasuo Shimada ; Makoto Iwata | Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study |
002A73 |
Melvin D. Yahr [États-Unis] ; Marina R. Mendoza [États-Unis] ; Daniel Moros [États-Unis] ; Kenneth J. Bergmann [États-Unis] | Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline) |
002A78 |
Bernard Scatton ; France Javoy-Agid [France] ; Liliane Rouquier ; Bruno Dubois [France] ; Yves Agid [France] | Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease |
002A80 |
U. K. Rinne [Finlande] | Problems associated with long‐term levodopa treatment of Parkinson's disease |
002A84 |
P. Riederer [Autriche] ; K. Jellinger [Autriche] | Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline) |
002A89 |
Reijo J. Marttila [Finlande] | Diagnosis and epidemiology of Parkinson's disease |
002A90 |
F. Gerstenbrand [Autriche] ; G. Ransmayr [Autriche] ; Werner Poewe [Autriche] | Deprenyl (selegiline) in combination treatment of Parkinson's disease |
002A98 |
Bruno Dunois ; Merle Ruberg ; France Javoy-Agid ; Alain Ploska ; Yves Agid [France] | A subcortico-cortical cholinergic system is affected in Parkinson's disease |
002B07 |
M. Markianos [Grèce] ; M. Hadjikonstantinou [Grèce] ; E. Bistolaki [Grèce] | Urinary noradrenaline and serotonin metabolites in drug‐free Parkinson patients and the effect of L‐dopa treatment |
002B17 |
Claudio Villardita [Italie] ; Pietro Smirni [Italie] ; Francesco Le Pira [Italie] ; Giuseppe Zappala [Italie] ; Francesco Nicoleiti [Italie] | Mental deterioration, visuoperceptive disabilities and constructional apraxia in Parkinson's disease |
002B19 |
James R. Tweedy [États-Unis] ; Carlos A. Garcia [États-Unis] | Lecithin treatment of cognitively impaired Parkinson's patients |
002B91 |
Reijo J. Marttila [Finlande] ; Urpo K. Rinne [Finlande] | Changing epidemiology of Parkinson's disease: Predicted effects of levodopa treatment |